
Downloaded from: http://researchonline.lshtm.ac.uk/id/eprint/4655268/

DOI: https://doi.org/10.17037/PUBS.04655268

Usage Guidelines:

Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
THE ROLE OF INSULIN IN RELATION TO
STRESS AND NUTRITIONAL STATE:
GLUCOSE HOMEOSTASIS AFTER SURGERY, IN OBESITY
AND OLD AGE

A thesis submitted in part fulfilment of the requirements
for the Degree of
DOCTOR OF PHILOSOPHY
In
the Faculty of Medicine
University of London
by
Watujo Somero Scojjalbrato

Clinical Nutrition and Metabolism Unit,
Department of Human Nutrition,
London School of Hygiene and Tropical Medicine,
London
1976
## CONTENTS

PART I. INSULIN AND GLUCOSE HOMEOSTASIS  

Chapter I. Introduction  
A. History  
B. Insulin and Its Structure  

Chapter II. Glucose Homeostasis  
A. Energy Balance  
B. Glucose as an Energy Source  
C. Fate of Exogenous Glucose added to the Blood Circulation  
D. Maintenance of Blood Glucose Level  

Chapter III. Gluconeogenesis  
A. Definition  
B. Liver and Gluconeogenesis  
C. Cori Cycle  

Chapter IV. Stress and Glucose Metabolism  
A. Definition  
B. Classification of Stress  

Chapter V. Protein Energy Malnutrition (PEM)  
A. Aetiology  
B. PEM and Blood Glucose Levels  
C. PEM and Insulin Levels  

Chapter VI. Purpose of the Study
### PART II. GLUCOSE HOMEOSTASIS IN PATIENTS AFTER SURGERY

<table>
<thead>
<tr>
<th>Chapter I. Introduction</th>
<th>36</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Trauma and Catabolism</td>
<td>36</td>
</tr>
<tr>
<td>B. Anti-Insulin Hormones</td>
<td>37</td>
</tr>
<tr>
<td>C. Trauma and Endocrine Balance</td>
<td>39</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Chapter II. Material and Methods</th>
<th>41</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Subjects</td>
<td>41</td>
</tr>
<tr>
<td>B. Nitrogen Balance Study</td>
<td>43</td>
</tr>
<tr>
<td>C. Blood Samples</td>
<td>46</td>
</tr>
<tr>
<td>D. Glucose Infusion</td>
<td>48</td>
</tr>
<tr>
<td>E. Analytical Methods</td>
<td>49</td>
</tr>
<tr>
<td>F. Assessment of the Data</td>
<td>55</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Chapter III. Results</th>
<th>56</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Nitrogen Balance</td>
<td>56</td>
</tr>
<tr>
<td>B. Urinary Nitrogen Excretion</td>
<td>56</td>
</tr>
<tr>
<td>C. Faecal Nitrogen Excretion</td>
<td>56</td>
</tr>
<tr>
<td>D. Urinary Creatinine Excretion</td>
<td>59</td>
</tr>
<tr>
<td>E. The Relationship between Nitrogen Balance and Daily Hormonal and Substrate Values</td>
<td>59</td>
</tr>
<tr>
<td>F. Substrate and Hormonal Changes during Glucose Infusion</td>
<td>66</td>
</tr>
</tbody>
</table>

| Chapter IV. Discussion | 71 |
PART III. GLUCOSE HOMEOSTASIS IN OBESITY

Chapter I. Introduction
A. Definition
B. Problem of Obesity
C. Aetiology of Obesity
D. Insulin's Role in Obesity

Chapter II. Material and Methods
A. Subjects
B. Tests
C. Analytical Methods
D. Dietary Treatment
E. Assessment of the Data

Chapter III. Results
A. Oral GTT
B. iv GTT and iv GTT
C. Correlation between Biochemical Results and Degree of Obesity
D. The Effect of Dietary Restriction on Weight Loss in the Obese Patients

Chapter IV. Discussion
<table>
<thead>
<tr>
<th>PART V. GENERAL DISCUSSION</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chapter I. Introduction</td>
<td>165</td>
</tr>
<tr>
<td>Chapter II. Methods</td>
<td>167</td>
</tr>
<tr>
<td>A. Choice of Subjects</td>
<td>167</td>
</tr>
<tr>
<td>B. Choice of Tests</td>
<td>169</td>
</tr>
<tr>
<td>C. Skinfold Measurements</td>
<td>173</td>
</tr>
<tr>
<td>Chapter III. Study in Surgical Patients</td>
<td>174</td>
</tr>
<tr>
<td>A. Insulin Resistance</td>
<td>174</td>
</tr>
<tr>
<td>B. Significance of Insulin Therapy</td>
<td>174</td>
</tr>
<tr>
<td>C. Nitrogen Balance</td>
<td>175</td>
</tr>
<tr>
<td>Chapter IV. Study in Obesity and Elderly Subjects</td>
<td>176</td>
</tr>
<tr>
<td>A. Impaired Glucose Tolerance</td>
<td>176</td>
</tr>
<tr>
<td>B. Possible Role of the Liver</td>
<td>176</td>
</tr>
<tr>
<td>C. Insulin Sensitivity</td>
<td>179</td>
</tr>
<tr>
<td>Chapter V. Diagnostic Significance of the Tests</td>
<td>186</td>
</tr>
<tr>
<td>Chapter VI. Conclusions and Future Works</td>
<td>187</td>
</tr>
<tr>
<td>A. Surgical Patients</td>
<td>187</td>
</tr>
<tr>
<td>B. Obese Subjects</td>
<td>188</td>
</tr>
<tr>
<td>C. Elderly Subjects</td>
<td>189</td>
</tr>
</tbody>
</table>
Acknowledgements

I am indebted to Professor J.C. Waterlow, Head of the Department of Human Nutrition, London School of Hygiene and Tropical Medicine, for the privilege of working in his Department.

I am also indebted to my supervisor, Dr. C.R.C. Heard for his constant advice and encouragement.

I am grateful to Professor C.O. Clark, Department of Surgery, University College Hospital, for the opportunity to study his surgical patients and to Professor A.N. Exton-Smith, Department of Geriatrics, University College Hospital, for giving me access to elderly patients.

I should like to thank Dr. S.R. Bloom, Post-Graduate Medical School, London, for the immuno assay of glucagon; Mr. J.D. Few, Department of Environmental Physiology, London School of Hygiene and Tropical Medicine, for the steroid analysis.

I should also like to thank present and past members of the C.N.M. unit, London School of Hygiene and Tropical Medicine, firstly for clinical advice (Dr. W.P.T. James, Dr. A. Tompkins, Dr. M. Golden) and equally important for skilled technical help (Miss Pauline Wright, Dr. S. Poerwokoesoemo, Mrs. Sylvia Frangi, Miss Shree Dalal and Mr. P. Broadbent).
Permission to carry out this work was given by the Committee on the Ethics of Clinical Investigation, University College Hospital, for clinical investigations on surgical, obese and geriatric patients; and by the Committee on Experiments Involving Human Subjects, London School of Hygiene and Tropical Medicine for studying normal control subjects.
ABSTRACT

Since the discovery of the hormone (Banting and Best, 1922), extensive research on insulin has been going on. Insulin is important not only in relation to carbohydrate metabolism, and thus in relation to diabetes mellitus, but also as one of the important hormones in protein and fat metabolism.

There is much evidence showing an impairment of insulin action in stress, whether the stress is physical or psychological. The way in which insulin resistance develops and its effects on metabolism may vary in different stress situations. This work investigates three forms of physical stress and attempts to show the role of insulin in each of these situations. The metabolic and clinical implications of this problem are discussed.

First, the effects of surgery were studied in eleven patients. Their mean age was 52 years, mean weight was 68 kg, and mean % ideal body weight was 94%. A nitrogen balance study showed that the negative balance after surgery coincided with elevated levels of plasma glucagon, non-esterified fatty acids, branched-chain amino acids, urinary free cortisol, urinary 17-OH-corticosteroids and with a decrease of total plasma amino acids. A temporary insulin resistance occurred in post-surgical patients, shown by hyperglycaemia and hyperinsulinaemia during a two hour glucose infusion. The clinical significance of hyperglycaemia is discussed.

The second study was of twenty nine obese patients (fasting blood glucose ≤6.11 mmol/l). Their mean age was 40 years, mean weight was 109 kg, and mean % ideal body weight was 166% (from 115% to 233%). These patients showed an average an impaired response to the oral glucose tolerance test (oral GTT), intravenous glucose tolerance test (iv GTT) and intravenous glucose insulin tolerance test (iv GTT).
for insulin sensitivity. This impairment was related to hyperinsulinaemia which followed glucose administration (oral or iv). These obese patients seemed to fall into two groups: those with % ideal body weight < 160% showed impaired tolerance to glucose but relatively normal plasma insulin responses; those > 160% showed marked hyperinsulinaemia.

It is suggested that these responses represent those of 'active' and 'passive' obesity, but that the former may include a pre-clinical stage when insulin sensitivity is very high.

Thirdly, twenty three geriatric patients (fasting blood glucose < 6.11 mmol/l) were studied. Their mean age was 79 years and mean weight was 56 kg. These patients also showed an impairment in the oral GTT, iv GTT and iv GTT. The impairment was greater than that found in obese patients. Insulin response to glucose administration (oral or iv) was sluggish, but the actual levels of insulin were not significantly lower than those found in young normal subjects (except for the peak value during iv GTT). The major cause of impaired glucose tolerance was diminished insulin sensitivity, either in the peripheral tissue, or, more probably in the liver, resulting in relative inability to switch off glucose output. An intravenous alanine tolerance test was carried out in eight elderly subjects (mean age was 78 years, mean weight was 52 kg), to assess gluconeogenic capacity of the liver, and again indicated the relative inability of endogenous insulin to suppress glucose production.
PART I

INSULIN AND GLUCOSE HOMEOSTASIS
CHAPTER 1
INTRODUCTION

A. History:

Insulin is a hormone which is traditionally associated with diabetes mellitus. Although this hormone was discovered not more than fifty years ago (Banting and Best, 1922), the disease itself had long been recognized. It was first described by a Roman physician, Aretaeus of Cappadocia, as "a moist and cold wasting of flesh and limbs into the urine" (A.D. 30 to A.D. 90). 'Diabetes' is a Greek word meaning 'siphon', and is descriptive of the body siphoning away through the urine. It was a dreaded disease and remained so for many years to come. Avicenna (Ibn Sina), a famous Arab physician (930-1033) (Fig. 1), gave a very complete description of the disorder, including some of the complications, such as diabetic gangrene, furunculosis, phthisis, and also the presence of a honey-like substance in the patient's urine. But many centuries before Aretaeus and Avicenna, old Chinese, Japanese and Hindu writings indicate that the disease had long been known to these peoples also.

The observations of Thomas Willis (1662) of glycosuria in urine however, marked the beginning of a new era when glycosuria was becoming an accepted diagnostic test for diabetes mellitus. Brunner (1683) observed in animal experiments that polyuria and polydipsia occurred after removal of the pancreas, but it was Cawley (1788) who probably was the first to associate diabetes with the pancreas when he found multiple calculi and destruction of pancreatic tissue at an autopsy of a patient who had died from diabetes.
Figure 1. An old woodcut of Avicenna (Ibn Sina) (980 - 1037) (Courtesy of the Royal Society of Medicine, London). (Chased, 1908)
Insulin is produced in the islets of Langerhans, named after Paul Langerhans (1869) who first discovered them and described their structure embedded in the tissue of the pancreas. Their function and significance were then however still unknown.

The metabolic relationship between diabetes mellitus and the pancreas was clearly shown by Von Mering and Minkowski (1890). They found that pancreatectomy on dogs produced hyperglycaemia and glycosuria and the dogs finally died in ketosis and coma. Their conclusion was that the pancreas elaborates a substance that keeps the blood sugar low and restores the metabolism to normal.

The whole world owes its thanks to Frederick Banting and Charles Best (1922), who discovered "the blood sugar lowering substance" now known as insulin. Their discovery led to the therapeutic use of insulin, thus saving thousands of lives, and has opened the doors to the possibility of its ultimate synthetic production.

It was not long before Abel (1926) achieved the crystallization of the hormone, but over twenty more years passed before Sanger and his co-workers successfully pioneered the study of the sequence of amino acids in the insulin molecule (Sanger, 1949; Ryle, Sanger, Smith & Kitai, 1955).

Since its discovery and especially at present, extensive research on insulin has been going on in relation not only to diabetes, but also to wider aspects of body metabolism. Insulin is, no doubt, the principal hormone in carbohydrate metabolism, but it is also an equally important hormone in protein (Manchester, 1970).
and in fat metabolism (Avruch, Carter and Martin, 1972). This gives a significance much wider than the specialised limits of diabetes. In particular, since insulin has a central role in the disposal of energy and in synthesis of proteins, its relationship to short and long term nutritional status is receiving increasing attention.

B. Insulin and Its Structure:

Insulin is produced and stored in the pancreatic islets of Langerhans (McLeod, 1922). There is no evidence that it is produced normally elsewhere in the body (Best, Jephcott and Scott, 1932). Although in some very rare cases it is produced in non-pancreatic tumours (Shames, Dhurandar and Blackard, 1968; Omenn, 1970).

Insulin is a polypeptide, and consists of two parallel chains of amino acids. They are the A (acid) and B (basic) chains, and are joined to each other by two disulphide bridges. The third disulphide bridge is connecting two cysteine molecules within the A chain (Steiner, Kemmler, Clark, Oyer and Rubenstein, 1972). Although the detailed amino acids composition of insulin differs somewhat from one species to another, this two-chain structure and the relative positions of the three pairs of disulphide bridges are constant structural features (Fig. 2). Several kinds of experimental evidence indicates that these bridges are essential to the normal structural integrity and biological activity of the hormone (Humbel, Bossard and Zahn, 1972).

Insulin is derived from a larger single polypeptide precursor, 'proinsulin' or 'big insulin'. In proinsulin, the A and B chain of insulin are joined in series by a further sequence of amino acids (the C-peptide), thus forming a continuous chain, with the same three pairs of disulphide bridges as in insulin (Fig. 3). (Oyer, Cho,
Figure 2. Primary structure of human insulin (from Steiner, et al., 1972).
Figure 3. Primary structure of human proinsulin (from Oyer, et al., 1971).
Peterson and Steiner, 1971). Proinsulin is synthesized in the β-cell and is then cleaved within the β-cell by proteolytic action into two-fragment insulin and C-peptide (Clark, Cho, Rubenstein and Steiner, 1969).

Some proinsulin is released with insulin into the circulation and although cross-reacting with insulin antibodies, it does not appear to be a serious source of error in insulin immunoassays. However, proinsulin is also biologically active, although its effectiveness is only between 2 to 20 per cent of the biological activity of insulin (Rubenstein and Steiner, 1971).
CHAPTER II
GLUCOSE HOMEOSTASIS

A. Energy Balance:

Energy balance in man is a complex and highly integrated system of supply and utilization of energy, derived mainly from carbohydrate, fat and protein. The metabolizable energy of these nutrients is linked with requirements through energy couplers such as high energy phosphate compounds, e.g. adenosine triphosphate (ATP) and reduced forms of coenzymes, particularly reduced nicotinamide adenine dinucleotide phosphate (NADPH\(\text{+H}^+\)). In muscle, creatine phosphate has a specialized short term role in energy storage. This system of intermittent supplies and continuous but variable demands involved the deposition of nutrient stores during periods of excess fuel intake, and conversely, their mobilization in periods of dietary nutrient deprivation. Hormonal control has an important function in this regulation of fuel supplies. Under normal circumstances, insulin action predominates during exogenous fuel excess (just after ingestion of food), whereas contra-regulatory hormones become operative during the fasting phase, when energy has to be mobilized from endogenous stores.

Carbohydrate, fat and protein from exogenous sources are hydrolyzed and absorbed within the gastro-intestinal system. The major endogenous fuel stores are in the forms of glycogen in the muscle and liver, triglyceride in adipose tissue, and if all fails, protein in the peripheral muscle. The main function of protein however, is to form the structural, contractile and enzymatic component of cells.
B. Glucose as an Energy Source:

Most tissues in the body use non-esterified fatty acids (NEFA) as their main source of energy to generate ATP. But there are several tissues which are dependent on glucose. They are divided into two groups:

1. Tissues which oxidize glucose completely (rich in mitochondria):
   a. The brain and nervous tissues: The reason why these tissues do not use NEFA as their energy source is not yet clearly known. In these tissues, glucose is oxidized to pyruvate and some ATP is generated, then pyruvate is oxidized further to CO\(_2\) in the mitochondria with much greater ATP generation.
   b. Red muscle: Although NEFA comprise the main fuel for red muscle, this tissue is able to use glucose also, and oxidizes it completely to CO\(_2\), thus generating the maximum yield of ATP.

2. Tissues dependent on glycolysis (mitochondria absent or deficient):
   a. Red blood cell: This tissue does not have mitochondria, and glucose can, therefore, be oxidized only to pyruvate. This oxidation is coupled with the reduction of pyruvate to lactate. Lactate is then transferred to the liver where it is converted back to glucose. Only small amounts of ATP are generated (2 moles per one mole of glucose) in oxidizing glucose to pyruvate, but recycling of pyruvate through lactate and the Cori cycle increases the energy yield of glycolysis considerably (see Chapter III C. on Cori cycle).
b. White muscle during exercise: This tissue does not have enough mitochondria for the complete oxidation of glucose.

During exercise, therefore, lactate is formed in the red blood cells, and this lactate is then also transferred to the liver to be converted back to glucose (see Chapter III C. on Cori cycle).

C. Fate of Exogenous Glucose added to the Blood Circulation:

The "carbohydrate given by mouth can be converted into fat by the metabolic processes of the body is now an accepted fact" (Macdonald, 1967). Whether the tissues are glucose or NEFA dependent or whether mobilization of endogenous fuel stores involves glycogen or triglyceride, all may therefore, indirectly or directly be derived from dietary carbohydrate. However, the immediate fate of dietary glucose or of the glucose load during oral or intravenous glucose tolerance tests is much less certain.

In man there is a little comprehensive evidence on this question. Some suggested that up to 50 per cent of the ingested carbohydrate (oral) is taken up by the liver (Ensinck and Williams, 1972). This figure, however, is very likely to be too high, since after a glucose load, gluconeogenesis is suppressed in the liver (Madison, 1969) and studies on the rate of disappearance of glucose after oral or intravenous glucose load without using radioactive glucose tracer could be misleading. Thus experiments on rats, in which the orally administered glucose included a tracer dose of 14C-glucose, showed that after 180 minutes only 15 to 18 per cent of the ingested glucose had been taken up by the liver (Curtis-Prior, Trethewey, Stewart & Hanley, 1969; Jellicoe and Moody, 1969). However, even 15 per
cent uptake by the liver means that this organ is disproportionately active (relating to weight). It is instructive to look at some of the other organs in the same way and to compare intravenous and oral administration of glucose (Table 1). The data are from an experiment of Curtis-Prior et al. (1969). In this experiment an intravenous dose (750 mg/kg) and an intragastric dose (1500 mg/kg) of glucose were given to rats, in each case together with a tracer dose of \((U-^{14}C) D\)-glucose. The results are summarized in Table 1.

The data in Table 1 show the amount of radio-active counts in each organ, therefore, they may not necessarily be that of glucose. It could be in the form of glucose products (e.g. glycogen, pyruvate, lactate). A correction figure for recycling is not included. Nevertheless, they provide us with a fair picture of the fate of exogenous glucose once it enters the circulation.

The body composition of a normal man may not necessarily be the same as that of a rat. Table 2 shows the normal body composition of a normal male, weighing 70 kg.
Table 1

Distribution of radioactivity in organs of 200 g rats following an intravenous (750 mg/kg) or intragastric (1500 mg/kg) load of glucose, together with a tracer dose of (U-14C) D-glucose (derived from Curtis-Prior et al., 1969)

<table>
<thead>
<tr>
<th>Tissue</th>
<th>% of body weight</th>
<th>% (U-14C) present</th>
<th>Intravenous load</th>
<th>Intra gastric load</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>5 min.</td>
<td>40 min.</td>
</tr>
<tr>
<td>1. Skeletal muscle</td>
<td>38</td>
<td></td>
<td>30.3</td>
<td>30.5</td>
</tr>
<tr>
<td>2. Skin</td>
<td>20</td>
<td></td>
<td>28.1</td>
<td>11.1</td>
</tr>
<tr>
<td>3. Blood</td>
<td>7</td>
<td></td>
<td>13.1</td>
<td>5.0</td>
</tr>
<tr>
<td>4. Liver</td>
<td>3</td>
<td></td>
<td>8.9</td>
<td>9.4</td>
</tr>
<tr>
<td>5. Adipose tissue</td>
<td>16</td>
<td></td>
<td>10.7</td>
<td>4.6</td>
</tr>
<tr>
<td>6. Alimentary tract</td>
<td>5.7</td>
<td></td>
<td>5.3</td>
<td>3.4</td>
</tr>
<tr>
<td>(+ content)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. Brain</td>
<td>0.7</td>
<td></td>
<td>0.7</td>
<td>8.0</td>
</tr>
<tr>
<td>8. Expired CO2</td>
<td>0.1</td>
<td></td>
<td>1.0</td>
<td></td>
</tr>
</tbody>
</table>
Table 2
Normal body composition of a 70 kg male

<table>
<thead>
<tr>
<th>Tissue</th>
<th>% of body weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Skeletal muscle</td>
<td>45.0%</td>
</tr>
<tr>
<td>2. Blood</td>
<td>7.6%</td>
</tr>
<tr>
<td>3. Adipose tissue</td>
<td>19.6%</td>
</tr>
<tr>
<td>4. Liver</td>
<td>1.9%</td>
</tr>
<tr>
<td>5. Alimentary tract</td>
<td>5.8%</td>
</tr>
<tr>
<td>6. Brain</td>
<td>2.0%</td>
</tr>
</tbody>
</table>

a. Derived from Munro (1969)
b. = = Olesen (1965)
c. = = Johnston and Willis (1954)
D. Maintenance of Blood Glucose Level:

1. Basal glucose levels

During fasting, exogenous glucose is not available, and since there is always a certain demand for glucose (see Chapter II B.), the body provides it by mobilization from stores (glycogen) and by gluconeogenesis. Cahill, (1970), summarized the substrate and hormone changes during a 24 hour fast in a normal man, 70 kg in body weight, with a daily energy expenditure of 7.5 kcal/day (1800 calories/day) in Fig. 4.

During this period of fasting, about 180 g of glucose is produced by the liver and enters the circulation. Most of this is 'new' glucose which is derived from amino acids (75 g) from the muscle. While recycled rather than 'new' glucose is derived from pyruvate and lactate (36 g) from muscle, nerve and blood cells, and kidney medulla. Glucose is also formed from glycerol (16 g) derived from fat

NEFA from the hydrolysis of triglyceride are oxidized in the liver, and also in the muscle. Some of the energy generated in this process is used in maintaining gluconeogenesis (see Chapter III on gluconeogenesis). 80 per cent of the glucose produced by the liver will be diverted to the brain and the remainder to the cellular elements of blood, peripheral nerves and kidney medulla. Where through the process of glycolysis, it is converted back to pyruvate and lactate, which is then transported to the liver for reconversion to glucose (Fig. 4).
Figure 4. Scheme of fuel disposition in normal man, fasting for 24 hours
(70 kg, daily energy expenditure 7.5 MJ/day). Glucose directed mainly
for cerebral consumption is released from hepatic glycogen, and new
glucose is generated in liver from precursors derived from fat, muscle,
blood cells, nerve, and renal medulla. NEFA from triglyceride hydrolysis
are oxidized in muscle and liver as alternate energy sources.
(from Cahill, 1970).
Cahill (1970) further suggested that in prolonged starvation there is a decline in the amount of new glucose generated in the liver with a concomitant decrease in protein catabolism. In this situation, the levels of anti-insulin hormones increase in the circulation and they counteract the insulin action. (See Part II, Chapter I B. of this thesis). During this period of prolonged starvation, hepatic gluconeogenesis is reduced to the levels necessary to recycle pyruvate formed in glycolytic tissues.

2. After ingestion of food:

After ingestion of food, the levels of glucose, amino acids, some gut hormones (e.g. gastrin, pancreozymin-cholecystokinin, secretin and enteroglucagon) are increased in the blood. These substrates and hormones stimulate increased release of insulin (Porte & Bagdade, 1970). It is known that glucose alone is a potent stimulator of insulin release, but the combination of glucose and amino acids with the hormones (entero-insular axis) is responsible for the greater release of insulin during oral glucose tolerance test (oral GTT) compared to that found during intravenous glucose tolerance test (IV GTT), where glucose loading is given directly into the blood circulation. These changes of substrates and hormonal levels during the period following the ingestion of food are summarized in Fig. 5.

When carbohydrate is fed, blood glucose rises, but seldom exceeds 8.88 m mol/l (160 mg/100 ml) and usually subsides to preprandial levels by two hours. The insulin released during nutrient absorption promotes storage of the metabolic fuels in appropriate compartments, (e.g. as glycogen in muscle and liver, and as triglyceride in adipose tissue). (Ensink and Williams, 1972). In muscle and fat, insulin enhances
Figure 1. A scheme of glucose disposition after ingestion of food (carbohydrate) in Man.

Glucose is absorbed in the gut and enters the circulation. Gut hormones which are increased by the presence of food in the gut, stimulate $\beta$ cells. On the other hand, blood glucose alone could also stimulate $\beta$ cells. $\beta$ cells produce insulin which promotes glucose uptake by muscle and adipose tissues. Blood glucose inhibits the secretions of anti-insulin hormones. These hormones oppose insulin actions in liver (inhibition of gluconeogenesis) and in muscle and adipose tissues (glucose uptake, inhibition of lipolysis and inhibition of protein breakdown).

Not all anti-insulin hormones exhibit every action shown in this diagram.
FOOD

Glucose in

Gut hormones ↔ Gut

α cells ↔ Blood glucose

Anti-insulin hormones

Liver ↔ CNS

Blood cells, kidney

Muscle and adipose tissues

stimulate or promote.

inhibit.
glucose oxidation. It also enhances glycogen synthesis, potassium and amino acid influx and protein synthesis in muscle (Reiser, 1967). Conversely, insulin inhibits the release of amino acids from muscle (Cahill, 1970). Insulin not only facilitates glucose entering adipose cells and thereby lipid synthesis, it also inhibits lipolysis. This is reflected in the decline in the circulating NEFA concentration which coincides with hyperglycemia and elevation of insulin concentrations in blood, (Reiser, 1967; Bates and Bagdade, 1970). After ingestion of carbohydrate, glucose is taken up by the liver, and most of the carbohydrate assimilated in the liver is deposited as glycogen, under the action of glycogen synthetase, an enzyme regulated by insulin (Reiser, 1967), and concomitantly, hepatic glycogenolysis and gluconeogenesis are abruptly reduced (Madison, 1969).

Fig. 6 summarized and simplifies the control of blood glucose level by insulin and anti-insulin hormones; e.g. growth hormones, epinephrine and glucagon.
Figure 6. The control of blood glucose concentration by insulin and anti-insulin hormones.
BLOOD GLUCOSE
(mg/100 ml)

Anti-insulin
Catabolic

Low
0
20

High
Insulin

Anabolic
Stimulate or promote.

breakdown.
CHAPTER III
GLUCONEOGENESIS

A. Definition:

Gluconeogenesis is strictly the "synthesis of new glucose from non-carbohydrate precursors", e.g. amino acid residues. But this process overlaps considerably with that whereby glucose is resynthesized from lactate and pyruvate. The term 'gluconeogenesis' is therefore used here to include all these processes. The liver is the main organ where gluconeogenesis takes place, although in prolonged starvation, the kidney becomes an important gluconeogenic organ as well. In this situation the kidney takes up amino acids to produce 'new' glucose as well as to produce NH$_3$ to counteract the ketosis which is developed during starvation, (Owen, Felty, Morgan, Wahren and Cahill, 1969).

Gluconeogenesis is important during starvation and other situations when carbohydrate intake from the alimentary canal is limited and the body glycogen stores are depleted. Pyruvate, lactate, glycerol and glucogenic amino acids are converted to glucose and glycogen. These amino acids, either from alimentary canal absorption or from protein breakdown in muscle, through gluconeogenesis, become an important source of energy.

B. Liver and Gluconeogenesis:

Amino acids enter the liver cell by a membrane transport system. Lactate, alanine, serine and glycine are converted into pyruvate in the cytosol (Fig. 7). Pyruvate enters the mitochondria, is converted into oxaloacetate by pyruvate carboxylase...
PATHWAY OF GLUCONEOGENESIS.

Abbreviations are: LAC, lactate; FTR, pyruvate; ALA, alanine; SER, serine; GLY, glycine; PA, fatty acid; AcCoA, acetyl-CoA; CIT, citrate; α-KG, α-ketoglutarate; SUCC, succinate; FUM, fumarate; MAL, malate; OAA, oxaloacetate; ASP, aspartate; GLUT, glutamate; THR, threonine; FEP, P-enol pyruvate; 2PG, 2-P-glycerate; 3PG, 3-P-glycerate; GIP, glycerinaldehyde-3-P; DHAP, dihydroxyacetone-P; GLYP, glycero1-1-P; GLL, glycerol; P6P, fructose-1, 6-di-P; F6P, fructose-6-P; G6P, glucose-6-P; GLI, glucose; G1P, glucose-1-P; GLN, glycogen.

(modified from Exton, 1972).
xylose or to acetyl coenzyme A by pyruvate dehydrogenase. Oxaloacetate is converted into malate and aspartate which leave the mitochondria or to citrate which is mainly metabolized in the Krebs cycle. Malate and aspartate are converted back to oxaloacetate, and oxaloacetate is then converted by phospho-enolpyruvate carboxykinase into phospho-enolpyruvate (PEP) (Extan, 1972). Two moles of high energy phosphate (ATP or GTP) are needed to convert one molecule of PEP. PEP is converted into fructose-1,6 diphosphate by a reversal of glycolysis. A further mole of ATP and a mole of (NADH + H+) are needed for each mole of PEP utilized. Fructose-1,6 diphosphate is hydrolysed to fructose-6 phosphate by fructose-1,6 diphosphatase. This enzyme is specific to tissues carrying out gluconeogenesis. Fructose-6 phosphate is converted to glucose-6 phosphate and glucose-6 phosphate is converted to glucose by another enzyme specific to gluconeogenesis, glucose-6 phosphatase. The overall conversion of two moles of lactate to one mole of glucose, therefore, requires six moles of ATP (or equivalent as GTP) and 2 moles of (NADH + H+). The former is provided by the oxidation of NEFA and the latter by the reduction of NAD+ to (NADH + H+) in the conversion of lactate to pyruvate. It has been suggested that pyruvate entry into liver mitochondria is a control point for gluconeogenesis which is influenced by epinephrine, cortisol and glucagon (Adam and Haynes, 1969).

Glycerol has a small but significant contribution in gluconeogenesis. It enters gluconeogenic pathway at the level of triose-phosphate by reacting with glycerokinase to form glycerol-1 phosphate which is then oxidised to dihydroxyacetone-phosphate by 3-glycerol-phosphate dehydrogenase.
C. Cori Cycle:

In muscle the complete oxidation of glucose involves production of pyruvate by a reaction in the cytosol (anaerobic) and the combustion of pyruvate by reactions in mitochondria (aerobic). Red muscle, (e.g. skeletal muscle), which is designed to work over long periods, depends upon the complete oxidation of glucose and fatty acids. Such muscle contains more mitochondria to sustain a constantly high rate of oxidation of acetyl coenzyme A and has a higher content of myoglobin to deliver the required oxygen for oxidation in the mitochondria. Whereas in white muscle (e.g. breast muscle of a chicken) which is designed for short bursts of heavy activity, utilizes ATP during such exercise at a much greater rate than could be sustained by mitochondrial oxidation. It therefore depends more upon a readily available high-energy phosphate store (viz. creatinine phosphate) and upon the rapid generation of ATP from the conversion of glucose to lactate in the cytosol. This kind of muscle has fewer mitochondria and less myoglobin. In reality, though, there is no clear cut division between red and white muscles. In exercising white muscle, glucose is converted into 2 molecules of lactate with the generation of 2 ATP in the cytosol. Lactate diffuses into the blood circulation and is taken up by the liver where it is converted back into glucose. (Fig. 8). This cyclic process of glycolysis (e.g. in muscle) and gluconeogenesis (in liver), using glucose and lactate as transport material is known as the Cori cycle (Fig. 7 and Fig. 8).

It is important to note that operation of Cori cycle does not result in a net increase in glucose formation for the body since lactate itself is derived from glucose.
Figure 6. COUR CYLE.
However, there is a transfer of energy, since NEFA from adipose tissue are oxidized in the liver to provide ATP in gluconeogenesis in the liver. Glucose recycling from lactate formed by glycolysis in blood cells, brain and other tissues may, in normal men, correspond to 10 to 33 per cent of total glucose turnover (Cahill, Herrera, Morgan, Soeldner, Steinke, Levy, Belchard and Kipnis, 1966).
CHAPTER IV
STRESS AND GLUCOSE METABOLISM

A. Definition:
The term 'stress' has a wide range of meanings depending upon the context or the situation in which this word is being used. The Concise Oxford Dictionary (Fifth Edition, 1963), gives a definition of 'stress' as: a) a constraining or impelling force, b) an effort or demand upon energy, c) an emphasis or accentuation, d) (in mechanics) a force exerted between continuous bodies or parts of a body. However, in medicine in general, 'stress' is considered as "any stimulus of such magnitude as to tend to disrupt the homeostasis of the organism" (Doell, 1966).

B. Classification of Stress:
Stress may be classified into two types; first is physical and the other is psychological stress.

Table 3 summarized some of the different kind of stress falling into these two broad groupings.

It is very rare that one type of stress operates in isolation. It is more usual for the primary stress to lead to a secondary stress of some other type, e.g.:
1. An operation (mechanical) is followed by a decrease of food intake (nutritional).
2. An infection (physical) is followed by a decrease in food intake (nutritional).
3. An old person is feeling sad and lonely (psychological), eats less food (nutritional, physical) and is likely to succumb more easily to diseases and infections (physical).


<table>
<thead>
<tr>
<th>Psychological</th>
<th>Physical</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Environmental (e.g., unfriendly neighbours)</td>
<td>1. Nutritional (e.g., fasting, starvation)</td>
</tr>
<tr>
<td>2. Endogenous (e.g., feeling sad)</td>
<td>2. Mechanical (e.g., fracture, operation)</td>
</tr>
<tr>
<td></td>
<td>3. Climatic (e.g., temperature, humidity)</td>
</tr>
<tr>
<td></td>
<td>4. Infection and disease</td>
</tr>
<tr>
<td></td>
<td>5. Physiological (e.g., pregnancy)</td>
</tr>
<tr>
<td></td>
<td>6. Exercise</td>
</tr>
</tbody>
</table>
It is obviously impossible to study all these interactions in a limited period of time. This thesis, therefore, attempts only to study three different kinds of stress, and concentrates only on measurable physical factors.

As indicated in the examples above, nutritional stress is often a secondary consequence of other forms of stress. This secondary nutritional stress usually has a component protein energy malnutrition (PEM), whatever other deficiencies may occur. The following chapter (Chapter V), therefore, deals with PEM and its effect on glucose homeostasis and insulin production and effectiveness, as a background to observations after surgery (Part II), in obesity (Part III) and in old age (Part IV).
CHAPTER V
PROTEIN ENERGY MALNUTRITION (PEM)

A. Aetiology

PEM is a major problem in the developing world today. Dietary deficiency of protein and energy can occur acutely from a sudden failure of food supply e.g. after a natural disaster such as flood or drought, or as a result of anorexia in illness or other acute stress, or even as a result of voluntary starvation in support of some political protest. Acute and prolonged starvation have both been studied by Cahill and his co-workers (Cahill et al., 1966; Owen et al., 1969; Cahill, 1970). In reality, however, in most cases nutritional deficiency is obviously not one of total starvation but various degrees of chronic or seasonal shortage of food. Some of the earlier, simple concepts of protein and calorie (energy) deficiency in the aetiology of kwashiorkor (Williams, 1933; Platt, 1958) and marasmus (Platt, 1958; Jelliffe, 1966, respectively, have become difficult to sustain (Garrow, 1966; Gopalan, 1968). Therefore, many workers prefer to use the general term of protein calorie malnutrition or protein energy malnutrition (PEM) (Waterlow and Alleyne, 1971).

However, protein, energy supplies and metabolism cannot be separated into isolated compartments. Thus PEM is related not only to derangements of protein metabolism (Waterlow and Alleyne, 1971), but also to a decrease in the ability of the body to regulate blood glucose levels owing to associated endocrine changes (Heard, Platt and Stewart, 1958; Stewart and Heard, 1959; Heard and Stewart, 1971).
B. PEM and Blood Glucose Levels:

Malnutrition is usually associated with hypoglycaemia. Baig and Edozien (1965) reported hypoglycaemia in kwashiorkor and Hadden (1967) also found hypoglycaemia in both kwashiorkor and marasmus. The actual levels of blood glucose reported vary from one investigator to another, probably owing to different degrees of severity of the disease. The levels of fasting blood glucose in marasmic children in Hungary (when some of the children later died) was between 0 to 1.4 m mol/l (0 to 25 mg/100 ml). Kerpel-Fronius and Kaiser, 1967, while reports from Uganda on children suffering from kwashiorkor showed fasting blood glucose levels less than 2.2 m mol/l (40 mg/100 ml) (Whitehead and Harland, 1966). However, James and Coore (1970) found that in series of 26 malnourished children the mean fasting blood glucose was 3.1 m mol/l (55 mg/100 ml) initially and became 3.9 m mol/l (70 mg/100 ml) after recovery. Although the degree of hypoglycaemia was significant it was perhaps not as great as might have been expected from earlier reports from Africa and Hungary. Later, workers in Jamaica in a study designed to investigate the hypoglycaemia of PEM were somewhat foiled by the absence of any primary nutritional hypoglycaemia. Hypoglycaemia was found only when PEM had been superimposed on congenital defect and it had a tendency to persist after recovery. (Kerr, Stevens, Robinson and Picou, 1973). Most workers agreed that when a low fasting blood glucose concentration does occur, it improves with recovery from malnutrition unless sufficient energy is not provided with the rehabilitation diet (Baig and Edozien, 1965; Hadden, 1967).
There is an impairment in glucose tolerance in patients suffering from kwashiorkor (Sloane, Teltz and Glichrist, 1961; Baig and Edozien, 1965) and marasmus (Oxman, Meccioni, Zuniga, Spada and Mönckeberg, 1968), although some reported that in marasmus GTT could still be within normal limits (Hadden, 1967; Bowie, 1964). Thus the blood glucose homeostatic mechanism seems to be disturbed in both directions, i.e. in diminished ability to deal with hypo- and hyperglycaemia.

C. PEM and Insulin Levels:

It has been shown in malnourished children that the fasting plasma insulin level is usually low (James and Coore, 1970; Milner, 1971), and that the rise of plasma insulin concentrations in response to intravenous glucose load is usually small or absent. Milner (1971) further could not show any increase in plasma insulin concentration after intravenous injection of glucagon. During recovery, insulin response to glucose is significantly improved, although it is still lower than in normal children (James and Coore, 1970).

However, the impairment in insulin sensitivity rather than the actual deficiency of insulin is probably the main contributor of poor glucose tolerance (Turner, 1964; Heard and Turner, 1967; Heard and Henry, 1969). Insulin sensitivity was measured in dogs either by injecting insulin alone (0.1 unit/kg BW) or by injecting insulin (0.1 unit/kg BW) together with glucose (0.4 g/kg BW). Insulin sensitivity is defined here as the effectiveness of insulin in lowering blood glucose concentration, and is expressed as a percentage rate constant for the fall in glucose concen-
Dogs fed with low protein diet showed abnormalities in carbohydrate metabolism, but glucose tolerance was correlated significantly with insulin sensitivity and not with circulating insulin levels (Heard and Henry, 1969).
CHAPTER VI
PURPOSE OF THE STUDY

There is no doubt, therefore, that dietary stress produces an impairment in glucose homeostasis, but the mechanism and the role of insulin and other related hormones may differ from one type of stress to another. It is particularly important to understand the extent to which changes in glucose homeostasis, insulin sensitivity, etc., are adaptive and protective to the 'stressed' organism. Almost inevitably phrases like 'impairment' in glucose tolerance or in insulin sensitivity will be used in this thesis, as in many other reports, to indicate a quantitative change, but it may not necessarily mean 'impairment' in the sense of being 'harmful'.

More information is needed on the complicated and sometimes obscure relationship between stress and insulin sensitivity. A study, therefore, was planned to investigate the effects of three types of physical stress on the role of insulin and other related hormones and substrates. This work concentrates on glucose homeostasis in patients undergoing surgery, in obesity and in old age.
PART II
GLUCOSE HOMEOSTASIS IN PATIENTS AFTER SURGERY
PART II

GLUCOSE HOMEOSTASIS IN PATIENTS AFTER SURGERY
A. Trauma and Catabolism:

Surgery is a type of physical trauma which consists of a mechanical stress (the actual operation) and is then often followed by dietary restriction (nutritional stress), (see Part I, Chapter IV on stress). Because it is usually elective, it is also preceded by other stresses derived from the condition which needs the operation and creates anxiety. As will be seen later, nutritional status before an operation is, therefore, not necessarily normal. Severe trauma, as in surgery, is a negative balance of body protein associated with negative nitrogen balance, and this is reflected by the increase in urinary nitrogen excretion (Cuthbertson, 1964; Munro, 1964). However, a negative nitrogen balance could also be found in immobilized, otherwise healthy subjects (Schenheyder, Hellskov and Olesen, 1954).

It is perhaps natural to assume that this period of negative nitrogen balance is due to increased catabolism, i.e. increased breakdown of protein. However, the loss of body nitrogen is associated with a fall in protein synthesis and no real evidence of an acute rise in the breakdown rates of body protein has been found in immobilized normal persons (Schenheyder, et. al., 1954), or in patients undergoing operations (O'Keefe, Sender and James, 1974; Crane, Picou, Smith and Waterlow, 1976). This change in synthesis may result from an altered flow of substrates (i.e., amino acids and high energy phosphates and/or specific change in the rate of initiation and elongation. Each of these changes is probably mediated by endocrine balance. The regulation of protein synthesis has been extensively reviewed by Munro (1970, 1976).
This part of the thesis concentrates on endocrine changes following surgery and in particular on the relationship in glucose homeostasis between insulin and its counterregulatory hormones, cortisol and glucagon (De Bodo and Altzuler, 1958; Ensink and Williams, 1972). But these same hormones that affect carbohydrate metabolism also influence protein metabolism so that findings in one area usually have relevance to the other.

B. Anti-Insulin Hormones:

Anti-insulin hormones are defined as hormones which at physiological concentrations show anti-insulin effects. The anti-insulin effects could be in carbohydrate, fat or protein metabolism. However, this report limits itself only to hormones which have anti-insulin effects on carbohydrate metabolism. These hormones are: Adrenocorticotropic hormone (ACTH), glucocorticoids (e.g. cortisol), glucagon, growth hormone and catecholamines (e.g. epinephrine).

Stress is usually associated with increased levels in blood of circulating ACTH (Cooper & Nelson, 1962), cortisol (Yates and Urquhart, 1962; Ross, Welborn, Johnston and Wright, 1966; Cuthbertson and Thoson, 1969), glucagon (Bloom, 1973; Lindsey, Santeusano, Breeten, Faloona and Unger, 1974; Wilmore, Mayland, Pruitt, Linsey, Faloona and Unger, 1974; Russell, Walker and Bloom, 1973), growth hormone (Greenwood and Landon, 1966), and catecholamines (Walker, Zilelli, Reutter, Schoemaker, Friend and Moore, 1959). ACTH stimulates the secretion of adrenocortical hormones (e.g. cortisol), while mechanism of the actions of the other hormones in muscle, liver and adipose tissue is summarized in Table 4.
Table 4

The mechanism of action of some anti-insulin hormones in muscle, liver and adipose tissue. (Derived from Ensinck and Willians, 1972.)

<table>
<thead>
<tr>
<th>Hormones</th>
<th>Muscle</th>
<th>Liver</th>
<th>Adipose tissue</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2. Inhibits glucose utilisation</td>
<td>2. Gluconeogenesis</td>
<td>2. Lipolysis</td>
</tr>
<tr>
<td>2. Glucagon</td>
<td>1. Protein breakdown</td>
<td>1. Glycogenolysis</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>2. Gluconeogenesis</td>
<td>1. Lipolysis</td>
</tr>
<tr>
<td>3. Growth hormone</td>
<td>1. Protein synthesis</td>
<td>1. Providing precursors for glyconeogenesis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2. Inhibits glucose utilisation</td>
<td></td>
<td>2. Inhibits glucose utilisation</td>
</tr>
<tr>
<td>4. Cortisol</td>
<td>1. Protein breakdown</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2. Glycogenolysis</td>
<td></td>
<td>3. Lipolysis</td>
</tr>
<tr>
<td></td>
<td>3. Inhibits glucose utilisation</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
This report limits itself to the measurement of cortisol and its metabolites and glucagon. Epinephrine, ACTH and growth hormone were not measured.

C. Trauma and Endocrine Balance:

Increased circulating levels and excretion of cortisol are accepted as the usual consequence of many forms of stress (including surgery). Ross, et. al., 1966; Cuthbertson and Tilstone, 1969, and recently it has become increasingly evident that the same is true of glucagon (Bloom, 1973; Lindsey, et. al., 1974; Wilmore, et. al., 1974; Russell, et. al., 1975). The situation with regard to insulin seems at first glance, rather doubtful. Some have claimed that severe trauma results in depression of plasma insulin levels in relation to blood glucose values (Wilmore, et. al., 1974; Lindsey, et. al., 1974), while others reported elevated values and other signs of insulin resistance (Ross, et. al., 1966; Cuthbertson and Tilstone, 1969). However, the evidence suggests that during the acute phase, plasma insulin levels in relation to blood glucose values are indeed low (Allison, et. al., 1968; Wilmore, et. al., 1974; Lindsey, et. al., 1974), and they become elevated in the later phase of trauma (Ross, et. al., 1966; Allison et. al., 1968).

Resolution of these problems has considerable practical importance in providing the rationale for effective dietary and possibly hormonal therapy after surgery and other forms of trauma. The present investigation seeks, therefore, to delineate the time and extent of hormonal and metabolic changes after surgery.
attempt to correlate these with nitrogen balance and in particular, with the patient's insulinogenic capacity in a two hour glucose infusion test, carried out one day after the operation (day 1) and on 'recovery' (Chapter III, D. on glucose infusion.)
CHAPTER II
MATERIAL AND METHODS

A. Subjects:

1. Patients:

Eleven patients undergoing abdominal operations were studied. They were admitted to the surgical ward, University College Hospital, London. Written consent was obtained from each patient for his participation in this study. None of the patients was diabetic. Their mean age was 52 ± 3.4 years, mean height was 173 ± 2.3 cm and mean body weight was 68 ± 3.9 kg. The body weights ranged between 93 per cent and 118 per cent of the ideal weight for a given height and age (the mean was 94 ± 4.8 per cent). The ideal weight for a given height and age used for comparison was from the data of average weights of adults in Geigy Scientific Tables, 1970; based on the data of “Insured Persons in the United States” (Society of Actuaries, 1959), (Table 5).

A complete nitrogen balance was done on three of the eleven patients, while serial 24 hour urine collections were carried out on each patient. Fasting blood samples were taken from each patient during pre-operative, post-operative and 'recovery' periods. In addition to this, one day after the operation (day 1) and on 'recovery' (days 9 - 21), a two hour glucose infusion test was carried out on each patient. 'Recovery' is defined here as the time when the surgeons considered that the patients were fit enough to be sent home, and this varied from patient to patients.

2. Controls:

Four healthy young subjects were used as controls. Their mean age was 27 ± 2.3 years, mean height was 170 ± 6.3 cm, and mean body weight was 62 ±
<table>
<thead>
<tr>
<th>Patient</th>
<th>Sex (M/F)</th>
<th>Age (years)</th>
<th>Weight (kg)</th>
<th>Height (cm)</th>
<th>% of ideal weight</th>
<th>Type of operation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. HG</td>
<td>M</td>
<td>34</td>
<td>85</td>
<td>172</td>
<td>118</td>
<td>Proximal gastric vagotomy</td>
</tr>
<tr>
<td>2. HT</td>
<td>F</td>
<td>61</td>
<td>90</td>
<td>168</td>
<td>74</td>
<td>Repair previous gastrectomy, Roux-en-Y conversion</td>
</tr>
<tr>
<td>3. NT</td>
<td>M</td>
<td>60</td>
<td>75</td>
<td>178</td>
<td>95</td>
<td>Vagotomy, pyloroplasty, fundoplication and dilatation of oesophagus</td>
</tr>
<tr>
<td>4. MC</td>
<td>M</td>
<td>57</td>
<td>69</td>
<td>179</td>
<td>111</td>
<td>Prostate hypertrophy, prostatectomy</td>
</tr>
<tr>
<td>5. MD</td>
<td>M</td>
<td>32</td>
<td>56</td>
<td>175</td>
<td>73</td>
<td>Spleenomegally, splenectomy</td>
</tr>
<tr>
<td>6. NB</td>
<td>F</td>
<td>50</td>
<td>74</td>
<td>158</td>
<td>110</td>
<td>Repair of previous gastrectomy</td>
</tr>
<tr>
<td>7. BS</td>
<td>M</td>
<td>61</td>
<td>73</td>
<td>179</td>
<td>92</td>
<td>Repair of previous colostomy</td>
</tr>
<tr>
<td>8. EC</td>
<td>M</td>
<td>63</td>
<td>61</td>
<td>170</td>
<td>77</td>
<td>Carcinoma colon, colectomy and colostomy</td>
</tr>
<tr>
<td>9. CL</td>
<td>F</td>
<td>59</td>
<td>49</td>
<td>160</td>
<td>93</td>
<td>Proximal gastric vagotomy, Finney type pyloroplasty</td>
</tr>
<tr>
<td>10. WD</td>
<td>M</td>
<td>53</td>
<td>70</td>
<td>179</td>
<td>87</td>
<td>Proximal gastric vagotomy</td>
</tr>
<tr>
<td>11. WT</td>
<td>M</td>
<td>55</td>
<td>71</td>
<td>174</td>
<td>93</td>
<td>Proximal gastric vagotomy</td>
</tr>
</tbody>
</table>

Mean (± S.E.M.) 52 ± 3.4  68 ± 3.9  173 ± 2.3  94 ± 4.8

*Compared with the data from Geigy Scientific Tables (1970).
4.2 kg. The body weights ranged between 86 per cent and 100 per cent of the ideal body weight for the given height and age (the mean was 92 ± 3.2 per cent), (Table 6). There was no significant difference between either the mean absolute body weights (p > 0.05) or the mean percentage ideal body weights of the controls and the patients (92 per cent and 94 per cent). These controls received the similar two hour glucose infusion test as given to the patients.

B. Nitrogen Balance Study:

Three patients participated in this study.

1. Sample preparation:
   a. Food samples:

   The patients were asked to eat or drink only food or liquid which was given by the hospital. The amount of food offered was recorded and protein content was calculated from Food Tables (McCance and Widdowson, 1960). Nitrogen content of the food was calculated from the protein content, using the equation: 1g nitrogen equal to 6.25 g protein. Any food which was left over was collected for each 24 hour period. Special plastic bags (weights known) were used for the food collection. The left over food was then weighed, mixed with water and was homogenized in a 'Kenwood' mixer. Then it was made to 500 ml with more water, and re-homogenized. Aliquots were put into universal containers and stored at -20°C until analysed for nitrogen.
**Table 6**

Sex, age, height and body weight of control subjects

<table>
<thead>
<tr>
<th>Subjects</th>
<th>Sex (M/F)</th>
<th>Age (years)</th>
<th>Height (cm)</th>
<th>Weight (kg)</th>
<th>% of ideal weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. PW</td>
<td>F</td>
<td>22</td>
<td>159</td>
<td>54</td>
<td>100</td>
</tr>
<tr>
<td>2. WS</td>
<td>M</td>
<td>32</td>
<td>159</td>
<td>55</td>
<td>86</td>
</tr>
<tr>
<td>3. PG</td>
<td>M</td>
<td>30</td>
<td>178</td>
<td>68</td>
<td>97</td>
</tr>
<tr>
<td>4. GG</td>
<td>M</td>
<td>24</td>
<td>183</td>
<td>70</td>
<td>93</td>
</tr>
<tr>
<td>Mean (± S.E.M.)</td>
<td></td>
<td>27 ± 2.3</td>
<td>170 ± 6.31</td>
<td>62 ± 4.2</td>
<td>92 ± 3.2</td>
</tr>
</tbody>
</table>

*Compared with the data from Goigy Scientific Tables (1970)*
b. Faecal samples:

Daily faecal excretions except for a few days following the operation when there were none, were also collected. The same plastic bags (weights known) were used for these collections. These bags fitted to special tin containers which enabled the patients to perform the collections easily. The faeces were also weighed, mixed with water and were homogenized in a 'Kenwood' mixer. They were also made to 500 ml with more water and re-homogenized. Aliquots were also put into universal containers and stored at -20°C until analyzed for nitrogen.

c. Urine samples:

Urine collections were done to all of the patients. Urine was preserved with 6N HCl (20 ml/24 hour collection). After measuring the volume of each 24 hour collection, samples of urine were put into universal containers and stored at -20°C until analyzed for nitrogen. Separate aliquots for steroid estimation (see Section E, on analytical methods) had a few drops of chloroform added.

d. Calculations:

Aliquots of food and faeces and of urine were analyzed for nitrogen content. (See Section E on analytical methods.)

The daily nitrogen balance was given as:

\[ ND = (NF + NE + N(U)g)\]

where: \( ND \) = total nitrogen (g) offered in 24 hours
\[ \text{NR} = \text{total nitrogen content (g) of food residue and waste in 24 hours} \]
\[ \text{NF} = \text{total faecal nitrogen (g) in 24 hours} \]
\[ \text{Ny} = \text{total urinary nitrogen} \]

ND was calculated from food tables, while NR, NF and Ny were obtained by direct analysis. Attempts were made to have duplicate meals, one was given to the patients and the other was analyzed for nitrogen content instead of getting the values of nitrogen from food tables. But these attempts proved to be too much time and energy consuming, and the results were more or less similar to the results done through food tables and did not give any more accuracy as it was first expected.

C. Blood Samples:

1. Collection of blood and separation and storage of plasma

Fasting blood samples were taken almost every morning on the first three patients, but in the others they were taken two days before the operation, the first three days after the operation, day 8 and on 'recovery'. Fasting blood was taken at 8.30 a.m. after the patients had been fasted from midnight. Patients who were still having intravenous fluids, had normal saline substituted for glucose at midnight.
For glucagon estimation, 4.5 ml of blood was added to a heparin tube containing 0.5 ml cold solution of TrasyloL (10,000 KIU/ml Bayer) and after rapid centrifugation the supernatant was frozen immediately. The rest of the blood was put into another heparin tube and an aliquot of 0.05 ml was taken for blood glucose estimation. The tube was then centrifuged and the plasma separated. 0.05 ml of plasma was used for plasma glucose estimation and the rest was put into a polythene specimen tube and stored at -20°C until the day of estimation. Stored plasma samples were used later for estimations of plasma insulin, plasma NEFA, plasma amino acids and plasma cortisol.

2. Whole blood or plasma for glucose estimations

It has been reported that plasma glucose concentration is usually about 4 percent higher than blood glucose (Ingram, Ingram, Tustin, Sturrock and Applegarth, 1971). Plasma is the 'carrier system' which carries glucose either from gastrointestinal tract or from the liver to various tissues, including the blood cells. However, most results are usually reported in terms of blood glucose (e.g., W.H.O. definition of diabetic, etc.). In the present work, both blood and plasma glucose were measured (see Section E, on analytical methods). Although our values for plasma glucose were mostly higher than values for blood glucose, the difference was not always 4 percent as reported by Ingram et al. (1971). But we also found that with fasting values or in situations when the subjects were given insulin (see Part III and Part IV of this thesis) and the glucose concentration falls below fasting values, the blood glucose concentration is usually higher than that of plasma.

These differences in the values of plasma and blood glucose did not give any significant difference to the results of the various tests. Another benefit of measuring
plasma glucose is that it could be used as a check if there was a technical error in
the blood glucose estimation (e.g. using a wrong pipette, etc.), since when the
blood is centrifuged and plasma separated, we were not able to repeat the blood
glucose estimation. In this thesis, to avoid pointless duplication, plasma glucose
values are not included in the results.

D. Glucose Infusion:

This test was used rather than the lVGT seen in the obese (Part III) and
geriatric patients (Part IV) because it was thought to be the least burden to the
patients, especially on the day immediately after the operation (day 1). And
because continuous intravenous glucose infusion is the usual ‘dietary regime’ for
most patients during the post-operative period, therefore, the substrates and
hormonal changes would be measured in the most usual circumstances.

All glucose infusion tests were carried out in the morning. Fasting blood
was taken at 8.30 a.m. as usual. A Halter Roller pump (Extra Corporal Medical
Specialistics Ltd.) was used for infusing glucose through a butterfly needle inserted
into an ante-cubital vein of one arm. The rate of glucose infusion was 0.35 g kg⁻¹
h⁻¹ (Reaven and Farquhar, 1969), and the test lasted for two hours. Another
butterfly needle in the collateral ante-cubital vein was used for withdrawing blood
samples. Normal saline was used to fill the latter butterfly needle to prevent the
blood from clotting. Sometimes the blood did clot despite the regular flushing of
the butterfly needle with saline, and we had to find another vein to insert another
needle. This was later solved by mixing heparin (Heparin Injection BP, 1000 units/ml) with the normal saline (2000 units heparin/500 ml saline). In preliminary work this concentration of heparin appeared to be the optimum for producing constant flow of blood without clotting, while still not affecting the NEFA concentration. Stronger solution of heparin (2000 units/20 ml saline) gave very high and erratic values for plasma NEFA concentration. (The values could be as high as 3000 µmol/l to 4000 µmol/l).

After the initial fasting blood sample had been taken, further blood samples were taken at 15', 30', 60', 90' and 120' after the start of the infusion. The blood samples were treated as described in the previous section (see Section C.1. in this chapter).

E. Analytical Methods:

1. Nitrogen (N):
   
e. Food and faeces:

   Aliquots of 0.5 g of food and faecal homogenate were digested with 3 ml concentrated sulphuric acid and selenium catalyst in a Kjeldahl flask. Glass beads were used to prevent bumping. After the samples had cleared, digestion was continued for a further one hour. The samples were then allowed to cool and were diluted with distilled water to 100 ml. They were then analyzed for nitrogen by the
sodium phenate method for NH₃ in the Technicon autoanalyser, using (NH₄)₂SO₄ as standards. The nitrogen content of the standards ranged between 5 µg/ml to 150 µg/ml. Samples which fell outside the range of the standards were redigested if the final nitrogen concentration was too low, and made to more appropriate volume or the final solutions were diluted, if the concentration was too high. Samples were run in the autoanalyser at a rate of 36 seconds sampling and 48 seconds washing (Technicon).

b. Urine:
All aliquots of 0.1 ml urine were digested with 0.5 ml concentrated sulphuric acid and selenium catalyst in a Kjeldahl flask. Glass beads were also used to prevent bumping. After the samples had cleared, digestion was continued for a further half hour. They were then allowed to cool and were diluted with distilled water to 10 ml. The rest of the procedure was similar to that of nitrogen analysis for food and faecal homogenate. From time to time, analysis for nitrogen content of random samples of food and faecal homogenate and urine were done manually using the Markham method (Wootton, 1964) to compare results with those done on autoanalyser.

2. Creatinine:
Creatinine was estimated in the urine. Urine samples were diluted with distilled water (1/20 dilution) and were put into the autoanalyser (Technicon). Creatinine solutions ranged between 1.0 mg/100 ml to 15.0 mg/100 ml were used as standards. Any samples which fell outside the range of the standards had the urine rediluted and the assay
repeated. Samples were run through the autoanalyser at a rate of 36 seconds sampling and 48 seconds washing (Technician). Some urine samples chosen at random were analysed manually as a comparison to results obtained from autoanalyser.

3. Glucose:

Glucose in blood and plasma was measured enzymatically using the glucose oxidase Perid method and kit of Boehringer Corporation (London) Ltd. Aliquots of 0.05 ml of blood or plasma was mixed with 1.0 ml uranylacetate solution (160 mg/100 ml of normal saline) to precipitate the protein. After centrifugation, 200 µl of supernatant were mixed with 5 ml glucose oxidase solution. The blank (200 µl of water) and standard (200 µl of diluted Boehringer standard) were treated similarly. After standing 30 minutes at room temperature, the samples and the standard were read against the blank at 420 nm in a Unicam Spectrophotometer (Unicom SP600), using 10 mm glass cuvette. For the standard, the solution supplied with the Boehringer kit (100 mg glucose/100 ml) was diluted 1:1 with water.

4. NEFA:

The Boehringer kit for NEFA estimation was used (Boehringer Corporation, London Ltd.). Aliquots of 200 µl of plasma and standard (500 µmol/l) were mixed with 5 ml of chloroform and 1 ml of solution comprising a mixture of 0.27 M copper nitrate and 0.45 M triethanolamine buffer. For the blank, a tube containing all of the reagents but no plasma or standard was treated similarly. After 10 minutes shaking and 5 minutes centrifugation at 3000 RPM, the supernatant together with interfacial protein layer were removed by aspiration. A 2 ml aliquot of the remaining
chloroform extract was then added to 0.2 ml of 9 mM diethyl-dithiocarbamate. The samples and the standard were read against the blank in a Unicam spectrophotometer (Unicam SP600) at 436 nm, using 10 mm glass cuvette.

In the later part of this work, we observed that the reading of the standard in the spectrophotometer was getting lower and lower, resulting in apparent higher values of NEFA concentration in the plasma samples we were analysing. It was found out later that the standard supplied with the kit, contained less than the amount indicated in the label (500 μmol/l). We had to repeat some of our last few NEFA assays using palmitic acid (488 μmol/l) as the standard. A complaint was sent to Boehringer Corporation (London) Ltd. Their head office (Mannheim, West Germany) confirmed our findings. They apologised, promised to withdraw the faulty standard, and also promised us some compensation. They did send the compensation, unfortunately there were only few new NEFA kits. From then on, we always used palmitic acid (488 μmol/l) as the standard.

5. Insulin:

Plasma insulin was estimated by the radioimmuno assay method of Hales and Randle (1963), using the kit supplied by the Radiochemical Centre, Amersham, England. The method is based on a principle that the insulin in plasma and in standard solutions compete with the added radioactive insulin (125I-insulin) for reaction with an antibody specific to insulin. The insoluble insulin-antibody complex which is formed, is filtered out and measured for radioactivity. The level of radioactivity in the filter paper is related in an inverse manner to the amount of insulin.
The amount of unlabelled insulin present in plasma is calculated as follows:

\[
\frac{C_0}{C_1} = \frac{1}{\frac{1}{I} + 1}
\]  \hspace{1cm} (Fig. 9)

Where:

- \( I \) = the concentration of unlabelled insulin
- \( \frac{1}{I} \) = the slope of the line
- \( C_0 \) = the radioactivity of insulin-antibody complex when the concentration of unlabelled insulin is zero
- \( C_1 \) = the radioactivity of insulin-antibody complex when the concentration of unlabelled insulin is \( I \)

\( C_0/C_1 \) is linearly related to \( I \). In practice, the slope of the line is obtained by having a series of standard solutions made from human insulin standard provided by the kit. The standard solution ranged between 5 \( \mu \text{unit/ml} \) to 244 \( \mu \text{unit/ml} \), and any samples which fell outside this range had to have the assay repeated. The plasma had to be diluted if the concentration was too high, or a larger amount of plasma sample was needed if the concentration was too low. An aliquot of 0.05 ml of plasma was used in this assay. In addition to this, a solution of unlabelled human insulin (40 \( \mu \text{unit/ml} \)) was made, put into a series of polythene tubes and stored at -20\(^\circ\) Centigrade. This unlabelled human insulin solution was always included in each insulin assay and served as a quality control, and one batch of quality control overlapped with the next batch.

The counting of radioactivity was done using a well type X-scintillation counter (ECKO Electronics Ltd., England).
Figure 9. Radio-immuno assay of Insulin with Insulin-antibody Precipitate.

Theoretical relationship between the ratio of the radioactivities in the insulin-antibody complex in the absence and presence of unlabelled insulin. (See details given in the text).

$C_0^r$ - radioactivities in the insulin-antibody precipitate in the absence of unlabelled insulin.

$C_1^r$ - radioactivities in the insulin-antibody precipitate in the presence of unlabelled insulin.

(from Hales and Randle, 1963).
4. Plasma Amino Acids:

Plasma amino acids were estimated using the ninhydrin method (Spackman, Stein & Moore, 1958) in an amino acid analyser (Locarte, England).

7. Glucagon:

Plasma glucagon was measured by radioimmuno-assay using a pancreatic glucagon specific antiserum (Russell et al., 1975).

8. Corticosteroids:

a. Plasma cortisol:

Plasma cortisol was measured by the competitive binding method of Few and Cashmore (1971).

b. Urinary free cortisol:

Urinary free cortisol was measured similarly to plasma cortisol but the extracted cortisol was purified by paper chromatography and losses monitored by the addition of $^{14}$C-cortisol.

c. Urinary 17-OH-corticosteroids:

These steroids were measured by the sodium borohydride reduction, sodium periodate oxidation method (Gray, Baron, Brooks and James, 1969).

F. Assessment of the Data:

Paired t test (Armitage, 1971) was used in assessing changes within the patients. The ordinary student's t test was used when comparing data from the patients with those of the controls.
CHAPTER III
RESULTS

A. Nitrogen Balance:

A complete nitrogen balance study in three patients indicated the extent and
duration of negative balance which was equivalent to about 50 g protein loss per day,
for a period of 5 to 6 days after the operation. Since during the first part of this
period the patients neither received food nor had any faecal losses, urinary (nitrogen)
excretion adequately reflected the changes in the (negative) balance. However, this
figure did not include the amount of blood transfusion (if any) or blood loss. The mean
nitrogen balance in the three patients is shown in Fig. 10.

By day 10, a positive nitrogen balance had been re-established with a fall in
urinary nitrogen excretion and an increase in food intake.

B. Urinary Nitrogen Excretion:
The 24 hour urinary nitrogen excretion showed an increase during the period
following the operation. The mean values for eleven patients showed that the
increases were significant compared to the mean pre-operative levels, on days 1, 2
and day 3 (p < 0.05, paired t test), and a significant decrease on day 6 (p < 0.01,
paired t test) (Fig. 10).

C. Faecal Nitrogen Excretion:

During the days immediately following the operation, there was no faecal
excretion. Table 7 shows the daily values of faecal nitrogen excretions in the three
patients studied.
Figure 10. Mean (± SEM) 24 hour urinary nitrogen excretions in 11 patients (vertical lines), and mean nitrogen balance in 3 patients (vertical blocks) before and after operation.

There were significant increases (from preoperative values) in urinary nitrogen excretions on day 1, 2 and 3 \( (p < 0.05) \), and a significant decrease on day 6 \( (p < 0.01) \) (paired t test).
### Table 7

**Daily faecal nitrogen excretion in *Helicobacter pylori***

<table>
<thead>
<tr>
<th>Subject</th>
<th>-3</th>
<th>-2</th>
<th>-1</th>
<th>Operation</th>
<th>Day (g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MG</td>
<td>2.1</td>
<td>2.2</td>
<td>3.4</td>
<td></td>
<td>2.2</td>
</tr>
<tr>
<td>HT</td>
<td>3.8</td>
<td>6.3</td>
<td>0.4</td>
<td></td>
<td>3.4</td>
</tr>
<tr>
<td>NT</td>
<td>1.3</td>
<td>0.7</td>
<td></td>
<td></td>
<td>0.2</td>
</tr>
</tbody>
</table>

- = no faecal excretion
blank = not measured
D. Urinary Creatinine Excretion:

The 24-hour urinary creatinine excretion in eleven patients followed closely the pattern of urinary nitrogen loss. There were significant increases from the mean pre-operative levels on days 1, 2 and 3 (p < 0.05, paired t test), and significant decreases on days 5 and 6 (p < 0.05, paired t test). Fig. 11 shows the daily values of urinary creatinine excretion in the eleven patients studied.

E. The Relationship between Nitrogen Balance and Daily Hormonal and Substrate Values:

1. Plasma insulin:

   The period of negative nitrogen balance coincided with increased fasting plasma insulin level, although it was only on day 1 that the difference between the values reached a significant level (p < 0.05, paired t test) (Table 8).

2. Plasma glucagon:

   The fasting plasma glucagon level was also significantly raised from pre-operative levels in the first few days after the operation (paired t test) (Table 8).

3. Plasma cortisol:

   The fasting plasma cortisol level, like insulin, was significantly raised from pre-operative levels only on day 1 (p < 0.05, paired t test) (Table 8).

4. Urinary steroids:

   The 24-hour excretion of urinary 17-OH-corticosteroids, however, was significantly raised for the first few days after the operation (paired t test) (Fig. 12), as also was the 24-hour urinary free cortisol excretion (paired t test) (Fig. 12).
There were significant increases (from preoperative values) on day 1, 2 and 3 ($p < 0.05$), and significant decreases on day 5 and 6 ($p < 0.01$ and $p < 0.05$ respectively).
Table 8

Mean fasting levels of blood glucose, plasma insulin, plasma glucagon, plasma cortisol and NEFA in patients and controls (± SEM). Paired t test was used for comparing pre-operative values with the values on the days following the operation.

<table>
<thead>
<tr>
<th>POST-OPERATION</th>
<th>No. of patients</th>
<th>Pre-operation</th>
<th>Day 1</th>
<th>Day 2</th>
<th>Day 3</th>
<th>Day 8</th>
<th>'Recovery'</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood glucose (mmol/l)</td>
<td>10</td>
<td>5.3±0.14</td>
<td>5.9±0.23</td>
<td>5.6±0.37</td>
<td>5.6±0.30</td>
<td>5.6±0.15</td>
<td>5.1±0.15</td>
<td>5.1±0.35</td>
</tr>
<tr>
<td>Plasma insulin (unit/ml)</td>
<td>10</td>
<td>16±0.8</td>
<td>25±2.2</td>
<td>24±4.0</td>
<td>18±3.1</td>
<td>20±2.5</td>
<td>16±1.8</td>
<td>15±2.5</td>
</tr>
<tr>
<td>Plasma glucagon (ng/l)</td>
<td>10</td>
<td>60±10.0</td>
<td>173±35.1</td>
<td>136±24.1*</td>
<td>64±19.6</td>
<td>66±16.3</td>
<td>35±12.1</td>
<td>35±12.3</td>
</tr>
<tr>
<td>Plasma cortisol (nmol/l)</td>
<td>9</td>
<td>399±26.5</td>
<td>486±57.1</td>
<td>282±30.1</td>
<td>339±18.2</td>
<td>386±36.2</td>
<td>315±19.6</td>
<td>306±12.3</td>
</tr>
<tr>
<td>NEFA (mmol/l)</td>
<td>9</td>
<td>357±58</td>
<td>625±75</td>
<td>432±56*</td>
<td>432±56*</td>
<td>465±18</td>
<td>459±100</td>
<td>500±197</td>
</tr>
</tbody>
</table>

Significant difference: *p<0.05; **p<0.01; ***p<0.001. (Paired t test)
Figure 12. Mean values of 24 hour urinary excretions of 17-OH-corticosteroids in 10 (± SEM), and free cortisol in 5 patients:

There were significant increases (from preoperative values) in urinary 17-OH-corticosteroids on day 1, 2 and 3 \( (p < 0.05) \), and in urinary free cortisol on day 1 and 2 \( (p < 0.05) \) (paired t test).
mg 17-OH-CORTICOSTEROIDS, $10^{-1}$ x ug FREE CORTISOL / 24 h.

DAYS

FREE CORTISOL

URINARY

17-OH-CORTICOSTEROIDS

OPERATION
5. Blood glucose:

The fasting blood glucose level, like insulin, was significantly raised from pre-operative level only on day 1 (p < 0.05, paired t test) (Table 8).

6. Plasma NEFA:

The fasting plasma NEFA concentration was significantly raised from pre-operative level during the first few days following the operation (paired t test) (Table 8).

7. Plasma amino acids:

There was a decrease in the levels of fasting total plasma amino acids. However, fasting levels of plasma leucine, iso-leucine and valine were raised in concentration (Table 9).

These substrate and hormonal changes in relation to nitrogen balance are shown in Fig. 13 for one patient (HG).

The overall picture is one of an acute rise in blood glucose, and in plasma insulin and cortisol on day 1 after the operation. This may be compared with the sustained changes lasting for about the period of the negative nitrogen balance, in plasma glucagon, in urinary glucorticoids excretion in plasma amino acid and NEFA concentrations.
Table 9

Daily values of fasting plasma amino acids in patients and controls (± SEM). During the first few days after the operation, there was a decrease in the fasting levels of total plasma amino acids, but an increase in the fasting levels of leucine, isoleucine and valine.

<table>
<thead>
<tr>
<th>Subjects</th>
<th>Pre-operation</th>
<th>Day 1</th>
<th>Day 2</th>
<th>Day 3</th>
<th>Day 4</th>
<th>Day 8</th>
<th>'Recovery'</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>TOTAL PLASMA AMINO ACIDS (µmol/l)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HT</td>
<td>2152</td>
<td>1545</td>
<td>1614</td>
<td>1431</td>
<td>2139</td>
<td>2412</td>
<td></td>
</tr>
<tr>
<td>NT</td>
<td>2581</td>
<td>2045</td>
<td>1973</td>
<td>1838</td>
<td>1810</td>
<td>2115</td>
<td>2675</td>
</tr>
<tr>
<td>MC</td>
<td>2391</td>
<td>2260</td>
<td>2222</td>
<td>2567</td>
<td>2884</td>
<td>2686</td>
<td>2201</td>
</tr>
<tr>
<td>MD</td>
<td>3678</td>
<td>2501</td>
<td>2501</td>
<td>3108</td>
<td>1991</td>
<td>3037</td>
<td></td>
</tr>
<tr>
<td>NB</td>
<td>2333</td>
<td>2689</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3469</td>
</tr>
<tr>
<td>Controls</td>
<td>2893 ± 175 (n = 4)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ISO-LEUCINE (µmol/l)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HT</td>
<td>45</td>
<td>46</td>
<td>62</td>
<td>71</td>
<td>83</td>
<td>73</td>
<td>84</td>
</tr>
<tr>
<td>NT</td>
<td>54</td>
<td>73</td>
<td>81</td>
<td>95</td>
<td>113</td>
<td>65</td>
<td>81</td>
</tr>
<tr>
<td>MC</td>
<td>62</td>
<td>63</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MD</td>
<td>83</td>
<td>63</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NB</td>
<td>64</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Controls</td>
<td>52 ± 10.1 (n = 4)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>LEUCINE (µmol/l)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HT</td>
<td>81</td>
<td>97</td>
<td>101</td>
<td>104</td>
<td>73</td>
<td>107</td>
<td></td>
</tr>
<tr>
<td>NT</td>
<td>153</td>
<td>147</td>
<td>163</td>
<td>166</td>
<td>174</td>
<td>150</td>
<td>109</td>
</tr>
<tr>
<td>MC</td>
<td>126</td>
<td>137</td>
<td>167</td>
<td>176 *</td>
<td>193</td>
<td>146</td>
<td>132</td>
</tr>
<tr>
<td>MD</td>
<td>148</td>
<td>167</td>
<td></td>
<td></td>
<td>222</td>
<td>119</td>
<td>185</td>
</tr>
<tr>
<td>NB</td>
<td>135</td>
<td>160</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>140</td>
</tr>
<tr>
<td>Controls</td>
<td>114 ± 11.6 (n = 4)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>VALINE (µmol/l)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HT</td>
<td>120</td>
<td>148</td>
<td>156</td>
<td>168</td>
<td>107</td>
<td>107</td>
<td>162</td>
</tr>
<tr>
<td>NT</td>
<td>205</td>
<td>207</td>
<td>219</td>
<td>210</td>
<td>223</td>
<td>211</td>
<td>139</td>
</tr>
<tr>
<td>MC</td>
<td>231</td>
<td>224</td>
<td>256</td>
<td>270</td>
<td>327</td>
<td>230</td>
<td>232</td>
</tr>
<tr>
<td>MD</td>
<td>259</td>
<td>276</td>
<td></td>
<td></td>
<td>342</td>
<td>207</td>
<td>286</td>
</tr>
<tr>
<td>NB</td>
<td>274</td>
<td>322</td>
<td></td>
<td></td>
<td></td>
<td>277</td>
<td></td>
</tr>
<tr>
<td>Controls</td>
<td>195 ± 17.7 (n = 4)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Figure 11. Daily values before and after the operation for one patient (HG) showing changes in nitrogen balance, in urinary 17-OH-corticosteroids excretion, and in fasting concentrations of glucagon, insulin, cortisol, glucose and NEFA in plasma.
Except for the fasting levels (p < 0.05), there was no significant difference between the glucose values at any one time in Infusion I (day 1) and at the same time in Infusion II ('recovery'), but there was a trend to a higher 2-hour level on day 1 (12.08 m mol/l against 10.36 m mol/l). However, both curves were significantly higher than in normal subjects where the mean blood glucose levels reached a plateau at 6.07 m mol/l, Fig. 14).

Glucose infusion caused a substantial fall in plasma glucagon concentration (Fig. 14) but because of the higher fasting glucagon levels, plasma glucagon levels continued to be significantly higher during the infusion on day 1 than at similar times during the infusion done on 'recovery' (p < 0.05). Similarly, the mean glucagon curve during infusion on 'recovery' was higher than in controls, but the difference was not statistically significant (p > 0.05).

Infusion of glucose also decreased the levels of plasma NEFA, total plasma amino acids and plasma cortisol on both occasions in the patients and also in the controls (Table 10), but the changes in plasma cortisol during glucose infusion in controls were not significantly different from those found in normal subjects at rest (J. D. Few, unpublished data).

Plasma insulin levels during glucose infusion were significantly higher on day 1 than on 'recovery' both in respect to the fasting levels (p < 0.001) and the levels reached during glucose infusion, in which a significant difference was reached at 30 minutes (p < 0.05). At both times the patients had levels which were significantly higher than those of the normal controls. A significant difference between the patients'...
Figure 14. Mean (± SEM) blood glucose, plasma insulin and plasma glucagon concentrations during 2 hour glucose infusion (0.55 g Kg⁻¹h⁻¹) in patients’ infusion I (Δ), patients’ infusion II (O) and infusion of controls (□).

Significance of differences:

Fasting values: See Table 8.

Glucose concentration: Infusion I x infusion II, non significant. Infusion I and II x controls, from 60' p < 0.01.

Insulin concentration: Infusion I x infusion II, from 30' p < 0.05. Infusion II x Controls, from 90' p < 0.05.

Glucagon concentration: Infusion I x infusion II, all times p < 0.05. Infusion II x controls, non significant.

The data were from 10 patients and 4 healthy control subjects. The paired t test was used for comparing values in patients’ infusions I and II, and Student’s t test for comparison of patients and control subjects.
Table 10

The effect of 2 hour glucose infusion (0.35g kg\(^{-1}\) h\(^{-1}\)) on NEFA, total amino acids and cortisol levels in plasma of patients and controls (± SEM). Student's t test was used for comparing mean values between controls' and patients' infusion I (II) and between controls' and patients' infusion II (III). Paired t test was used for comparing values within individuals.

<table>
<thead>
<tr>
<th></th>
<th>Plasma NEFA (nmol/l)</th>
<th>Total plasma amino acids (nmol/l)</th>
<th>Plasma cortisol (mnmol/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Fast</td>
<td>Post infusion</td>
<td>Fast</td>
</tr>
<tr>
<td>Infusion I</td>
<td>624 ± 75</td>
<td>132 ± 20</td>
<td>2208 ± 192</td>
</tr>
<tr>
<td>No. of patients</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infusion II</td>
<td>439 ± 103</td>
<td>121 ± 36</td>
<td>2579 ± 179</td>
</tr>
<tr>
<td>Controls</td>
<td>500 ± 197</td>
<td>208 ± 67</td>
<td>2803 ± 175</td>
</tr>
<tr>
<td>No. of controls</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Significant differences: *p < .05; **p < .01; ***p < .001
Infusion I and controls' infusion was reached at 30 minutes (p < 0.01), and between patients' Infusion II and controls' Infusion at 90 minutes (p < 0.05) (Fig. 14).

Although the high levels of plasma insulin during the glucose infusion were associated with a higher level of blood glucose, the insulin levels tended to be higher for a given glucose value in the immediate post-operative period. Thus after 1 hour the mean blood glucose levels in the patients' two infusions were identical (Fig. 14) but the corresponding insulin values in the immediate post-operative state were almost twice those found in 'recovery'.

Fig. 15 shows the regression lines between plasma insulin and blood glucose concentrations during glucose infusion of controls and during infusion I and II of patients. A given glucose level tended to be associated with a higher insulin level in Infusion I than in Infusion II of the patients, and higher in Infusion II of the patients than in control infusions.
Figure 1b. Regression lines between plasma insulin and blood glucose concentrations during patients' infusion I, patients' infusion II and infusion of controls.

Data from 10 patients and 4 healthy control subjects.
CHAPTER IV
DISCUSSION

When surgery is followed by a period of dietary deprivation, alleviated only by the use of intravenous glucose, patients obviously suffer from both acute protein and energy deficiency. This is manifested by negative nitrogen balance and an increase in the levels of those hormones and metabolites known to change in response to starvation.

Increased levels of glucagon, which promote rapid mobilization of fuel from carbohydrate, fat and protein (Foa, 1972 and cortisol, which affects gluconeogenesis (De Bodo and Altzuler, 1958) are features of the body's response to fuel shortage. The increased output of urinary nitrogen in the face of a falling protein intake illustrates the effectiveness of energy mobilization and gluconeogenesis, which have a priority in the short term over protein retention.

The major difference between the effects of surgery and those of fasting in otherwise healthy subjects may lie in the insulin response. The immediate acute response to surgery is the same as to starvation, i.e. reduced levels of plasma insulin. After surgery this is followed by a period in which basal plasma insulin levels are raised (Lindsey, et. al., 1974) and we have found that glucose infusion results in an elevated insulin:glucose ratio compared with ratios found on recovery or in normal control subjects (Fig. 15). Therefore, the apparent discrepancies between reports of low insulin:glucose ratios and ours of high ratios, are indeed related to the time of observation.
During the initial acute phase of trauma, insulin secretion is probably blocked by the high circulating levels of catecholamines (Cerasi, Luft and Efendie, 1971). Our measurements were made, however, 24 hours after surgery at a time when the nutrient supply may well dominate the hormonal response.

The elevated levels of basal plasma insulin and high values for the insulin:glucose ratio in our patients can be interpreted as a compensation in insulin output as a result of peripheral insulin resistance (Porte, 1975). This resistance may be an innate response to trauma since patients after surgery when infused with amino acid solution alone, though having lower absolute levels of insulin and glucose, have the same insulin:glucose ratio as patients receiving parenteral glucose (Blackburn, Flatt, Clowes and O'Donnell, 1973). In the early stages after surgery, analgesia and the degree of surgical trauma certainly play a role in the metabolic response of hepatic and peripheral tissues (Long, Spencer, Kinney and Geiger, 1971; Wiklund and Jorfeldt, 1975). High circulating levels of catecholamines can induce lipolysis (Rosell, 1966), blockade the release of insulin (Cerasi et al., 1971) and stimulate the output of glucose from the liver (Beam, Billing and Sherlock, 1951). Appropriate analgesia in the post-operative period can reduce the circulating NEFA and glucose levels and the rate of release of glucose from the liver (Wiklund and Jorfeldt, 1975). Elevated levels of NEFA may themselves be expected to induce a reduction in the rate of glucose outflow from the circulation with the glucose intolerance and insulin resistance (Randle, Hales, Garland and Newsholme, 1963; Balasse and Neef, 1974) although our NEFA results are not particularly high. Thus, overproduction of glucose by the liver and slower uptake by the periphery may both lead to increase blood glucose levels and an altera-
tion in either process may be responsible for evidence of insulin resistance (Felig and Wahren, 1975).

This resistance seems to take some time to return to normal. There was no evidence of obesity in the patients, a condition which would explain a persistently low glucose tolerance and high insulin:glucose ratio (see Part II of this thesis). Furthermore, the age of the patients would lead one to expect lower insulin:glucose ratios (see Part IV of this thesis). The persisting increase in plasma glucagon in the patients studied in the "recovery" phase argues against their hormonal status having returned completely to a pre-operative level despite being studied two weeks after surgery.

The demonstration of high circulating levels of glucagon after surgery is in keeping with the results of other studies of patients in the post-operative phase (Lindsey et al., 1974; Russell et al., 1975). The elevation of glucagon persists despite the mildly raised blood glucose level but the glucose infusion led to a suppression of glucagon towards normal. This impaired suppression presumably reflects the resistance in the response of the $\alpha$-cell to glucose and may be part of the more generalised insulin resistance at a cellular level (Samols, Tyler and Merkes, 1972).

While glucagon itself may play an important role in the control of gluconeogenesis and glucose production, there is increasing evidence that its role in producing hyperglycaemia depends on insulin deficiency itself and the glucagon:insulin ratio as being of less importance in the pre-diabetic state (Sherwin, Fesher, Handler and Felig, 1976). Thus enhanced hepatic glucose output after surgery may reflect either a direct short term effect of catecholamines or glucagon on glycogenolysis or the combined
effects of insulin resistance and hyperglucagonaemia on gluconeogenesis. The additional role of enhanced corticosteroid secretion in stimulating gluconeogenesis probably operates over the 4-5 days after surgery as judged from the urinary data (Fig. 12).

It is not possible from the present evidence to quantitate the relative roles of hepatic overproduction of glucose and peripheral resistance to glucose uptake and oxidation despite the use of an infusion of glucose which might be expected to repress hepatic gluconeogenesis. Our infusion rate was approximately five times the basal glucose turnover rate in normal man (Bower and Moorhouse, 1973) and it seems very unlikely in healthy controls that this quantity of glucose did not suppress gluconeogenesis (Madison, 1969). In favour of the suppression of hepatic glucose production in our patients, as well as in the controls during glucose infusion were the similar falls in glucagon, NEFA and amino acid levels, but we have no direct evidence that substrate supply for gluconeogenesis became rate limiting, or that the peripheral tissues were more or less sensitive to insulin than the hepatic cell.

A diminished protein synthetic rate post-operatively (O'Keefe et al., 1974; Crane, et al., 1976) might be the result of insulin resistance, but this aspect of protein metabolism requires further investigation. The net increase of protein breakdown is shown by the increased fasting plasma levels of branched-chain amino acids (Table 9). The rise of these amino acids, however, may not be specific to this phenomenon since prolonged starvation alone may also give a similar or even a greater rise (Adibi, 1968; Felig, Owen, Wahren and Cahill, 1969).
Therapeutic attempts to compensate for insulin resistance, assuming the resistance is undesirable, have sometimes taken the form of massive insulin administration (Hinton, Allison, Littlejohn and Lloyd, 1971). Insulin sensitivity may differ between various organs and tissues and even between different actions of insulin within the same tissue. This suggests caution in the use of insulin. Furthermore, it could even be argued that insulin resistance protects the subject from the less desirable feature of elevated insulin levels. An alternative approach would be to give parenteral amino acids rather than glucose (Blackburn, et al., 1973). The lower levels of insulin induced by amino acid infusions would permit more ready mobilization of lipids and, therefore, allow the conservation of protein and glucose. Interestingly, plasma NEFA levels in our patients given glucose were not particularly high. If, however, the development of insulin resistance places the patient at a disadvantage, this could be countered not only by giving insulin but also by blocking the release of insulin antagonists. It has been shown that surgery under morphine anaesthesia is not accompanied by the usual elevation of plasma cortisol and growth hormone concentration, and that the lack of adreno-cortical stimulation had no adverse clinical effect (George, Reier, Lanese and Rower, 1974).

It is shown, therefore, that after surgery, metabolic responses have some elements in common with starvation, but exacerbated and modified by hormonal stress responses. Similarly, there are resemblances with the diabetic, e.g. in hyperglucagonaemia, but in surgical patients the suppressibility of glucagon with glucose, possibly via elevated insulin levels, marked a clear distinction between the two states.
PART III
GLUCOSE HOMEOSTASIS
IN
OBESITY
CHAPTER I
INTRODUCTION

A. Definition:

Obesity is defined as a state in which an excessive amount of fat accumulates and where the body weight exceeds by at least 20 per cent the normal or desirable weight for a given height and age (i.e. 'ideal body weight') (Stern and Hirsch, 1972; Davidson, Passmore, Brock and Truswell, 1975). Others take 10 per cent above the ideal weight as the upper limit for normal weight, (Craddock, 1973). In the present work 'ideal' body weight for a given height and age was derived from the data of average weights of adults in Geigy Scientific Tables (1970). These are based on the data of insured persons in the United States (Society of Actuaries, 1959). Some may not agree with the use of relative excess of body weight as an indication of obesity, since this excess of body weight may not necessarily be fat (Lesser, Deutsch and Markofsky, 1971). But as a practical measure, most authorities accept the use of this parameter, since it is true to say that, in most cases (apart from a few pathological conditions, e.g. oedema) the higher the relative body weight, the higher the body's fat content (Garrow, 1974).

B. Problem of Obesity:

Millions of people in the developing world suffer and die from inadequate food intake, while ironically, millions of their counterparts in the western countries are in the opposite situation. They eat a lot and some even too much, and have too little physical exercise, which inevitably leads to obesity.
To some, obesity simply means an aesthetic problem, yet to many it comes as a serious health hazard. Obesity is known to be related to several diseases, e.g. diabetes (Joslin, 1921; Smith and Levine, 1964); hypertension (Marks, 1970); cardiorespiratory failure (Barleyne, 1958); and many others. Not surprisingly, therefore, obesity is also related to an increase in the rate of mortality and morbidity (Marks, 1970).

C. Aetiology of Obesity:

The question is inevitably asked whether obesity is always a simple problem of overeating and lack of physical exercise. The answer obviously would not be as simple as that.

Under normal conditions, the body is capable of regulating its energy balance quite accurately and the body weight of a healthy adult remains relatively steady. The human body has the ability to interrupt its food intake. Therefore, it is capable of having meals at certain times of the day, rather than as repeated small snacks, and thus it is able to do creative work during the day and have long intervals of sleep at night. All this is possible only because of the body’s ability to store energy when it is available in excess of immediate requirements, and use it later when external energy supply falls below its requirements. However, interestingly in other higher primates such as gorillas and orang-utans, they spend most of their day time foraging for food and this is interrupted only by brief periods of rest and sex. This may be due to the type of food they eat rather than a major physiological difference the apes and man. The apes do not eat high energy density foods as humans do, therefore, they have to eat a lot to be able to meet their energy requirements.
For some curious reasons, our delicate energy balance can be disrupted resulting in an excessive amount of energy being stored, i.e. more than will be used in the interval before the next meal. This extra energy is stored mostly in the form of fat in adipose tissue. This may be the result of simple over eating, either caused by social pressure or other psychological stress; or may be due to something much more complicated and have an actual organic cause resulting in metabolic malfunctions. The latter could be of genetic, hypothalamic or endocrine origin (Mayer, 1957). This work does not attempt to investigate these complicated forms of obesity, although from the range of patients we studied, such forms of obesity cannot be excluded.

D. Insulin's Role in Obesity:

Excessive energy is stored mostly in adipose tissue as triglyceride. In fact 80 to 85 per cent of adipose tissue in an adult consists of triglyceride (Craddock, 1973). In the presence of insulin, fat synthesis is enhanced, while when insulin is absent, glucose enters adipocytes less easily and the supply of lipogenic precursors is diminished. At the same time lipolysis in adipose tissue is accelerated.

It is known that obesity is usually related to insulin resistance (Franckson, Malaisse, Amouil, Rasio, Oams, Balasse, Conrad and Bastenie, 1966; Chlouverakis, and White, 1969), and is associated with hyperinsulinaemia (Beck, Koumans, Winterling, Stein, Daughaday and Klipnis, 1964; Franckson et. al., 1966; Perley and Klipnis, 1966; Chiles and Tzagourlis, 1970). Insulin resistance could be defined here as the relative inability of insulin either endogenous or exogenous, to lower the blood glucose concentration. The glucose tolerance test in obesity may sometimes still be
within the normal limits (Perley and Kipnis, 1964) but most often it is impaired (Paullin and Sauls, 1922; Beck et al., 1964; Perley and Kipnis, 1966; Chiles and Tzagoumis, 1970). Whether the degree of insulin resistance correlates with the degree of obesity and whether the amount of circulating insulin may in a way be the major factor in contributing to obesity, are being investigated in this work. This work concentrates mainly on the role of insulin in obese subjects faced by a glucose load, either oral or intravenous (iv), and compares them with the data collected from young normal adults. This work was not planned as an attempt to unravel the mysteries of obesity. Rather, the studies were planned to extend the range of conditions exhibiting altered glucose tolerance, insulin sensitivity and plasma insulin levels. Insofar as the obesity is known to be associated with varying degrees of diminished glucose tolerance and increased insulin resistance and enhanced insulinogenic response to glucose, the biochemical signs of obesity are similar to those of the post-surgical patients. Yet such patients suffer from undernutrition while the obese struggle with overnutrition. It was hoped to find some clues why these very different nutritional states end up with a similar metabolic picture.
A. Subjects:

1. Patients:

Twenty nine patients were studied (Table 11). Their mean age was $40 \pm 2.9$ years, their mean height was $165 \pm 6.5$ cm, their mean body weight was $109 \pm 5.5$ kg and they ranged from 115 per cent to 233 per cent of their ideal body weight (the mean was $166 \pm 6.7$ per cent). These patients were either from the obesity clinic, University College Hospital, or patients admitted from this clinic to the metabolic ward (Manson Ward, Hospital for Tropical Diseases), both of the University College Hospital Group. The patients were asked whether apart from their course of treatment, they would be willing to consider participating in our study. It was then explained in detail what kinds of tests were going to be involved in their study, and consent (oral or written) was obtained. None of the patients were known diabetic and all had fasting blood glucose concentrations less than $6.11 \text{ mmol/l} (110 \text{ mg/100 ml})$. $6.11 \text{ mmol/l}$ is the upper limit for normal fasting blood glucose recommended by a working party appointed by the College of General Practitioners, England (1963). None of the patients had glycosuria.

The daily energy intake of the out-patients prior to the tests was not studied, but from information given by the patients it was estimated at between 8.4 and 12.6 MJ/day (2000 to 3000 Calories/day) including a reasonable carbohydrate intake. Patients who were admitted to the ward, received a diet of 8.4 MJ/day (2000 Calories/day) with a carbohydrate content of 200 g/day, for 3 to 4 days before they underwent
## Table 11

List of Obese Patients

<table>
<thead>
<tr>
<th>Subject</th>
<th>Sex</th>
<th>Age (years)</th>
<th>Height (cm)</th>
<th>Weight (kg)</th>
<th>% Ideal body weight*</th>
<th>Oral GTT (20 patients)</th>
<th>Iv GTT and Iv GTT (10 patients)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CF</td>
<td>F</td>
<td>31</td>
<td>156</td>
<td>67</td>
<td>141</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>CL</td>
<td>F</td>
<td>28</td>
<td>175</td>
<td>159</td>
<td>218</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>QR</td>
<td>F</td>
<td>41</td>
<td>168</td>
<td>79</td>
<td>115</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>BL</td>
<td>F</td>
<td>45</td>
<td>162</td>
<td>91</td>
<td>140</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>PF</td>
<td>M</td>
<td>56</td>
<td>179</td>
<td>114</td>
<td>142</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>DB</td>
<td>F</td>
<td>50</td>
<td>162</td>
<td>103</td>
<td>156</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>SW</td>
<td>F</td>
<td>37</td>
<td>154</td>
<td>79</td>
<td>130</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>DR</td>
<td>F</td>
<td>43</td>
<td>159</td>
<td>81</td>
<td>134</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>SZ</td>
<td>F</td>
<td>17</td>
<td>157</td>
<td>71</td>
<td>129</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>BK</td>
<td>F</td>
<td>48</td>
<td>156</td>
<td>132</td>
<td>218</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>KM</td>
<td>F</td>
<td>68</td>
<td>154</td>
<td>124</td>
<td>202</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>OF</td>
<td>F</td>
<td>18</td>
<td>168</td>
<td>122</td>
<td>207</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>RA</td>
<td>M</td>
<td>50</td>
<td>178</td>
<td>178</td>
<td>218</td>
<td>Yes</td>
<td>No Insulin not measured</td>
</tr>
<tr>
<td>MC</td>
<td>M</td>
<td>29</td>
<td>169</td>
<td>132</td>
<td>192</td>
<td>Yes</td>
<td>No Insulin not measured</td>
</tr>
</tbody>
</table>

*Compared with the data from Guy's Scientific Tables (1970)
<table>
<thead>
<tr>
<th>Subject</th>
<th>Sex</th>
<th>Age (years)</th>
<th>Height (cm)</th>
<th>Weight (kg)</th>
<th>% Ideal body weight*</th>
<th>Oral GTT (20 patients)</th>
<th>Iv GTT and Iv GTT (10 patients)</th>
</tr>
</thead>
<tbody>
<tr>
<td>DR</td>
<td>F</td>
<td>33</td>
<td>166</td>
<td>110</td>
<td>175</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>HG</td>
<td>F</td>
<td>21</td>
<td>173</td>
<td>125</td>
<td>213</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>MR</td>
<td>F</td>
<td>17</td>
<td>160</td>
<td>90</td>
<td>160</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>MB</td>
<td>F</td>
<td>47</td>
<td>160</td>
<td>128</td>
<td>217</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>BC</td>
<td>F</td>
<td>42</td>
<td>175</td>
<td>86</td>
<td>116</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>FH</td>
<td>F</td>
<td>22</td>
<td>162</td>
<td>75</td>
<td>122</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>WT</td>
<td>F</td>
<td>14</td>
<td>161</td>
<td>94</td>
<td>177</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>GR</td>
<td>M</td>
<td>20</td>
<td>176</td>
<td>180</td>
<td>233</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>KY</td>
<td>F</td>
<td>27</td>
<td>161</td>
<td>107</td>
<td>179</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>CW</td>
<td>F</td>
<td>53</td>
<td>162</td>
<td>80</td>
<td>119</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>AD</td>
<td>F</td>
<td>68</td>
<td>158</td>
<td>79</td>
<td>123</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>AR</td>
<td>M</td>
<td>45</td>
<td>168</td>
<td>120</td>
<td>164</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>VR</td>
<td>F</td>
<td>53</td>
<td>156</td>
<td>96</td>
<td>156</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>GG</td>
<td>F</td>
<td>51</td>
<td>155</td>
<td>100</td>
<td>164</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>PR</td>
<td>F</td>
<td>31</td>
<td>168</td>
<td>123</td>
<td>191</td>
<td>No</td>
<td>Yes</td>
</tr>
</tbody>
</table>

*Compared with the data from Gelgy Scientific Tables (1970)

Insulin not measured
any treatment or any further dietary restriction. The tests on these in-patients reported in this work were done during the end of this period.

2. Normal subjects:

Fourteen young non-obese normal subjects were used as controls (Table 12). Their mean age was 27.6 ± 1.3 years, their mean height was 169.2 ± 2.72 cm, their mean body weight was 61 ± 2.21 kg, and ranged between 85 per cent and 108 per cent of their ideal body weight (the mean was 94 ± 1.9 per cent). All the control subjects were told to eat sufficient food for at least three days prior to the test, including a reasonable carbohydrate intake.

B. Tests:

Most subjects, patients as well as the controls, received three kinds of test. Each was done in the morning.

1. Oral glucose tolerance test (oral GTT):

A butterfly needle attached to an antecubital vein on one arm was used for drawing blood samples. The fasting blood sample was taken at 9.30 a.m., after the subjects had been fasted from midnight. A drink of 50 g glucose in 250 ml water was given and serial blood samples were taken at 15', 30', 60', 90', 120' and 150' after the oral glucose. Heparin tubes were used to prevent the blood from clotting. An aliquot of 0.05 ml of blood was taken for blood glucose estimation. The blood tubes were centrifuged and the plasma separated. An aliquot of 0.05 ml of plasma was then used for plasma glucose estimation, and the rest of the plasma was stored. Plasma samples were stored at -20°C until analyzed for plasma insulin and NEFA (see Part II, Chapter II, Methods).
## Table 12

List of Normal Subjects

<table>
<thead>
<tr>
<th>Subjects</th>
<th>Sex</th>
<th>Age (years)</th>
<th>Height (cm)</th>
<th>Weight (kg)</th>
<th>% Ideal body weight*</th>
<th>Oral GTT (15 subjects)</th>
<th>Iv GTT and Iv GTT (10 subjects)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SW</td>
<td>M</td>
<td>26</td>
<td>165</td>
<td>60</td>
<td>92</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>PG</td>
<td>M</td>
<td>30</td>
<td>178</td>
<td>68</td>
<td>90</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>MG</td>
<td>F</td>
<td>27</td>
<td>178</td>
<td>60</td>
<td>90</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>ED</td>
<td>F</td>
<td>25</td>
<td>165</td>
<td>60</td>
<td>108</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>DA</td>
<td>M</td>
<td>24</td>
<td>185</td>
<td>72</td>
<td>92</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>HP</td>
<td>F</td>
<td>24</td>
<td>158</td>
<td>52</td>
<td>100</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>JD</td>
<td>F</td>
<td>23</td>
<td>157</td>
<td>52</td>
<td>100</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>MS</td>
<td>F</td>
<td>22</td>
<td>160</td>
<td>51</td>
<td>100</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>WS</td>
<td>M</td>
<td>22</td>
<td>159</td>
<td>55</td>
<td>96</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>GG</td>
<td>M</td>
<td>24</td>
<td>183</td>
<td>70</td>
<td>92</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>CL</td>
<td>M</td>
<td>40</td>
<td>160</td>
<td>57</td>
<td>86</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>GC</td>
<td>M</td>
<td>20</td>
<td>160</td>
<td>78</td>
<td>96</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>SM</td>
<td>F</td>
<td>22</td>
<td>169</td>
<td>58</td>
<td>90</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>PB</td>
<td>M</td>
<td>27</td>
<td>168</td>
<td>55</td>
<td>87</td>
<td>No</td>
<td>Yes</td>
</tr>
</tbody>
</table>
If the whole glucose (or insulin) curve in an oral GTT is thought of as being made up of 15 minute units (Fig. 16), then the 0' - 15' period is one unit, 15' - 30' is one unit, but 30' - 60', 60' - 90' etc. are each 2 units. The total number of 15 minute units is 10.

The average values of glucose or insulin concentrations during an oral GTT were, therefore calculated as:

\[
\text{Average value} = \frac{C_0 + C_{15} + C_{30} + C_{60} + C_{90} + C_{120} + C_{150}}{10}
\]

m mol/l (Fig. 16)

where \(C_0, C_{15}, C_{30}, C_{60}, C_{90}, C_{120}, \text{ and } C_{150}\) were blood (or insulin) concentrations at 0', 15', 30', 60', 90', 120' and 150'.

The molar concentration of insulin was calculated from the concentration measured in the assay (\(\mu\) unit/ml), on the basis of 1 unit of insulin being equivalent to 0.04167 mg (1 mg = 24 units) and the molecular weight of human insulin being 5807 (Scientific Tables, Geigy, 1970).

The insulin:glucose molar ratio during the oral GTT was calculated for each subject as follows:

\[
\text{molar ratio} = \frac{\text{Average insulin value (m mol/l)}}{\text{Average glucose value (m mol/l)}}
\]
Calculation of the average value of blood glucose concentration during oral glucose tolerance test (oral GTT).

(■) are observed concentrations of blood glucose at various times during the test.

(See details given in the text).
Blood glucose (mg/100 ml)
2. Intravenous glucose tolerance test (IV GTT):

This test was also done using a butterfly needle attached to an antecubital vein of one arm. A fasting blood sample was again taken at 9.30 a.m., and through the same needle a solution of 50 per cent glucose was injected. In the first obese patients an attempt was made to insert a butterfly needle in each arm, one for the injection of glucose and the other for blood sampling. However, it is difficult enough to find one suitable vein in grossly overweight subjects, without subjecting patients and operator to the added trauma of trying to do it twice. There was no evidence that the injected glucose in any way interfered with subsequent glucose sampling, especially as the tubing and needle were flushed in the normal saline after each operation (see Part II, Chapter II, Methods). The subjects received 0.33 g glucose/kg body weight (maximum 25 g per person) (Fronckson et al., 1966). Glucose was injected within 4 to 5 minutes and serial blood samples were taken at 5', 10', 20', 30', 40', 50' and 60' after glucose injection. The procedure for handling blood samples was similar to that in the oral GTT. The blood glucose concentration (mg/100 ml) was plotted against time in minutes on Log-Linear graph paper and the best fitting straight line drawn through the points (Fig. 17). The percentage removal rate of glucose ($K_G$) was calculated from this line using the equation:

$$K_G = \frac{2.303 (\log C_1 - \log C_2)}{t_2 - t_1} \times 100\% \, \text{min}^{-1}$$

where $C_1$ and $C_2$ were glucose concentrations read from the graph at any convenient times $t_1$ and $t_2$ minutes after glucose injection (Ikkos and Luft, 1957; Heard, 1966).

The validity of this test will be discussed in Part V (General Discussion).
Calculation of the % removal rate of glucose during intravenous glucose tolerance test (iv GTT) (K_u value).

(See details given in the text).
- observed concentrations.
- derived from the line.
It was found that plasma NEFA concentration, during the IV GTT, decreased in the same way as did blood glucose concentration, so that when the plasma NEFA concentration (μmol/l) was plotted against time on Log-Linear paper, a straight line could be drawn through these points also. From the best fitting line, the percentage removal rate of NEFA (Kp) was calculated using the same equation as for glucose.

3. Intravenous glucose insulin tolerance test (IV GITT):

This test was devised as a test of insulin sensitivity (with respect to blood glucose homeostasis), (Heard and Henry, 1969a). The principle is that having derived a value for Kg from IV GTT described above, the test is immediately repeated, but on this occasion with insulin added to glucose at a concentration which would swamp the body's endogenous circulating insulin. The differences between subjects in the percentage removal rate of glucose in this test (Kg + 1) cannot, therefore, be due to differences in plasma insulin concentration, and must be due to variations in responsiveness to insulin.

The validity of the IV GITT when carried out immediately after the IV GTT depends on the differences in results being due solely to the added insulin and not to any priming effect of the first glucose load on the disposal of the second.

Conard (1955) has reported that if a second IV GITT is carried out immediately after the first, they give no difference in the Kg. Similar results have been reported by Samols and Marks (1965), Heard and Henry (1969a).
The procedure in the IV GTT was similar to that in the IV GTT. Subjects were given a second equal dose of glucose at the end of the first test, but this time insulin (Insulin BP, Wellcome, 20 units/ml) was added to the glucose (10 units of insulin in 50 ml of 50 per cent glucose; 0.133 units insulin/kg body weight). Therefore, the maximal dose of insulin per person was 10 units. Blood samples were taken at 10', 20', 30', 40', 50' and 60' after the glucose and insulin administration, and $K_G$ was calculated in the same way as $K_G$. The procedure for handling blood samples was similar to that followed in the two previous tests.

C. Analytical Methods:

Analyzes of blood or plasma glucose, plasma insulin and plasma NEFA were carried out according to the procedures reported in the previous study in surgical patients (see Part II, Chapter II, Analytical Methods).

D. Dietary Treatment

Dietary treatment, general ward management, clinical investigations and all tests other than oral GTT, IV GTT and IV GITT, were under the clinical control of Professor J.C. Waterlow, Dr. Andrew Tompkins, the late Dr. Peter Sender, Dr. Susan Ell, Dr. Graeme Glugston, Mrs. Inger O'Moore and Miss Elizabeth Roe (dieticians), and all of the nurses in Manson Ward, Hospital for Tropical Diseases.

For the first 3 to 4 days in the ward, all the hospitalized obese subjects received 8.4 MJ/day (2000 Calories/day) before they were submitted to any further dietary restrictions. The dietary restrictions were not always the same from patient to patient. It depended on the clinical situation and the ability of the patients to
copes with the treatment. Basically the restriction consisted of two parts:

1. **Initial restriction:**

   The patients received a diet of either:

   a. A non-protein diet of 1.3 MJ/day (300 calories/day) as Hycal (63 per cent glucose syrup, Beecham Products, England) or as

   b. A diet of 2.1 MJ/day (500 calories/day) which contained 50 g protein. The initial restriction was given for a period of 2 to 3 weeks.

2. **Maintenance diet:**

   This diet followed the initial restriction and consisted of either:

   a. A diet of 2.1 MJ/day (500 calories/day) which contained 50 g protein, or as:

   b. A diet of 2.4 MJ/day (800 calories/day) which also contained 50 g protein, or:

   c. A diet of 4.2 MJ/day (1000 calories/day) which also contained 50 g protein.

Patients were sent home on this maintenance diet and were followed for periods of time which varied from patient to patient, depending on their cooperation.

An attempt to correlate the type of dietary restriction and weight loss, insulin sensitivity and weight loss in these patients is discussed in the latter part of this report.
E. Assessment of the Data:

The student’s t test was used for comparing the patients data with those of the controls.
CHAPTER III
RESULTS

A. Oral GTT:

Oral GTT was done in 20 obese patients and in 13 normal control subjects (Tables 11, 12). 16 of these patients had their plasma insulin measured. To avoid unnecessary repetition, results reported below were only the results of these patients who had their insulin levels measured. There was no difference in the mean glucose curve between these 16 patients and the mean curve of all the 20 patients.

1. Blood glucose:

The mean fasting blood glucose concentration was 4.89 ± 0.16 mmol/l (88.1 ± 2.93 mg/100 ml) in the obese patients against 4.62 ± 0.16 mmol/l (83.2 ± 2.92 mg/100 ml) in controls (Table 13). The difference was not significant (p > 0.05). However, during the test the concentrations of blood glucose in the patients continued to rise after 30' and the peak was at 60', whereas the peak in the controls was at 30'. Blood glucose concentrations in the patients were higher than in control subjects, throughout the rest of the test, and the difference reached significant levels after 60' (p < 0.05) (Fig. 18A).

The average value for blood glucose concentration during the oral GTT was 6.73 ± 0.28 mmol/l (121.2 ± 5.10 mg/100 ml) in the obese patients against 5.71 ± 0.18 mmol/l (102.8 ± 3.25 mg/100 ml) in control subjects. The difference was significant (p < 0.01) (Table 13).
Figure 18. Oral GTT in 16 obese patients (O) and 15 normal control subjects (•).

A. Mean blood glucose values during oral GTT.

There were significant differences in the mean fasting values ($p < 0.05$) and in the mean values at 60', 90', 120' and 150' ($p < 0.05$) between the two groups.

B. Mean plasma insulin values during oral GTT.

There were significant differences in the mean fasting concentrations ($p < 0.05$) and in the mean values at 60', 90', 120' and 150' ($p < 0.05$) between the two groups.

C. Mean plasma NEFA values during oral GTT.

The differences between the mean values at various times during the test were not significant.

(mean values of 6 obese and 7 normal control subjects).
2. Plasma insulin:

The mean fasting plasma insulin level was 21.4 ± 2.88 μunit/ml in the obese patients against 12.8 ± 1.31 μunit/ml in control subjects. The difference was significant (p < 0.05) (Table 13). During the test the levels of plasma insulin in the patients continued to rise after 30' and the peak was at 60', whereas the peak in the controls was at 30'. Plasma insulin levels in the patients were higher than in control subjects throughout the rest of the test and the difference reached significant levels after 60' (p < 0.05) (Fig. 1B).

The average value for plasma insulin concentration during oral GTT was 69.1 ± 10.65 μunit/ml in the obese patients against 33.5 ± 3.51 μunit/ml in control subjects. The difference was significant (p < 0.01) (Table 13).

During the selection of patients, any obvious diabetic (fasting blood glucose concentration higher than 6.11 m mol/l) were excluded. (See Chapter II A, Patients). WHO criteria for diabetes (1965) states that in normal oral GTT, the upper limit of 120 minute value for blood glucose concentration is 6.11 m mol/l (110 mg/100 ml). According to this criteria, among 16 obese patients studied, 7 were diabetic and 8 were non-diabetic! Therefore, we could divide the 16 obese patients into two groups. The non-diabetic obese group did not show any significant differences in the mean blood glucose concentrations at various times during oral GTT compared to the normal control subjects, although they showed differences in mean plasma insulin concentrations. The differences between these two groups of obese patients and between these two groups and normal control subjects are summarized in Table 14.
2. Plasma Insulin:

The mean fasting plasma insulin level was 21.4 ± 2.88 μunit/ml in the obese patients against 12.8 ± 1.31 μunit/ml in control subjects. The difference was significant (p < 0.05) (Table 13). During the test the levels of plasma insulin in the patients continued to rise after 30' and the peak was at 60', whereas the peak in the controls was at 30'. Plasma insulin levels in the patients were higher than in control subjects throughout the rest of the test and the difference reached significant levels after 60' (p < 0.05) (Fig. 1B).

The average value for plasma insulin concentration during oral GTT was 69.1 ± 10.65 μunit/ml in the obese patients against 33.5 ± 3.51 μunit/ml in control subjects. The difference was significant (p < 0.01) (Table 13).

During the selection of patients, any obvious diabetic (fasting blood glucose concentration higher than 6.11 m mol/l) were excluded. (See Chapter II A, Patients). WHO criteria for diabetes (1965) states that in normal oral GTT, the upper limit of 120 minute value for blood glucose concentration is 6.11 m mol/l (110 mg/100 ml). According to this criteria, among 16 obese patients studied, 7 were diabetic and 8 were non-diabetic. Therefore, we could divide the 16 obese patients into two groups. The non-diabetic obese group did not show any significant differences in the mean blood glucose concentrations at various times during oral GTT compared to the normal control subjects, although they showed differences in mean plasma insulin concentrations. The differences between these two groups of obese patients and between these two groups and normal control subjects are summarized in Table 14.
The mean values for fasting blood glucose and plasma insulin, average concentrations of blood glucose and plasma insulin, and insulin-glucose molar ratio during oral GTT, in patients and control subjects (± SEM). Number of observations in parenthesis.

<table>
<thead>
<tr>
<th></th>
<th>Mean fasting concentrations</th>
<th>Mean of the average value for 150 min.</th>
<th>$10^6 \cdot$ mean insulin: glucose molar ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Blood glucose (m mol/l)</td>
<td>Plasma insulin (µ unit/ml)</td>
<td>Blood glucose (m mol/l)</td>
</tr>
<tr>
<td>Patients (16)</td>
<td>4.89 ± 2.92</td>
<td>21.4 ± 2.88</td>
<td>6.73 ± 0.28</td>
</tr>
<tr>
<td>Controls (13)</td>
<td>4.62 ± 0.16</td>
<td>12.8 ± 1.81</td>
<td>5.71 ± 0.18</td>
</tr>
</tbody>
</table>

*p < 0.05; **p < 0.01; ns = not significant
Since there was no clear cut difference between the two groups of these obese patients, they will be reported in this work as one population.

The differences between non-diabetic and diabetic obese patients will be discussed later in Part V (General Discussion).

3. Insulin:glucose molar ratio:

The mean insulin:glucose molar ratio in the obese patients was \((75.3 \pm 11.09) \times 10^{-6}\) against \((42.2 \pm 4.50) \times 10^{-6}\) in control subjects. The difference was significant \((p < 0.05)\) (Table 13).

4. Plasma NEFA:

There was a great range in the levels of plasma NEFA both in the obese patients and in the controls. This applied to fasting levels as well as the levels during the test. The mean fasting plasma NEFA level in the obese patients was \(627 \pm 120 \mu \text{mol/l}\) against \(590 \pm 68 \mu \text{mol/l}\) in control subjects. The difference was not significant \((p > 0.05)\). In keeping with the elevated glucose and insulin values, there was a tendency to a lower 120' plasma NEFA value in the patients, but throughout the test, the difference in the mean plasma NEFA levels between the two groups was not significant \((p > 0.05)\) (Fig. 1BC).

5. iv GTT and iv GITT:

iv GTT and iv GITT were done in 16 obese patients and in 10 normal controls (Table 11 and Table 12).
1. $K_G$ values:

The mean $K_G$ values in the obese patients was $1.11 \pm 0.18 \%$/minute against $1.81 \pm 0.28 \%$/minute in control subjects. The difference was significant ($p < 0.05$) (Table 1.5).

There was no significant correlation between $K_G$ and fasting plasma insulin values during iv GTT, in the obese patients nor in the control subjects (Fig. 19A). A higher $K_G$ value was usually related to a lower fasting plasma insulin level.

There was also no significant correlation between $K_G$ and peak plasma insulin values, in the obese patients nor in the control subjects (Fig. 19B). However, again higher $K_G$ was usually related to a lower peak plasma insulin level.

2. Peak Insulin levels during oral GTT and iv GTT:

There were 5 obese patients and 9 normal control subjects who had both oral GTT and iv GTT done.

The mean peak insulin levels during oral GTT were higher than the mean peak insulin levels during iv GTT both in patients and in the control subjects. The differences, however, were not significant ($p > 0.05$) (Table 1.6).

The mean peak insulin level during oral GTT in the obese patients was $160.6 \pm 24.98 \mu$ unit/ml against $72.0 \pm 7.26 \mu$ unit/ml in the control subjects. The difference was significant ($p < 0.01$) (Table 1.6).
<table>
<thead>
<tr>
<th></th>
<th>Mean Values</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>KG (%/min)</td>
</tr>
<tr>
<td></td>
<td>KG +1 (%/min)</td>
</tr>
<tr>
<td></td>
<td>Kf (%/min)</td>
</tr>
<tr>
<td>Obese patients</td>
<td>1.11 ± 0.18</td>
</tr>
<tr>
<td></td>
<td>2.81 ± 0.35</td>
</tr>
<tr>
<td></td>
<td>2.86 ± 0.90</td>
</tr>
<tr>
<td>(16)</td>
<td>(16)</td>
</tr>
<tr>
<td>Controls</td>
<td>1.81 ± 0.28</td>
</tr>
<tr>
<td></td>
<td>4.55 ± 0.51</td>
</tr>
<tr>
<td></td>
<td>3.10 ± 0.73</td>
</tr>
<tr>
<td>(10)</td>
<td>(10)</td>
</tr>
<tr>
<td>ns &lt; 0.05</td>
<td>ns = not significant</td>
</tr>
</tbody>
</table>

Table 1.5

The mean values for KG, KG +1 and Kf in the obese patients and in normal control subjects (± SEM). Number of observations in parenthesis.
Figure 12.4. Correlation between $K_o$ and fasting plasma insulin values during iv GTT, in the obese patients (○) and normal control subjects (●).
Correlation between $k_q$ and peak plasma insulin values during iv GTT in the obese patients (○) and normal control subjects (●).
Peak insulin value during iv GTT (μ unit/ml).
The mean peak insulin level during iv GTT in the obese patients was 138.4 ± 11.17 μ unit/ml against 54.0 ± 13.60 μ unit/ml in the control subjects. This difference was also significant (p < 0.05) (Table 16).

3. **K_G** values:

   The mean K_G value in the obese patients was 2.81 ± 0.35 %/minute against 4.55 ± 0.51 %/minute in control subjects. The difference was significant (p < 0.05) (Table 15).

   There was no correlation between K_G and fasting plasma insulin values in the obese patients nor in the control subjects (Fig. 20A). However, the lower K_G values were usually related to the higher fasting plasma insulin levels. This, however, is really just saying that lower K_G values and higher fasting plasma insulin levels are both characteristic of obesity.

   There was also no correlation between K_G and peak plasma insulin values during iv GTT in the obese patients nor in the control subjects (Fig. 20B). A higher K_G was usually related to a lower peak plasma insulin level.

   There was a significant correlation between K_G and K_G values in the obese patients and in the control subjects (p < 0.001) (Fig. 21).

4. **K_p** values

   The mean K_p value in the obese patient was 2.86 ± 0.90 %/minute against 3.10 ± 0.73 %/minute in the normal subjects. The difference was not significant (Table 15).


The mean peak insulin levels (± SEM) during oral GTT and iv GTT in patients and normal control subjects. Number of observations in parenthesis.

<table>
<thead>
<tr>
<th></th>
<th>Mean Peak Insulin Level</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Oral GTT (µ-unit/ml)</td>
</tr>
<tr>
<td>Obese Patients</td>
<td>160.6 ± 24.98 ns</td>
</tr>
<tr>
<td>(5)</td>
<td></td>
</tr>
<tr>
<td>Controls</td>
<td>72.0 ± 7.26 ns</td>
</tr>
<tr>
<td>(9)</td>
<td></td>
</tr>
</tbody>
</table>

*p < 0.05; ** p < 0.01; ns = not significant
Correlation between the % removal rate of glucose during the intravenous glucose insulin tolerance test (iv GITT) ($K_{d-1}$ value) and fasting plasma insulin concentration, in the obese patients (△) and normal control subjects (△).
Fasting plasma insulin (µunit/ml).
Figure 20.1. Correlation between fast and peak plasma insulin values during IV GTT, in the obese patients (△) and normal control subjects (△).
Peak insulin value during iv GFF (μ unit/ml).
Regression line between the values of $K_d$ and $K_{on}$ in the pooled group of obese patients (○) and normal control subjects (●).
C. Correlation between Biochemical Results and Degree of Obesity:

1. Blood glucose:

Since subjects with a fasting blood glucose greater than 6.11 mmol/l (110 mg/100 ml) were excluded from this study, the range in the fasting blood glucose concentrations in patients as well as in controls was very narrow, lying between 3.39 mmol/l (61 mg/100 ml) and 6.05 mmol/l (109 mg/100 ml). In contrast to this, there was a very wide spread in the range of % ideal body weight in these subjects. The % ideal weights varied between 85 per cent (the lowest of the controls) and 233 per cent (the highest of the obese group) (Fig. 22A). There was no correlation between fasting blood glucose values and body weight as % ideal body weight.

2. Plasma insulin:

There was a positive correlation between the logarithm of the value of fasting plasma insulin concentration and % ideal body weight ($p < 0.001$). (Fig. 22B).

There was no statistical correlation between the peak plasma insulin concentration during oral GTT (or the logarithms of these values) and % ideal body weight. However, the lower values of peak plasma insulin concentration during oral GTT were usually related to lower values of % of ideal body weight. If we take 160 per cent of ideal body weight as a dividing line, the obese patients and normal control subjects could be divided into two groups. One group was made up of the subjects who had weights less than 160 per cent of their ideal body weight. Among 22 subjects (12 normal and 9 obese) in this group, all except 5 (1 normal and 4 obese) had peak plasma insulin concentrations less than 100 µ units/ml. The other group consisted of subjects...
Correlation between fasting blood glucose concentration and % ideal body weight in the obese patients (○) and normal control subjects (●).
Figure 22 B: Correlation between fasting plasma insulin concentration and % ideal body weight in the obese patients (○) and normal control subjects (■).
who all had weights higher than 160 per cent of their ideal body weight. Among 7 subjects (all obese) in this group, all except one had peak plasma insulin concentrations higher than 100 \( \mu \text{units/ml} \). However, only 5 out of 9 obese subjects who had weights less than 160 per cent ideal body weight, had low peak insulin concentrations as found in the normal control subjects (Fig. 2A).

There was no statistical correlation between the peak plasma insulin concentration during lv GTT and % of ideal body weight. However, here again, the lower values of peak plasma insulin during lv GTT were usually related to lower values of % ideal body weight. And if once more we take 160 per cent ideal body weight as a dividing line, there were 14 (10 normal and 4 obese) whose body weight was less than 160 per cent of their ideal body weight, and all except 2 (1 normal and 1 obese) had peak plasma insulin concentrations less than 80 \( \mu \text{units/ml} \). However, 4 of the obese who had weights less than 160 per cent ideal weight, 3 still had low peak plasma insulin concentrations as in normal control subjects. There were 9 others subjects (all obese) who had body weights higher than 160 per cent ideal body weight, and all except 1 had peak plasma insulin concentration higher than 80 \( \mu \text{units/ml} \). We chose 80 \( \mu \text{units/ml} \) instead of 100 \( \mu \text{units/ml} \), because usually there is a lower peak plasma insulin value for lv GTT compared to oral GTT, either in obese or in normal control subjects (Fig. 2B).

3. KG values

There was no statistical correlation between KG value during lv GTT and % ideal body weight. However, the lower values of KG were usually related to higher values of % ideal body weight. If, here again, we take 160 per cent ideal body weight as a dividing line, 15 subjects (10 normal and 5 obese) who had their weight less than 160
Figure 23 A. Correlation between peak plasma insulin value during oral GTT and % ideal body weight in the obese patients (□) and normal control subjects (■).
Figure B. Correlation between peak plasma insulin value during iv GTT and % ideal body weight in the obese patients (□) and normal control subjects (■).
per cent their ideal body weight, 9 (8 normal and 1 obese) had KG values higher than 1.20 %/min and only 6, (2 normal and 4 obese) had KG values lower than 1.20 %/min. 5 of the obese subjects who had weights less than 160 per cent ideal body weight, only 1 had KG value higher than 1.20 %/min, as in normal control subjects. And among 11 subjects who had their weights equal or higher than 160 per cent their ideal body weight (all obese), all except 2 had KG values lower than 1.20 %/min. (Fig. 24).

4. KG +1 values:

There was no statistical correlation between KG +1 value during iv GTT and % ideal body weight. However, the lower values of KG +1 were usually related to higher values of % ideal body weight. If, here also, we take 160 per cent of ideal body weight as a dividing line, 15 subjects (10 normal and 5 obese) who had weights less than 160 per cent their ideal body weight, 10 (8 normal and 2 obese) had KG +1 values higher and only 5 (2 normal and 3 obese) had KG +1 values lower than 3.20%/min. However, only 2 out of 5 obese subjects who had weights less than 160 per cent ideal body weight had KG +1 values higher than 3.20%/min as in normal control subjects. 11 subjects had their weight higher than 160 per cent their ideal body weight (all obese). All except 3 had KG +1 values less than 3.20%/min. (Fig. 25).

D. The Effect of Dietary Restriction on Weight Loss in the Obese Patients:

As mentioned above, dietary management of patients was related firstly to the need of the patients and secondly to those of the investigations a. the investigation of protein turnover by Professor J.C. Waterlow, Dr. P. Sender, Dr. Susan Ell,
Figure 24. Correlation between $R_2$ value and % ideal body weight in the obese patients (○) and normal control subjects (∗).
Figure 25. Correlation between $K_{G+1}$ value and % ideal body weight in the obese patients (○) and normal control subjects (●).
Figure 26. Weight loss during dietary restriction in some obese patients.

- (•) MC.
- (○) AR.
- (▲) DR.
- (+) KY.

- (■) CG.
- (□) CW.
- (♦) AS.
Dr. P. Garlick and Dr. G. Clugston (using radioactive tyrosine and leucine), and for this reason drug therapy was not usually employed except for a very small number who received thyroxine; b. our study of glucose homeostasis.

There was no statistical correlation between the weight loss in the patients (kg/day) and the type of diet during dietary restriction. There was also no statistical correlation between weight loss and $K_G$ or $K_G + \beta$ values. There was also no statistical correlation between weight loss and fasting values of plasma insulin or peak plasma insulin during oral GTT and iv GTT (Table 1).

Fig. 26 shows body weight changes during dietary treatment in some patients showing different patterns of weight loss.
The effect of various dietary restrictions in relation to $K_g$ and plasma insulina values in obese patients. The patients' numbers are the same as those given in Table 11.

<table>
<thead>
<tr>
<th>Patients</th>
<th>Age (years)</th>
<th>$K_g$ ($%$/min)</th>
<th>$K_{G+I}$ ($%$/min)</th>
<th>INITIAL DIET</th>
<th>MAINTENANCE DIET</th>
<th>INITIAL WEIGHT</th>
<th>INSULIN (munit/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>MJ/day</td>
<td>Duration (days)</td>
<td>Weight loss (Kg/day)</td>
<td>MJ/day Duration (days)</td>
<td>Weight loss (Kg/day)</td>
<td>Kg</td>
</tr>
<tr>
<td>23. KY</td>
<td>37</td>
<td>3.65 5.35</td>
<td>1.3</td>
<td>26 0.27</td>
<td>4.2 90 0.14</td>
<td>107</td>
<td>178</td>
</tr>
<tr>
<td>24. CW</td>
<td>53</td>
<td>1.41 4.20</td>
<td>1.3</td>
<td>33 0.21</td>
<td>2.1 33 0.11</td>
<td>80</td>
<td>119</td>
</tr>
<tr>
<td>25. AD</td>
<td>68</td>
<td>0.97 2.56</td>
<td>1.3</td>
<td>27 0.22</td>
<td>2.1 73 -0.05</td>
<td>79</td>
<td>123</td>
</tr>
<tr>
<td>26. AR</td>
<td>45</td>
<td>0.54 1.04</td>
<td>1.3</td>
<td>30 0.43</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>27. VR</td>
<td>53</td>
<td>0.74 2.31</td>
<td>1.3</td>
<td>14 1.14</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14. MC</td>
<td>29</td>
<td>1.15 2.34</td>
<td>1.3</td>
<td>18 0.44</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15. DR</td>
<td>33</td>
<td>1.09 2.00</td>
<td>1.3</td>
<td>10 0.40</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17. MR</td>
<td>17</td>
<td>1.05 3.01</td>
<td>2.1</td>
<td>13 0.46</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18. MB</td>
<td>47</td>
<td>0.76 2.04</td>
<td>2.1</td>
<td>30 0.37</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19. BC</td>
<td>42</td>
<td>1.03 2.67</td>
<td>2.1</td>
<td>20 0.20</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20. FH</td>
<td>22</td>
<td>0.94 3.75</td>
<td>2.1</td>
<td>30 0.23</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>28. GG</td>
<td>51</td>
<td>0.29 0.97</td>
<td>3.3</td>
<td>30 0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>29. PR</td>
<td>31</td>
<td>0.93 3.38</td>
<td>3.3</td>
<td>30 0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16. HG</td>
<td>21</td>
<td>1.04 5.68</td>
<td>3.3</td>
<td>20 0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. DB</td>
<td>58</td>
<td>Not measured</td>
<td>3.3</td>
<td>60 0.07</td>
<td>3.3 45 0.04</td>
<td>105</td>
<td>156</td>
</tr>
</tbody>
</table>

*Compared with the data from Geigy Scientific Tables, 1970.*
CHAPTER IV
DISCUSSION

The results show the familiar findings of an impairment in glucose tolerance in obesity (Paulin and Saul, 1922; Beck et al., 1964; Parley and Klipfel, 1966; Chiles and Tsagournis, 1970; Rubino, 1970), and that this impairment is usually accompanied by hyperinsulinemia.

A decrease in insulin sensitivity in respect to carbohydrate metabolism was present in these patients as shown by high blood glucose in the presence of high plasma insulin concentrations during the oral GTT (Fig. 18A; Fig. 18B and Table 13). Similarly, the iv GTT in the obese patients showed that lower $K_G$ values were usually related to higher insulin concentrations (Fig. 19A and 19B).

During iv GTT, the obese patients showed a significantly lower mean value of $K_G + 1$ than did the normal controls ($p < 0.01$; Table 15). The value of $K_G + 1$ is a measure of insulin sensitivity (in respect to carbohydrate metabolism), (Frankson et al., 1966; Heard and Henry, 1969a). Glucose tolerance ($K_G$ value) was significantly correlated to insulin sensitivity ($p < 0.001$) but not to the actual concentration of plasma insulin (Fig. 21, Fig. 19A and Fig. 19B). These results confirm similar findings reported in malnourished dogs on the significance of insulin sensitivity rather than insulin concentration in determining glucose tolerance (Turner, 1966; Heard and Turner, 1967; Heard and Henry, 1969a).
'Insulin sensitivity' or 'insulin resistance' are terms which have usually been used in the context of carbohydrate metabolism, (Franckson et al. 1966; Heard and Turner, 1967; Heard and Henry, 1969). Insulin resistance in respect to fat metabolism probably also occurred in the obese patients. Most reports show that obese subjects have slightly elevated plasma NEFA. In the present small series, however, there were no significant differences between the obese patients and control subjects in the values of fasting plasma NEFA (Fig. 1B), nor in the fall of plasma NEFA concentrations during oral GTT (Fig. 1B) and IV GTT (Kfp; Table 15). In all cases, however, the observed 'normal' values of NEFA in the obese subjects were accompanied by higher concentrations of plasma insulin (Fig. 1B), implying an overall resistance of fat metabolism to insulin.

Insulin inhibits lipolysis (Kipnis, 1965); on the other hand, insulin promoted glucose uptake and lipogenesis (Jeanrenaud and Renold, 1969). Either will result in the fall in plasma NEFA concentration. Only a very low level of insulin is needed to inhibit lipolysis, and once this level has been exceeded (Kipnis, 1965) any further effect of insulin on NEFA levels would be expected to operate via enhanced glucose uptake and reesterification of NEFA. The insulin resistance reflected in NEFA: insulin relationships might therefore be in large part another measure of insulin resistance in respect to glucose metabolism. Kipnis (1965) also showed that growth hormone administration resulted in an apparent dissociation between muscle and adipose tissue in response to insulin, and he discussed the question of whether this is due to different organ sensitivity to insulin or different responses of glucose uptake and inhibition of lipolysis.
Passmore, Melkiejohn, Dowar and Thow (1955) observed that weight gain in thin young men was less than expected when they were subjected to an overfeeding for 14 days. Whereas overfeeding in two fat young women resulted in a greater weight gain than that which was found in these thin men (Passmore, Swinndel and El Din, 1963). Not only are obese people still susceptible to increased energy intake, but they also seemed to have lost the capacity to burn the extra energy in the same way as thin people do. It is interesting to note that Rally (1921), more than fifty years ago showed that the specific dynamic action of food stuff was reduced to practically zero after the development of obesity. 'Specific dynamic action' is the term used to describe the effect of food in raising the metabolic rate above the value when fasting.

All obese patients must at some time eat in excess of their requirements in order to tip the energy balance and put on weight. This early stage could be described as an 'active' obesity, and reflects a 'normal' subject who eats to excess. He may, therefore, still have a normal insulin sensitivity (in respect of carbohydrate and fat). 'Active' obesity is represented here by the similarity between controls and some obese subjects under 160 per cent ideal body weight in the values of fasting insulin (Fig. 22B) and peak insulin during oral GTT (Fig. 23A) and iv GTT (Fig. 23B). Some of these patients, however, had started to have higher values of fasting insulin, peak insulin during oral GTT and iv GTT. Interestingly, most of them had already shown a decrease in iv glucose tolerance (KG, Fig. 24) and insulin sensitivity (KG + i1, Fig. 25). This group may represent a transition period before they go into a further stage, i.e. 'passive' obesity. 'Passive' obesity could be represented here by
the obese subjects above 160 per cent ideal body weight showing predominant pictures of high fasting insulin concentrations (Fig. 22A), high peak insulin during oral GTT (Fig. 23A) and iv GTT (Fig. 23B), low $K_g$ values (Fig. 24), and low insulin sensitivity ($K_g + \|$) (Fig. 25).

Some apparently 'normal' subjects showed very high values for $K_g$ and $K_g + \|$ (Figs. 21, 24 and 25). It is speculated that these subjects may be in an early phase of 'active' obesity. This speculation is based on the similar pattern of changes in $K_g$ and $K_g + \|$ found in experimental animals fed diets deficient in protein (Heard and Turner, 1967; Heard and Stewart, 1971). In all cases, early signs of hypersensitivity to insulin were later followed by an impairment of glucose tolerance and diminished insulin sensitivity. However, such speculation requires further investigation.

Our results are in line with the view that 'gorging' should be avoided, especially if the diet is rich in carbohydrate. 'Gorging' leads to a greater increase in lipogenesis (Gwinup, Byron, Roush, Kruger and Hanwl, 1973; Bray, 1972). This effect would be accentuated in those who are already obese and in whom any carbohydrate intake (oral or iv) leads to very high levels of plasma insulin (Table 12, Figs. 18B, 23A, and 23B).
It is very difficult to assess the effect of dietary restriction on body weight in these patients. It depends more on the willpower to stick to the diet and the mental attitude of the individual. Some followed the diet restriction properly, some did not, resulting in an inability to show any weight loss. As the patients primarily came for treatment, the type of diet may, therefore, differ from subject to subject.

None of the biochemical parameters measured in this work showed any predictive value in respect of effectiveness of dietary therapy.

This may seem surprising if obesity is to be regarded not as a 'disease', but rather as a 'gift'. The genetic development of obesity is not at all well understood in man. The genotype for obesity was assumed to be present since early human population (Montagu, 1966). To ancient people in the paleolithic times, or perhaps even at present, in areas where food could sometimes be scarce, the ability to become obese would have provided greater reserves of food supply upon which to draw in times of scarcity.
PART IV

GLUCOSE HOMEOSTASIS

IN

OLD AGE
A. Ageing Process:

In the past century, man's life expectancy has increased considerably (Department of Health and Social Security, England, 1976), through the advancing knowledge of modern medicine. This has been in two main areas: in preventive medicine, through improvement of the environmental sanitation, better management not only in maternal and child health care, but also the health of the population in general; and in the field of curative medicine, especially following the discovery of antibiotics. While the medical successes are considered a good thing, the results expose us to different kinds of new problems. The increasing number of old people in the community emphasizes the importance of seeking better knowledge of ageing processes, and better attitudes in caring for and understanding old people.

The word 'ageing' means to 'grow old' (Oxford Concise English Dictionary). However, in biological studies, this term could have many different connotations. Bellamy (1970) gave a definition of ageing as a "decline in the ability of the homeostatic system of the body to cope with fluctuations in the external world". In the process of growing old, there is a steady decline of physiological functions, in conjunction with a decline in anatomical, biochemical and hormonal features and performance (Norris and Shock, 1966). A decrease in physical activity with or without painful feelings in the bones and joints, a decrease in food intake, emotional disturbances and many other physical or psychological inadequacies show that old age and stress are closely associated. Old age, therefore, is not merely the passing of
years, but many malfunctions added together become a generalized picture of old age, and, whatever the original cause, some elements of stress either physical or psychological or both are always present in old age (see Part I, Chapter IV, Stress).

B. Aging and Carbohydrate Metabolism

Increasing age has always been associated with a decline in glucose tolerance, either oral GTT (Grant, 1960; Burch and O'Meally, 1967; Chlouverakis, Jarrett and Keen, 1967), or the IV GTT (Streeten, Gentstein, Merer, and Daisy, 1965; Frankson et al., 1966; Cockford, Herbeck and Williams, 1966). The decline in IV glucose tolerance is associated with a decrease in insulin production (Cockford et al., 1966). However, in the oral GTT, some have claimed that the prolonged hyperglycaemia resulted in higher levels of plasma insulin (Chlouverakis et al., 1967; Andres, Pozefsky, Swerdloff and Tobin, 1970).

It is important to try to decide whether we should apply the same criteria in diagnosing and treating diabetes in the elderly as are used for young adults. Most authorities would suggest making 'allowances' for age (WHO Expert Committee on diabetes mellitus, 1965; Andres, 1973). This seems reasonable if only because elderly people probably have diminished food intake and sometimes have impaired absorptive capacity (Webster and Leeming, 1975), and, therefore, do not, under normal circumstances, load their systems to the same extent as young people. In tolerance tests on the other hand, the same load is given to young and old alike.

Andres (1973), in his review claimed that impaired glucose tolerance (intravenous test) in the elderly was due, not to impaired sensitivity to insulin, but to
deficient insulin production. However, he also acknowledged that there was not yet any clear consensus between various workers about plasma insulin levels during the oral GTT.

In all the other situations we have studied, insulin sensitivity played as large a part (if not more) in determining glucose tolerance as did insulin levels. Therefore, we sought to differentiate between insulin levels and insulin effectiveness in the elderly.

Because of the gastro-intestinal tract changes in old people (Agate, 1963), including possible impairment in intestinal insulinogenic capacity, and also the inconclusive reports on insulin response during oral GTT, it was also desirable to compare the effects of oral and iv glucose loads on blood glucose and plasma insulin levels.

The decrease in glucose tolerance in old age could be due either to the decreased uptake of glucose by the liver and peripheral tissues, or due to the inability of insulin to stop liver gluconeogenesis. Therefore, we also compared the gluconeogenic capacity of the liver between the geriatric patients and normal control subjects. This was carried out by intravenous injection of L-alanine (Wise, Handler and Felig, 1973; Mestyan, Schultz and Harvath, 1974) and measuring the rise in blood glucose concentration, the changes in plasma insulin and glucagon, and the disappearance of injected L-alanine from the circulation. The % removal rate of injected L-alanine (Kd) was calculated the same way as those calculations for KG and KG + 1. (See Part III, Chapter II, Methods).
C. Intravenous L-alanine Tolerance Test and a Measure of Gluconeogenesis:

Gluconeogenesis is very difficult to measure. A number of different 'tolerance' tests have been used in which substrates capable of serving as glucose precursors have been administered. These include dihydroxyacetone or glycerol (Femondes, Koster, Gross and Sorgedrager, 1974), fructose (Pogliani, Karl, Kaating, Brown and Klipsis, 1972), pyruvate (Moorehouse, 1964), lactate (Kreisberg, Pennington and Boshell, 1970) and alanine (Felig, Metliss, Owen and Cahill, 1969; Wise et al., 1972; Mestyán et al., 1974). Alanine is of special importance. It has been suggested that alanine uptake by the liver amounts to 50 per cent of the total amino acid uptake by this organ (Felig, Wahren, 1971). This is accounted for by the fact that alanine is also released by the muscles in amounts far exceeding the alanine content of muscle protein. Protein contains only 5 to 7 per cent alanine (Kominz, Hough, Symond and Laki, 1954), yet alanine accounts for about 30 per cent of total amino acids released from muscle (London, Foley and Webb, 1965).

This production of alanine requires pyruvate to serve as an amino group acceptor in alanine amino transferase reactions. Pyruvate is derived from glucose by glycolysis in muscle. In the liver, pyruvate is regenerated from alanine, and then serves as a gluconeogenic precursor to replenish the glucose removed from the blood by muscle and other tissues, and so completes the 'glucose-alanine cycle' (Felig, 1973). The success of this process, therefore, depends upon the availability of glucose precursors and the efficiency of the liver in converting alanine into glucose.
Alamine is known to promote both gluconeogenesis and glycogenolysis through stimulation of glucagon production (Wise, Hendler and Felig, 1972). Thus, the rise in blood glucose concentrations after intravenous alanine administration cannot be attributed to gluconeogenesis alone, unless liver glycogen stores have been depleted by fasting. Ideally, the subject should be fasted 24 to 46 hours to be sure of more or less complete exhaustion of liver glycogen stores (Hultman and Nilson, 1971). However, such a procedure was not possible on geriatric patients. With this limitation taken into account, geriatric patients and normal control subjects were given an intravenous alanine test after fasting for 8 hours from midnight.
A. Subjects

1. Patients

Patients from the geriatric wards, St. Pancras Hospital, were studied. They were asked whether they would be willing to consider participating and the kinds of tests involved were explained in detail. Consent (oral or written) was thus obtained from each patient and control subject participating in the study. These patients were presented to us as non-diabetics and any subject who had a fasting blood glucose concentration higher than 6.11 mmol/1 (110 mg/100 ml) (working party, College of General Practitioners, 1963) were excluded. Their medical records showed that none of these patients had any glycosuria, and all received normal hospital diets.

The first three tests (oral GTT, iv GTT and iv GITT) were carried out on 23 patients (Table 18). Their mean age was 79 ± 1.1 years, their mean body weight was 56 ± 2.2 kg. For three to four days before the tests, each of them received an extra 150 g carbohydrate/day. This was to ensure that all the subjects had a reasonable carbohydrate intake before the tests were done. This extra carbohydrate was in the form of 150 g/600 ml solution consisting of 50 per cent orange juice and 50 per cent Caloreen (Scientific Hospital Supplies Ltd., England).

Unfortunately, some of the patients were not able to participate in the fourth test, the Intravenous (iv) alanine tolerance test. They were either unwilling or were
### Table 1A

List of geriatric patients who participated in oral GTT, iv GTT and iv GITT

<table>
<thead>
<tr>
<th>Subject</th>
<th>Sex</th>
<th>Age (years)</th>
<th>Body weight (kg)</th>
<th>Previous diseases</th>
</tr>
</thead>
<tbody>
<tr>
<td>GV</td>
<td>F</td>
<td>88</td>
<td>50</td>
<td>Gangrene of the toes, amputation</td>
</tr>
<tr>
<td>WT</td>
<td>F</td>
<td>87</td>
<td>51</td>
<td>Myocardial infarct</td>
</tr>
<tr>
<td>CH</td>
<td>M</td>
<td>74</td>
<td>60</td>
<td>Atherosclerosis</td>
</tr>
<tr>
<td>OV</td>
<td>M</td>
<td>83</td>
<td>60</td>
<td>Myocardial infarct</td>
</tr>
<tr>
<td>VL</td>
<td>M</td>
<td>83</td>
<td>60</td>
<td>Left hemiplegia</td>
</tr>
<tr>
<td>CR</td>
<td>M</td>
<td>74</td>
<td>73</td>
<td>Prostatectomy</td>
</tr>
<tr>
<td>ED</td>
<td>F</td>
<td>77</td>
<td>71</td>
<td>Kyphosis</td>
</tr>
<tr>
<td>EL</td>
<td>F</td>
<td>81</td>
<td>50</td>
<td>Rheumatoid arthritis</td>
</tr>
<tr>
<td>PS</td>
<td>F</td>
<td>77</td>
<td>60</td>
<td>Myocardial infarct</td>
</tr>
<tr>
<td>SH</td>
<td>F</td>
<td>76</td>
<td>50</td>
<td>Mitral stenosis</td>
</tr>
<tr>
<td>FD</td>
<td>M</td>
<td>73</td>
<td>62</td>
<td>Myocardial infarct</td>
</tr>
<tr>
<td>BJ</td>
<td>F</td>
<td>78</td>
<td>57</td>
<td>C.V.A., right hemiplegia</td>
</tr>
<tr>
<td>BX</td>
<td>F</td>
<td>82</td>
<td>43</td>
<td>Dementia</td>
</tr>
<tr>
<td>OT</td>
<td>M</td>
<td>79</td>
<td>37</td>
<td>Dementia</td>
</tr>
<tr>
<td>FL</td>
<td>F</td>
<td>82</td>
<td>47</td>
<td>C.V.A.</td>
</tr>
<tr>
<td>MR</td>
<td>M</td>
<td>78</td>
<td>67</td>
<td>C.V.A., paraplegia</td>
</tr>
<tr>
<td>EN</td>
<td>M</td>
<td>86</td>
<td>61</td>
<td>Prostate hypertrophy</td>
</tr>
<tr>
<td>MG</td>
<td>F</td>
<td>74</td>
<td>62</td>
<td>Cervical spondylitis</td>
</tr>
<tr>
<td>MC</td>
<td>M</td>
<td>78</td>
<td>53</td>
<td>C.V.A., right hemiplegia</td>
</tr>
<tr>
<td>PG</td>
<td>M</td>
<td>77</td>
<td>53</td>
<td>Mild left ventricular failure</td>
</tr>
<tr>
<td>DW</td>
<td>F</td>
<td>73</td>
<td>67</td>
<td>Dermoid tumour in the pelvis</td>
</tr>
<tr>
<td>PN</td>
<td>F</td>
<td>78</td>
<td>34</td>
<td>Carcinoma cervix</td>
</tr>
<tr>
<td>ST</td>
<td>M</td>
<td>68</td>
<td>49</td>
<td>C.V.A., right hemiplegia</td>
</tr>
</tbody>
</table>
unable to do so because of their clinical conditions. Therefore, a few more patients had to be added to make up a reasonable number. Fig. 19 shows the list of 8 geriatric patients who had the iv alanine tolerance test. Their mean age was 78 ± 1.6 years and their mean body weight was 52 ± 3.9 kg.

Due to the advanced age of all geriatric patients studied, we were unable to get a reliable measurement of their heights, thus also unable to calculate their % ideal body weight, and these measurements were not included in this report.

2. Normal subjects:

Normal control subjects for the oral GTT, iv GTT and Iv GTT were the same 14 young, non-obese subjects used as controls in the study on obesity (see Part III, Chapter II, Normal Subjects), (Table 12).

As with the patients, so also with the control subjects; some of the original volunteers were unwilling or not available to participate in further tests. More new volunteers were, therefore, recruited to make a reasonable number of control subjects for the Iv alanine tolerance test. Table 20 shows the list of 8 control subjects for the Iv alanine tolerance test. Their mean age was 28 ± 1.5 years, their mean height was 172 ± 3.5 cm, their mean weight was 63 ± 4.2 kg, and their mean %
Table 19

List of geriatric patients who participated in the Intravenous alanine tolerance test

<table>
<thead>
<tr>
<th>Subject</th>
<th>Sex</th>
<th>Age (years)</th>
<th>Body weight (Kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>JG</td>
<td>M</td>
<td>78</td>
<td>67</td>
</tr>
<tr>
<td>FL</td>
<td>F</td>
<td>82</td>
<td>47</td>
</tr>
<tr>
<td>EL</td>
<td>F</td>
<td>81</td>
<td>46</td>
</tr>
<tr>
<td>CL</td>
<td>F</td>
<td>82</td>
<td>41</td>
</tr>
<tr>
<td>AD</td>
<td>F</td>
<td>77</td>
<td>56</td>
</tr>
<tr>
<td>HE</td>
<td>M</td>
<td>71</td>
<td>60</td>
</tr>
<tr>
<td>BJ</td>
<td>F</td>
<td>78</td>
<td>57</td>
</tr>
<tr>
<td>JL</td>
<td>F</td>
<td>71</td>
<td>35</td>
</tr>
</tbody>
</table>
### Table 20

List of control subjects who participated in the intravenous alanine tolerance test

<table>
<thead>
<tr>
<th>Subject</th>
<th>Sex</th>
<th>Age (years)</th>
<th>Height (cm)</th>
<th>Weight (kg)</th>
<th>% Ideal weight*</th>
</tr>
</thead>
<tbody>
<tr>
<td>AT</td>
<td>M</td>
<td>34</td>
<td>181</td>
<td>76</td>
<td>94</td>
</tr>
<tr>
<td>SM</td>
<td>F</td>
<td>32</td>
<td>169</td>
<td>58</td>
<td>90</td>
</tr>
<tr>
<td>RA</td>
<td>M</td>
<td>31</td>
<td>170</td>
<td>70</td>
<td>97</td>
</tr>
<tr>
<td>JL</td>
<td>M</td>
<td>27</td>
<td>188</td>
<td>83</td>
<td>99</td>
</tr>
<tr>
<td>WS</td>
<td>M</td>
<td>32</td>
<td>159</td>
<td>55</td>
<td>86</td>
</tr>
<tr>
<td>SB</td>
<td>F</td>
<td>24</td>
<td>165</td>
<td>54</td>
<td>95</td>
</tr>
<tr>
<td>VP</td>
<td>M</td>
<td>23</td>
<td>178</td>
<td>74</td>
<td>102</td>
</tr>
<tr>
<td>CN</td>
<td>F</td>
<td>24</td>
<td>162</td>
<td>52</td>
<td>93</td>
</tr>
</tbody>
</table>

*Compared with the data from Geigy Scientific Tables (1970)
ideal body weight was 95 ± 1.0%.

D. The Tests

1. Oral GTT, IV GTT and IV G1TT:

The methods and procedures used in these tests, the calculation of the average glucose or insulin concentrations and insulin:glucose molar ratio during oral GTT; the calculation of KG and Kf in the IV GTT, and KG + Kf in IV G1TT, have all been described (see Part III, Chapter II, Methods).

Although all geriatric patients showed low values of KG and KG + Kf a few of the first patients tested showed hypoglycemic signs a few minutes after the end of the IV GTT. For that reason, all later patients received an extra 20 - 30 ml of 50 per cent glucose solution intravenously at the end of the IV GTT, and the nursing staff was asked to provide food and drink as soon as possible.

2. Intravenous alanine tolerance test (IV ATT):

This test was devised as a measure of the gluconeogenic capacity of the liver. The subjects were fasted from midnight and the test was carried out in the morning.

A butterfly needle attached to an antecubital vein of one arm was used for drawing blood sample. Two fasting blood samples (10 minutes apart) were taken at about 9.30 a.m. Through the same needle, a solution of 10 per cent l-alanine (0.15 g/kg body weight) (Wise et al. 1972) was injected. The alanine solution (see section B.3. below) was injected within 5 minutes, and serial blood samples through the same needle, were taken at 5', 10', 20', 30', 60' 90' and 120' after
the injection. The procedure for handling blood samples was similar to those in the oral GTT, iv GTT or iv GITT. Except that for glucagon estimation, that 4.5 ml of blood was also taken and added to another heparin tube containing 0.5 ml cold solution of Trasylol (10,000 KIU/ml, Bayer) and after immediate centrifugation the supernatant was frozen rapidly in solid CO₂ and stored at -20°C until the day of analysis.

Although none of the subjects complained of having any clinical complications from this test, a few of them however, experienced a slight stomach discomfort for several minutes following the injection of alanine.

3. 10% L-alanine solution:

Alanine solutions were made by dissolving sterile L-alanine (Kabi-Vitrum Pharmaceutical, Sweden) in sterile distilled water as a 10% solution. This solution was buffered to a pH between 7.0 and 7.3 with sodium hydroxide. It was then passed through a Millipore filter and autoclaved at 120°C for 10 minutes (Mestyan et al., 1974).

This alanine solution was made by the Department of Pharmacy, University College Hospital. We attempted to make our own solutions, but the Hospital refused to allow us to do the test unless the solution was made by the Hospital's own Pharmacy and from time to time the quality control of the solution was checked.

C. Analytical Methods:

Analysis for blood or plasma glucose, plasma NEFA, plasma insulin and plasma glucagon were carried out according to the procedures reported in the previous study (see Part II, Chapter II, Methods). Plasma alanine was analysed by an enzymatic
method, using l-alanine dehydrogenase (Reilly, 1975) with reagents supplied by the Boehringer Corporation, London Ltd.

D. Assessment of the Data:

Student's t test was used for comparing the patients data with those of the controls.
CHAPTER III
RESULTS

A. Oral GTT:

The oral GTT was carried out in 23 geriatric patients and in 13 normal control subjects (Tables 12 and 23).

1. Blood glucose:

   The mean blood glucose concentration was \( 4.92 \pm 0.11 \text{ mmol/l} \) \( (98.6 \pm 2.02 \text{ mg/dl}) \) in the geriatric patients against \( 4.62 \pm 0.16 \text{ mmol/l} \) \( (83.2 \pm 2.92 \text{ mg/dl}) \) in control subjects (Table 21, Fig. 27). The difference was not significant \( (p > 0.05) \), but during the test the concentrations of blood glucose in the patients continued to rise after 30' and the peak was at 90', whereas the peak in the controls was at 30'. Blood glucose concentrations in the patients were higher than in control subjects throughout the rest of the test. And the difference reached significant levels after 60' \( (p < 0.01) \), and from 90' \( p < 0.001 \) (Fig. 27A).

   The average value for blood glucose concentration during the oral GTT was \( 7.72 \pm 0.28 \text{ mmol/l} \) \( (139.1 \pm 5.03 \text{ mg/dl}) \) in the geriatric patients against \( 5.71 \pm 0.18 \text{ mmol/l} \) \( (102.8 \pm 3.25 \text{ mg/dl}) \) in control subjects. The difference was significant \( (p < 0.01) \) (Table 21).

2. Plasma insulin:

   The mean fasting plasma insulin concentration was \( 12.3 \pm 0.54 \text{ \mu unit/ml} \) in the geriatric patients against \( 12.8 \pm 1.31 \text{ \mu unit/ml} \) in control subjects. The difference was not significant \( (p > 0.05) \) (Table 21). During the test the concentrations
Oral GTT in 23 geriatric patients (○) and 11 normal control subjects (●).

A. Mean blood glucose values during oral GTT.
There were significant differences in the mean values at 60' (p < 0.01), and at 90', 120' and 150' (p < 0.001) between the two groups.

B. Mean plasma insulin values during oral GTT.
There were significant differences in the mean values at 30' (p < 0.01), at 120' (p < 0.05) and at 150' (p < 0.01) between these two groups.

C. Mean plasma NEFA values during oral GTT.
Except for the mean fasting levels (p < 0.05), the differences in the mean levels at various times during the test between the two groups were not significant.
(mean values of 12 geriatric and 7 normal control subjects).
of plasma insulin in the geriatric patients did not rise as high as in the control subjects, but continued to rise after 30', and the peak was at 90'. Whereas the peak in the controls was at 30'. Plasma insulin concentrations in the patients were lower than in control subjects, up to 60' (significant difference at 30', p < 0.01). But, while the insulin concentration after 60' decreased in the control subjects, the insulin concentration in the patients remained high, and was significantly greater than in the controls at 120' and 150' (p < 0.05 and p < 0.001 respectively). (Fig. 27B).

The average value for plasma insulin concentration during oral GTT was 31.6 ± 2.52 μ units/ml in the geriatric patients against 32.5 ± 3.51 μ units/ml in control subjects. The difference was not significant (p > 0.05) (Table 21).

As also in the study of obesity (Part III, Chapter II, Patients) any overt diabetics (fasting blood glucose higher than 6.11 m mol/l) were excluded during the initial selection of patients. WHO (1965) further gave as a criterion for a 'normal' oral GTT, that the 120' blood glucose value should be less than 6.11 m mol/l (110 mg/100 ml) and gave the lower limit for diabetes as a 120' value of 7.22 m mol/l (130 mg/100 ml). Having regard to the advanced age (mean 79 ± 1.1 years) of these patients we arbitrarily chose 7.77 m mol/l (140 mg/100 ml) for an upper limit for 'non-diabetic' geriatric subjects. According to this new criterion, among 23 geriatric patients studied, 15 could be classified as 'diabetic' and 8 as 'non-diabetic' geriatrics (Table 22). Fortuitously, the dividing line of 7.77 m mol/l corresponded closely with the mean
Table 21

The mean values for fasting blood glucose and plasma insulin, average concentrations of blood glucose and plasma insulin, and insulin-glucose molar ratio during oral GTT, in geriatric patients and control subjects (± SEM). Number of observations in parenthesis.

<table>
<thead>
<tr>
<th></th>
<th>Mean fasting concentrations</th>
<th>Mean of the average value for 130 min.</th>
<th>10⁶ x mean insulin: glucose molar ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Blood glucose (m mol/l)</td>
<td>Plasma insulin (µ unit/ml)</td>
<td>Blood glucose (m mol/l)</td>
</tr>
<tr>
<td>Patients (23)</td>
<td>4.92 ± 0.11</td>
<td>12.3 ± 0.54</td>
<td>7.72 ± 0.28</td>
</tr>
<tr>
<td></td>
<td>ns</td>
<td>ns</td>
<td>**</td>
</tr>
<tr>
<td>Controls (13)</td>
<td>4.62 ± 0.16</td>
<td>12.8 ± 1.31</td>
<td>5.71 ± 0.18</td>
</tr>
<tr>
<td></td>
<td>ns</td>
<td>ns</td>
<td>**</td>
</tr>
</tbody>
</table>

* p < 0.05  ** p < 0.01  ns = not significant
120' blood glucose value for all 23 patients (8.12 m mol/l).

3. Insulin:glucose molar ratio:

The mean insulin:glucose molar ratio in the geriatric patients was \((29.8 \pm 2.27) \times 10^{-6}\) against \((42.2 \pm 4.50) \times 10^{-6}\) in control subjects. The difference was significant \((p = 0.01)\) (Table 21).

4. Plasma NEFA:

There was a great range in the levels of plasma NEFA both in the geriatric patients and in control subjects. This applied to the fasting concentrations as well as to the concentrations during the test. The mean fasting plasma NEFA concentration in the geriatric patients was \(866 \pm 86 \mu \text{mol/l}\) against \(590 \pm 68 \mu \text{mol/l}\) in control subjects. The difference was significant \((p < 0.05)\). Although the plasma insulin concentrations during the oral GTT were lower in the geriatric patients, there were no significant differences in the mean NEFA concentrations at any time during the test between the geriatric patients and the normal controls. The NEFA curve during the oral GTT in the patients mirrored their sluggish insulin curve, showing a delayed and prolonged reaction. Thus at 150' the mean NEFA concentration was lower in the patients than in the controls, since in the latter the NEFA concentration had started to rise again (Fig. 27C).

5. Iv GTT and Iv GITT:

The Iv GTT and Iv GITT were carried out in 23 geriatric patients and in 10 normal controls (Tables 23 and 12).

1. KG values:

The mean KG value in the geriatric patients was \(0.98 \pm 0.09 \% / \text{min}\) against
Table 22

Mean blood glucose and plasma insulin concentrations during oral GTT in the 'diabetic' and 'non-diabetic' geriatrics and in normal control subjects (± SEM). Number of observations in parenthesis.

<table>
<thead>
<tr>
<th>Oral GTT</th>
<th>Mean blood glucose concentrations (mmol/l)</th>
<th>Mean plasma insulin concentrations (μ unit/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0'</td>
<td>15'</td>
</tr>
<tr>
<td>I</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>±</td>
<td>±</td>
</tr>
<tr>
<td>I × II</td>
<td></td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>4.62</td>
<td>5.77</td>
</tr>
<tr>
<td></td>
<td>±</td>
<td>±</td>
</tr>
<tr>
<td>II × III</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I × III</td>
<td></td>
<td></td>
</tr>
<tr>
<td>II × III</td>
<td></td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>4.62</td>
<td>6.15</td>
</tr>
<tr>
<td></td>
<td>±</td>
<td>±</td>
</tr>
<tr>
<td></td>
<td>0.16</td>
<td>0.36</td>
</tr>
</tbody>
</table>

*p < 0.05  **p < 0.01  ***p < 0.001
1.81 ± 0.28%/min in the control subjects. The difference was significant (p < 0.001) (Table 23).

There was no statistical correlation between $K_q$ and fasting plasma insulin values during iv GTT in the combined group of geriatric patients and the normal controls (Fig. 28A).

There was also no correlation between $K_q$ and peak plasma insulin values, in the geriatric patients and control subjects (Fig. 28B). However, a higher $K_q$ was usually related to a lower peak plasma insulin concentration.

2. Peak insulin concentrations during oral GTT and iv GTT:

There were 23 geriatric and 9 normal control subjects who had both oral and iv GTT done.

The mean peak insulin concentrations during the oral GTT were higher than the mean peak insulin concentrations during iv GTT both in the geriatric patients and in the control subjects. The differences, however, were not significant (p > 0.05) (Table 24). Whereas in the control subjects the peak insulin concentrations during the oral GTT were always higher than the peak during the iv GTT, in the geriatric patients however, 8 out of 23 patients had peak insulin concentrations during the iv GTT higher than the peak during the oral GTT. This suggested that in these 8 geriatric patients there was some degree of small intestinal malabsorption. The mean peak insulin concentration during the oral test in the geriatric patients was $48.0 ± 5.34$ μ unit/ml against $72.0 ± 7.26$ μ unit/ml in the control subjects. The difference was significant (p < 0.05) (Table 24).
Table 23

The mean values for $K_G$, $K_G + 1$, $K_F$ in the geriatric patients and in normal control subjects ($\pm$ SEM). Number of observations in parenthesis.

<table>
<thead>
<tr>
<th></th>
<th>$K_G$</th>
<th>$K_G + 1$</th>
<th>$K_F$</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(% / min)</td>
<td>(% / min)</td>
<td>(% / min)</td>
</tr>
<tr>
<td>Geriatric patients</td>
<td>0.98 ± 0.09</td>
<td>2.29 ± 0.16</td>
<td>2.21 ± 0.34</td>
</tr>
<tr>
<td>(23)</td>
<td>(23)</td>
<td>(10)</td>
<td></td>
</tr>
<tr>
<td>Control subjects</td>
<td>1.31 ± 0.28</td>
<td>4.55 ± 0.51</td>
<td>3.10 ± 0.73</td>
</tr>
<tr>
<td>(10)</td>
<td>(10)</td>
<td>(6)</td>
<td></td>
</tr>
</tbody>
</table>

*** $p < 0.001$; ns = not significant
Figures 28 A. Correlation $K_g$ and fasting plasma insulin values during iv GTT in the geriatric patients (O) and normal control subjects (●).

28 B. Correlation between $K_g$ and peak plasma insulin values during iv GTT in the geriatric patients (△) and normal control subjects (▲).
The mean peak insulin concentration during iv GTT in the geriatric patients was 41.4 ± 5.13 µ unit/ml against 54.0 ± 13.60 µ unit/ml in the control subjects. This difference was not significant (p > 0.05) (Table 24).

3. K4 values:

The mean K4 value in the geriatric patients was 2.29 ± 0.16%/minute against 4.55 ± 0.51%/minute in the control subjects. The difference was significant (p < 0.001) (Table 25).

There was no correlation between K4 and fasting plasma insulin values in the geriatric patients nor in control subjects (Fig. 29 A).

There was also no correlation between K4 and peak plasma insulin values during iv GTT in the geriatric patients nor in control subjects (Fig. 29 B).

There was a highly significant correlation between K4 and K4 values in the combined geriatric patients and normal control subjects. (r = 0.71, p < 0.001) (Fig. 30).

4. K4 values:

The mean K4 value in the geriatric patients was 2.21 ± 0.34%/minute against 3.10 ± 0.73%/minute in the normal control subjects. The difference was not significant (Table 25).
Table 24

The mean peak insulin concentrations during oral GTT and iv GTT (± SEM), in geriatric patients and normal control subjects. Number of observations in parentheses.

<table>
<thead>
<tr>
<th></th>
<th>Oral GTT</th>
<th>Iv GTT</th>
<th>Ratio of oral:iv peak insulin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Geriatric patients (23)</td>
<td>48.0 ± 5.34</td>
<td>41.6 ± 5.13</td>
<td>1.18</td>
</tr>
<tr>
<td>Controls (9)</td>
<td>72.0 ± 7.36</td>
<td>54.0 ± 13.40</td>
<td>1.33</td>
</tr>
</tbody>
</table>

*p < 0.05; ns = not significant
Correlation between $K_{C+I}$ and fasting plasma insulin values during iv GTT in the geriatric patients (O) and normal control subjects (•).

Correlation between $K_{C+I}$ and peak plasma insulin values during iv GTT in the geriatric patients (△) and normal control subjects (•).
Regression line between the values of $K_u$ and $K_{G+I}$ in the combined group of psychiatric patients (○) and normal control subjects (●).
C. Iv Alanine Tolerance Test (Iv ATT):

1. **Blood glucose:**

   The mean fasting blood glucose concentration was $4.77 \pm 0.17$ mmol/l ($85.9 \pm 3.02$ mg/100 ml) in the geriatric patients against $4.92 \pm 0.07$ mmol/l ($88.6 \pm 1.32$ mg/100 ml) in the control subjects (Fig. 2A). The difference was not significant ($p > 0.05$). During the test in the geriatric patients, blood glucose concentration continued to rise after 10' and reached a plateau only at 30', whereas the blood glucose concentration in the control subjects only rose and reached a peak at 10' before falling again. Blood glucose concentrations in the geriatric patients were significantly higher than in the control subjects from 30' onwards ($p < 0.01$) (Fig. 3A).

2. **Plasma insulin:**

   The mean fasting plasma insulin concentration was $7.8 \pm 0.86$ µunits/ml in the geriatric patients against $10.9 \pm 1.22$ µunits/ml in the control subjects. The difference was significant ($p < 0.01$) (Fig. 3B). During the test the levels of plasma insulin in the control subjects continued to rise and the peak was at 30', whereas the peak in the geriatric patients was at 5'. Throughout the test the plasma insulin concentrations in the control subjects were always higher than in the geriatric patients. The differences were significant at 10' and 20' ($p < 0.001$), at 30'
Intravenous Alanine tolerance test (0.15 g l-alanine/Kg BW) in 8 geriatric patients (○) and 8 normal control subjects (∙).

Mean blood glucose concentration following the iv injection of alanine.

There was no significant difference in the mean fasting blood glucose levels, but in the geriatric patients blood glucose was raised and remained elevated throughout the test. The difference in the mean levels reached significant level after 30' (p < 0.01).

Mean plasma insulin values at various times during the test.

There was a significant difference in the fasting values between the two groups (p < 0.01); at 10', and 20' (p < 0.001), at 30' and 60' (p < 0.01).
and 60' (p < 0.01) (Fig. 31B).

3. Plasma alanine:

The mean fasting plasma alanine concentration was 398 ± 64 µ mol/l in the geriatric patients against 387 ± 52 µ mol/l in the control subjects. The difference was not significant (Table 25).

The peak plasma alanine concentration was 5536 ± 562 µ mol/l in the geriatric patients against 5436 ± 661 µ mol/l in the control subjects. Both were at 5' after an injection of 1-alanine and the difference was not significant (Table 25).

The mean % removal rate of alanine (K_A) was 2.93 ± 0.18 %/min in the geriatric patients against 5.31 ± 0.71 %/min in the control subjects. The difference was highly significant (p < 0.001) (Table 25).

4. Plasma glucagon:

Radioimmuno assay of glucagon is carried out in Dr. S. R. Bloom's laboratory, The Royal Post Graduate Medical School, London. At present, they are having difficulty with the assay technique, and at the time of writing this thesis, results of plasma glucagon levels during the iv alanine test have not been received. The glucagon results cannot therefore be included in this report, but it is hoped to add them as a separate appendix as soon as they are available.
The mean fasting and peak concentrations and the mean percentage removal rate of plasma alanine ($K_A$) during iv alanine tolerance test (± SEM) in the geriatric patients and in the control subjects. Number of observations in parenthesis.

<table>
<thead>
<tr>
<th></th>
<th>Mean fasting concentration (µmol/l)</th>
<th>Mean peak concentration (at 5')</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Geriatric patients</strong></td>
<td>$398 \pm 64$</td>
<td>$5536 \pm 362$</td>
</tr>
<tr>
<td>(4)</td>
<td>$2.93 \pm 0.18$</td>
<td>$\ast$</td>
</tr>
<tr>
<td><strong>Control subjects</strong></td>
<td>$387 \pm 62$</td>
<td>$5456 \pm 661$</td>
</tr>
<tr>
<td>(4)</td>
<td>$5.31 \pm 0.71$</td>
<td>$\ast$</td>
</tr>
</tbody>
</table>

$\ast$ $p < 0.05$; na = not significant
Our results show the familiar findings of an impairment in oral GTT in old age (Brant, 1960; Burch and O'Meally, 1967; Chlouverakis, et al., 1967; Smith and Hall, 1973) (Fig. 27A). Insulin secretion showed a sluggish response to the glucose load, with a delayed peak at 90' (Fig. 27B). The peak of plasma insulin corresponded with the peak of the glucose curve. There was no significant difference in the mean fasting concentration and the mean average concentration of plasma insulin during the oral GTT, between the geriatric patients and normal control subjects. However, the insulin:glucose molar ratio was significantly lower in the geriatric patients ($p < 0.01$) (Table 21).

This work has demonstrated that looking only at a single time for insulin during the oral GTT, e.g. the 60' value as reported by Chlouverakis, et al. (1967), could be very misleading, since at that stage (60') insulin concentration in geriatric patients was still rising (peak at 90') whereas in the control subjects it was in the process of going down (peak at 30'). Therefore, at this time (60'), there was an apparently higher mean plasma insulin value in the geriatric subjects (Fig. 27B). Our results are in line with those reported by Smith and Hall (1973), where they also had serial measurements of plasma insulin during the oral GTT.

It is interesting to note that the decrease in the level of plasma NEFA during the oral GTT was not significantly different between the geriatric patients and normal controls (Fig. 27C), despite the fact that the geriatric patients had a delayed insulin curve. This suggests that insulin levels in the geriatric patients were still
able to prevent NEFA release from adipose tissue. Plasma NEFA concentrations, like those of plasma insulin also showed a sluggish response to glucose administration in the elderly.

Our results also confirmed earlier findings that old people have an impairment in iv GTT (Streeten et al., 1965; Franckson et al., 1966; Cockford et al., 1966). There were significant differences in the mean $K_G$ ($p < 0.001$) and $K_G + 1$ ($p < 0.001$), but not in the mean $K_F$ values, between the geriatric patients and the normal controls (Table 23). This may suggest that old age affects carbohydrate more than fat metabolism (represented by anti-lipolytic action of insulin).

The patients had suffered at variable times before the test from the usual range of clinical conditions found in geriatric wards, e.g. cardiovascular accident (C.V.A.), myocardial infarct, gangrene, etc. Some still had the results of their previous illnesses such as hemiplegia, paraplegia, kyphosis, etc., at the time of the test (Table 18). However, all were in reasonably 'good health'. None of these previous illnesses (e.g. myocardial infarct), show any correlation with the results of glucose tolerance. This was seemingly surprising for ischaemic cardiovascular diseases show correlation with impaired glucose homeostasis in the 50 to 60 year old adults (Wahlberg and Thomason, 1968). Possibly in the younger people, low $K_G$ values as other indices of impaired glucose homeostasis may be signs associated with those more prone to heart attacks. But, by the advanced age of the patients in this work, all seem to have reached such a degree of impairment, that differences due to factors other than age are difficult to distinguish.
Drug treatments received by these patients (if any) were discontinued for at least 12 hours before the test.

The mean peak insulin level during the oral GTT was significantly lower \((p < 0.05)\) in the geriatric patients compared with normal control subjects. The mean peak insulin level during the IV GTT was also lower in the elderly but not significantly so \((p > 0.05)\) (Table 24). These findings of low peak levels of insulin response to glucose load, appear to support the hypothesis of Andres (1973), who gave prime importance to the decreased \(\beta\)-cell response to glucose stimulus in contributing to the impairment of carbohydrate metabolism in old age.

As in the study in obesity, the results for geriatric patients show that insulin sensitivity \((K_g + 1\) value) is a more important factor in determining glucose tolerance than the actual plasma insulin concentration. This is shown first by the highly significant correlation between \(K_g\) and \(K_g + 1\) values in the combined group of geriatric patients and normal control subjects \((r = 0.71, p < 0.001)\) (Fig. 30), and secondly by the fact that there was no statistical correlation between \(K_g\) and fasting or peak plasma insulin values during the IV GTT (Figs. 28A and 28B). Nor did sensitivity to insulin relate to basal or peak insulin levels during the IV GTT, since there was no statistical correlation between \(K_g + 1\) and fasting or peak insulin values during IV GTT (Figs. 29A and 29B).

Glucose absorption by the small intestine (during oral GTT) must also play a part in determining the shape of the curve, Webster and Leaming (1973), using a modified
xylose tolerance test and the method of Roe and Rice (1948) for determining xylose
concentration, showed that 26 per cent of geriatric subjects showed some degree of
malabsorption. If this is true, the delayed entry of glucose into the circulation would
add its effect to those of other factors responsible for prolonged hyperglycaemia, and
increase its severity (Fig. 27A). Hepatic glucose production is the most obvious non-
dietary candidate for the cause of delayed hyperglycaemia in the oral GTT. It was
hoped that this could be assessed by l-alanine administration, but in order to separate
the hepatic from gut factors, alanine had to be given intravenously.

Injection of l-alanine produced a significantly higher concentration of blood
glucose in the geriatric patients than in control subjects (Fig. 31A). It seemed that
in the geriatric patients, plasma insulin (which was low compared to normal control
subjects) was unable to suppress gluconeogenesis by the liver (Fig. 31B). Therefore,
the glucose level remained high, whereas in the control subjects it went down after
10'. Unfortunately glucagon values during this test are not yet available at the time
of writing.

Glycogen content in the liver must have been low if not depleted altogether
(at least in the geriatrics) as shown by low fasting values of blood glucose in both
groups (Fig. 31A), (Hultman and Nilsson, 1971), so that the new glucose must in
large part be due to the conversion of alanine rather than glycogenolysis in the liver.

The fact that fasting must have been reasonably adequate is shown also by the
fact that alanine produced, even in control subjects, only a modest increase in
insulin secretion (Fig. 31B). If the glucagon results had been available, they would
probably have shown a marked rise (Unger, 1972). Only if glucose is available does alanine have a marked stimulation effect on the $\beta$-cell and under such circumstances the effect on glucagon release is minimal.

Within the limitations of this simple test, l-alanine injections seemed to indicate some inability of endogenous insulin to suppress glucose production by the liver in the geriatric subjects. However, the alanine results on their own do not really prove that the higher glucose values in the geriatric patients are not simply due to the shortage of insulin.

As in the study in obesity, the geriatric patients were also divided into two groups based on 120' blood glucose value during oral GTT. The 'diabetic' group has 120' blood glucose value higher than 7.77 m mol/l (140 mg/100ml) and the 'non-diabetic' group values lower than 7.77 m mol/l. Fortuitously, the dividing line (7.77 m mol/l), which had been arbitrarily chosen, corresponded closely with the mean 120' blood glucose value for all 23 patients (8.12 m mol/l) and with the 50th percentile value for the 120' blood glucose value of 80 year olds given by Andres (1973). The degree of impairment in oral GTT in these two groups was not related to the degree of hypoinsulinemia (Table 22). In fact, the average insulin values during oral GTT were almost identical for the 'diabetic' and 'non-diabetic' groups, each being slightly less than for normal controls. The only difference lay in the shape of the curves. This confirms the argument advanced earlier for the geriatric patients as a whole, that insulin deficiency was not the main cause of impaired glucose tolerance.
The question really is, if the elderly do indeed produce less insulin in response to a glucose challenge than young people, does insulin 'deficiency' constitute a limiting factor in glucose homeostasis? Another way of looking at this problem is to pick only control subjects who had low insulin:glucose molar ratio during oral GTT (low-ratio controls). In these low-ratio controls (LRC) \((n = 5)\), their mean insulin:glucose molar ratio was 27.8 ± 1.33 against 29.8 ± 2.29 in the elderly \((p > 0.05)\).

The mean average plasma insulin concentration during oral GTT in the LRC was 20.8 ± 0.55 μunit/ml against 31.6 ± 2.52 μunit/ml in the geriatric patients. The difference was also not significant. However, the LRC, despite the fact that they had slightly lower mean value of plasma insulin, were able to manage to have a significantly lower mean value ("normal") of average blood glucose concentration during the oral GTT. This mean value was 5.38 ± 0.25 mmol/l in these LRC against 7.72 ± 0.26 mmol/l in the geriatric patients. The difference was highly significant \((p < 0.001)\) (Table 26). These results again show that hypoinsulinaemia was not the main cause of impaired glucose tolerance in the elderly.

Our results show significant differences in carbohydrate metabolism between old and young people, and we are convinced that the liver plays an important role. Future work should attempt to define this role more clearly. For instance, if a tracer dose of labelled glucose accompanied the test load, measurements of specific activity of plasma glucose at various times during the test would throw some more light on
The mean values for average concentrations of blood glucose and plasma insulin, and insulin-glucose molar ratio during oral GTT in controls, 5 controls with low insulin-glucose molar ratio (low-ratio controls), and in geriatric patients (± SEM). Number of observations in parenthesis.

Mean of the average value for 150 min.

<table>
<thead>
<tr>
<th></th>
<th>Blood glucose (mmol/l)</th>
<th>Plasma insulin (µunit/ml)</th>
<th>(10^6) x mean insulin: glucose molar ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(m mol/l)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I Controls (13)</td>
<td>5.71 ± 0.18</td>
<td>33.5 ± 3.51</td>
<td>42.2 ± 4.50</td>
</tr>
<tr>
<td></td>
<td>ns</td>
<td>ns</td>
<td>ns</td>
</tr>
<tr>
<td></td>
<td>ns</td>
<td>ns</td>
<td>vs</td>
</tr>
<tr>
<td>II Low-Ratio Controls (5)</td>
<td>5.38 ± 0.35</td>
<td>20.8 ± 0.55</td>
<td>27.8 ± 1.33</td>
</tr>
<tr>
<td>II x III</td>
<td>***</td>
<td>ns</td>
<td>ns</td>
</tr>
<tr>
<td>III Geriatric patients</td>
<td>7.72 ± 0.28</td>
<td>31.6 ± 2.52</td>
<td>29.8 ± 2.27</td>
</tr>
</tbody>
</table>

*p < 0.01; **p < 0.001; ns = not significant;
the significance of liver gluconeogenesis.

As with carbohydrate metabolism, it is not surprising that protein synthesis and protein turnover is also reduced in the elderly (Young, Steffee, Pencharz, Winterer and Schirmshaw, 1975; D.J. Millward, personal communication). Our results show that added alanine disappeared significantly more slowly (low $K_a$) from the blood of the elderly than from normal young people ($p < 0.001$; Table 25). This may indicate that transfer rates for amino acids like alanine become diminished in old age. Dr. D.J. Millward (personal communication) reports that infusion of labelled amino acids takes considerably longer to reach plateau levels in old rats than in young rats. Possibly, impaired glucose tolerance may even be a part of this general phenomenon.
PART V

GENERAL DISCUSSION
The common thread running through this work is the role of insulin in glucose homeostasis in three different situations, each of which may be regarded as presenting some degree of stress viz. surgery, obesity and old age. Each of these topics has already been discussed individually in some detail. The object of the present discussion is to comment briefly on a few general points which have escaped earlier reference or which are of general importance across the whole area of this investigation.
CHAPTER II

METHODS

A. Choice of Subjects:

Patients participating in the study of glucose homeostasis after surgery were chosen by the surgical staff, Department of Surgery, University College Hospital, London (Head: Professor C.G. Clark), based on our specification (see Part II, Chapter II, Subjects).

This study was planned in such a way that each patient would be his own control by comparing tests carried out on day 1 post-operatively, and on 'recovery'. Four young normal subjects were also included in the study and were referred to as 'controls'. However, they could not serve as 'controls' in the pure sense, because, although their mean body weights and mean % ideal body weight were not significantly different from those of the patients, they were significantly younger. The mean age of the normal subjects was 27 ± 2.3 years against 52 ± 3.4 years, in the patients (P < 0.01). (See Part II, Chapter II, Subjects). If work with glucose infusion were to continue, it might be useful in the future to recruit more volunteers to make up the number, and extend the age range, so that it covers the age range of the patients. However, in the present work, any differences between the surgical patients and the 'control' subjects could, therefore, not only be due to the effect of surgery and food deprivation, but also the effect of age.

If age (52 years) were a significant factor in determining the results of glucose infusion, one would expect at least a trend towards impaired rather than heightened insulin secretion in response to glucose (compare geriatric patients, Part IV).
Therefore, the effect of age in the surgical study is likely to have been minimal.

In the choice of patients in the study in obesity, we had 29 obese subjects who attended the Nutrition Clinic, University College Hospital and willing to participate in our study, but not all agreed to have the three tests carried out on them. Some agreed to having the oral GTT while the others agreed only to participate in the iv GTT and iv GITT (these two tests were carried out one after another on the same morning). And only 7 subjects agreed to have all three tests carried out (Table II).

It is hoped that in future work a larger number of obese patients will be studied, so that they can be classified not only according to % ideal body weight alone (as in the present study), but to be extended to the possible classification of patients by combined age and % ideal body weight.

Fortunately, in the study in the elderly, we were able to persuade the volunteers (geriatric patients) to participate in all of the three tests (oral GTT, iv GTT and iv GITT). Basically, most of these patients were lonely, and they loved to have someone show interest in them. In general they were less concerned about the trauma (pain) of the needle used during the test, compared to the attitudes of the surgical and obese patients, and even more, the healthy controls.

However, we also faced difficulties when we asked the elderly patients to participate in the iv alanine tolerance test. This may be due to the fact, apart from some of the patients not being available, the iv alanine tolerance test gave a slight stomach discomfort to some, for 10 to 30 minutes after the injection of l-alanine.
As this became known, the difficulty in obtaining volunteers increased, not only in the elderly but also among potential 'control' subjects.

II. Choice of Test:

It would be ideal if we could have the same test for all three studies (surgery, obesity and old age). However, each test has its own merits and disadvantages.

1. Glucose Infusion test:

This test was considered the best for surgical patients, because it represents only a minor change (a pump instead of the usual infusion drips) in the method of infusing glucose which most patients received as usual post-operative 'dietary' therapy. It was, therefore, of minimal burden to these immediate post-operative patients (day 1) and included those who participated in this study and most of them did not seem to mind this change. However, during the 'recovery' period the presence of the operator together with his infusion set and infusion pump was not a welcome sight.

The amount of glucose infused (0.35 g kg\(^{-1}\) h\(^{-1}\)) would certainly have suppressed hepatic glucose output (Madison, 1987). Therefore, when a plateau of blood glucose concentration had been reached, we could discount the hepatic factor, and the rate of infusion at this stage represents the peripheral glucose uptake, unless blood glucose concentration exceeds the renal barrier, in which case some would be lost through urine.

Since the rate of infusion was the same on all occasions, so also was the total glucose uptake. Now total glucose uptake = concentration \(\times\) fractional rate.
of uptake (Franckson, et al. 1966). Therefore, those patients who showed the highest plateau concentrations of blood glucose (day 1, post-operatively) must have had the lowest fractional rates of glucose removal (equivalent to the lowest KG values).

We also tried similar glucose infusions on some obese and geriatric patients. They also shared the view of those recovering surgical patients (during the 'recovery' period), of not being keen on having this test carried out. This, together with other technical problems such as the difficulty in getting two nice veins, one in each arm, in some obese subjects, meant that there seemed no good reason to persist with glucose infusion as opposed to the other tests.

2. Oral GTT:

This test is straightforward and has not been associated with any complaints of discomfort from patients or subjects. Its main obvious advantage is that it is physiological, in that the glucose enters by mouth and is subject to the full range of factors before it reaches the tissues. Its main disadvantage is that one is presented with a curve or a set of results rather than a single answer. This may necessitate quite difficult value judgements, e.g. in deciding the weight to be attached to fasting or 120' blood glucose values in diagnosing 'diabetes'. (Working Party, Royal College of General Practitioners, 1963, WHO, 1965).

The fact that the oral GTT has been so widely used under fairly standardised conditions in a large variety of subjects, makes it a valuable reference test in comparing data from one source with another.
3. **IV GTT:**

The test is relatively unfamiliar to most clinicians compared with the oral GTT, and its advantages are the short duration of the test (60 minutes) and the fact that the test has a result which can be expressed as a single figure ($K_C$). This permits statistical comparison between individuals or groups and between the same subject at different periods of time. Moreover, since it bypasses the gut, the IV GTT eliminates the complication of having to consider the absorption and gut insulinogetic factors. However, it also has some disadvantages.

Lafferty, Geddings and Mangnall (1975) argued that $\%$ disappearance rates ($K_g$ values) for glucose were without value and absolute removal rates alone have any meaning. It can, however, be argued that 'normality' in absolute glucose removal rates alone tells us very little about the state of the subjects. For instance, in the earlier discussion (2.1.) on surgical patients, it was pointed out that all had the same absolute glucose removal rates, but because blood glucose concentrations differed, $K_g$ values must have differed similarly (but inversely). The $K_g$ values gave a measure of insulin sensitivity (they significantly correlate with $K_g + I$ values; Table 27), and tell us that subjects differ in this respect. Absolute blood glucose and insulin levels reveal the extent and manner of adaptation to this changing sensitivity to insulin. It is in fact difficult to see how absolute glucose removal rates could be impaired, unless there was a severe failure in the $\beta$ cell or wastage of glucose via the urine.

4. **IV GTT:**

This test is extensively used in animals (Turner, 1966; Heard and Turner,
Table 27

Correlation between $K_G$ and $K_G + 1$ values in control subjects, obese and geriatric patients, and in the combined three groups.

<table>
<thead>
<tr>
<th></th>
<th>No.</th>
<th>Regression Line</th>
<th>$r$</th>
<th>$P$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control subjects</td>
<td>10</td>
<td>$y = 0.33x + 0.32$</td>
<td>0.60</td>
<td>$&gt; 0.05$</td>
</tr>
<tr>
<td>Obese patients</td>
<td>16</td>
<td>$y = 0.34x + 0.15$</td>
<td>0.65</td>
<td>$&lt; 0.01$</td>
</tr>
<tr>
<td>Geriatric patients</td>
<td>22</td>
<td>$y = 0.23x + 0.44$</td>
<td>0.43</td>
<td>$&lt; 0.05$</td>
</tr>
<tr>
<td>Combined group</td>
<td>49</td>
<td>$y = 0.33x + 0.21$</td>
<td>0.70</td>
<td>$&lt; 0.001$</td>
</tr>
</tbody>
</table>
1967; Heard and Henry, 1969, a, b) resembles others which have been used in man
(e.g. Franckson, et al., 1966) and is in part, identical to that of Silverstone.
Bruntonbrner, Shock and Ylengst, (1957). The key difference is that in the present
test the iv GITT should be coupled with iv GTT and measurements of plasma insulin,
to give simultaneous assessment of glucose tolerance and insulin status and sensitivity.
The iv GITT is then, a good measure of insulin sensitivity (Table 27).

The administration of a relatively large dose of exogenous insulin in this
test should certainly switch off glucose output from the liver, and, therefore, any
differences in the KG + I values can only be due to the differences in peripheral
tissue responsiveness.

The 10' values of plasma insulin concentration after the injection of glucose
and insulin, could be as high as 150 to 300 μ unit/ml in the normal subjects, and
even higher in some of the obese patients.

C. Skinfold Measurements:

Skinfold measurements were carried out in some obese, elderly and control
subjects, as a measure of their nutritional status. These measurements, however,
were so unreliable in the obese, especially the extremely obese (reproducibility
very poor). They seemed to have better reproducibility in the elderly, but the
present data for comparison (Dumin and Womersley, 1974) did not cover very old
subjects (the highest was 50 + years). The measurements of the elderly subjects
(mean age 79 years) if compared with their data, gave apparently lower values of
body fat content. This may be due to the fact that in the very old the elasticity
of the skin had become very poor, and the measurements gave a false, lower reading
of skinfold thickness.
A. Insulin Resistance:

The patients showed a 'temporary' insulin resistance, manifested in infusion I, by high plateau values for blood glucose (i.e. low $K_g$ values; see Chapter II, B.1), in the presence of levels of insulin which were higher than normal. In infusion II blood glucose plateau concentrations were almost the same as in infusion I, and therefore $K_g$ values had not changed significantly, but plasma insulin values were lower. Therefore, presumably insulin resistance had diminished, but had not returned to normal (compare with young 'control' subjects).

In infusion I, the development of insulin resistance was probably due to the high circulating levels of cortisol and glucagon and probably other anti-insulin hormones (e.g. catecholamines and growth hormone).

B. Significance of Insulin Therapy:

As discussed earlier, insulin administration has been advocated and practiced to overcome the insulin resistance of trauma (Hinton, et. al., 1971) (see Part II, Chapter IV). It must be acknowledged that insulin treatment is probably necessary for very serious trauma, like burns. The very high catabolic state in burns would deplete glycogen stores and enhance lipolysis. This increase in lipolysis causes raised levels of NEFA, which were shown to cause massive deposition of fat in the liver (Feligson, Pfaff, Karmen and Stienberg, 1961). On the other hand in moderate or minor types of surgery (or other physical trauma), lipolysis is probably desirable, to enable the body to use its energy reserves of fat rather than protein.
Giving amino acids, instead of the usual glucose, would then permit the improvement of negative nitrogen balance and by not encouraging release of high levels of insulin in the circulation would permit lipolysis (Blackburn, et al., 1973).

C. Nitrogen Balance.

As judged by the degree of the urinary nitrogen excretion (mean between 9 and 11 g nitrogen loss per day), the degree of trauma in the present series of surgical patients appears low, compared with, for instance, massive urinary nitrogen excretion reported by Cuthbertson (1964), from patients following fracture. However, his patients received a diet with 70 g protein/day, unlike the surgical patients who received none for the first few days following the operation. Another factor to be borne in mind is the influence of previous diet. If low in protein, this might lead to minimal increased loss of urinary nitrogen following trauma (Munro, 1964). Conclusions drawn from urinary nitrogen figures alone are dangerous. A proper nitrogen balance must be estimated.
CHAPTER IV
STUDY IN OBESITY AND ELDERLY SUBJECTS

A. Impaired Glucose Tolerance

The obese and elderly subjects showed a chronic or permanent form of insulin resistance.

Both groups showed impaired glucose tolerance, shown by the significantly higher mean values for average blood glucose concentrations during oral GTT (Table 28), higher and delayed peak of glucose levels during oral GTT (Fig. 18A and Fig. 27A), and significantly lower values of $K_G$ during iv GTT (Table 29), compared with the mean values in the normal subjects.

The impaired glucose tolerance in the obese subjects was related to higher mean levels of average plasma insulin concentrations and peak insulin response during oral GTT (Tables 28 and 30), and to significantly higher mean peak plasma insulin concentration (Table 30) during iv GTT, than in the normal control subjects.

In contrast to the obese, impaired glucose tolerance in the elderly was associated with normal or marginally diminished insulin levels during oral GTT and iv GTT (Tables 28 and 30).

B. Possible Role of the Liver:

The main feature of the oral GTT in the elderly was the delayed and exaggerated peak glucose values. The main cause of which probably the impaired ability of the liver (in the elderly) to switch off glucose production in response to endogenous insulin. This impairment resulted in prolonged hyperglycaemia. But one must also
Table 28

The mean values for fasting blood glucose and plasma insulin, average concentrations of blood glucose and plasma insulin, and insulin:glucose molar ratio during oral GTT in control, obese and geriatric subjects (± SEM). Number of observations in parenthesis.

<table>
<thead>
<tr>
<th></th>
<th>Mean fasting concentrations</th>
<th>Mean of the Average Value for 150 min.</th>
<th>10^6 × mean insulin: glucose molar ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Blood glucose (m mol/l)</td>
<td>Plasma insulin (μ unit/ml)</td>
<td>Blood glucose (m mol/l)</td>
</tr>
<tr>
<td>Controls (13)</td>
<td>4.62 ± 0.16</td>
<td>12.8 ± 1.31</td>
<td>5.71 ± 0.18</td>
</tr>
<tr>
<td>I x II</td>
<td></td>
<td></td>
<td>240.4 ± 25.2</td>
</tr>
<tr>
<td>I x III</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>II Obese (16)</td>
<td>4.89 ± 2.93</td>
<td>21.4 ± 2.86</td>
<td>6.73 ± 0.28</td>
</tr>
<tr>
<td>II x III</td>
<td></td>
<td></td>
<td>495.8 ± 76.4</td>
</tr>
<tr>
<td>III Geriatric (23)</td>
<td>4.92 ± 0.11</td>
<td>12.3 ± 0.54</td>
<td>7.72 ± 0.28</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>227.0 ± 18.1</td>
</tr>
</tbody>
</table>

* p < 0.05; ** p < 0.01; *** p < 0.001
Table 29

The mean values for $K_G$, $K_G + 1$, and $K_F$ in the control, obese and geriatric subjects (± SEM). Number of observations in parenthesis.

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>Obese</th>
<th>Geriatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>$1.81 ± 0.28$ (10)</td>
<td>$1.11 ± 0.18$ (14)</td>
<td>$0.98 ± 0.86$ (23)</td>
</tr>
<tr>
<td></td>
<td>$4.55 ± 0.51$ (10)</td>
<td>$2.81 ± 0.35$ (14)</td>
<td>$2.29 ± 0.16$ (23)</td>
</tr>
<tr>
<td></td>
<td>$3.10 ± 0.73$ (6)</td>
<td>$2.86 ± 0.90$ (4)</td>
<td>$2.21 ± 0.34$ (10)</td>
</tr>
</tbody>
</table>

* $p < 0.05$; ** $p < 0.001$; ns = not significant
acknowledge that the insulin response to oral glucose administration was sluggish in the elderly as shown by the delayed peak insulin level during this test.

It is unlikely that the delayed peak insulin level was the result of delayed absorption rate of glucose, as suggested by Smith and Hall (1973), but proof is lacking. The evidence which is against this argument is a. the increase in blood glucose level was equal in the elderly and in young people during the first 30'; b. after 30' the elderly still increased their blood glucose level nearly as much again as they did in the first 30 minutes. The peak level of blood glucose corresponded with the peak insulin level at 90'; and c. the simple iv alanine tolerance test showed that the elderly has increased levels of blood glucose which were not suppressed by their endogenous insulin secretion.

The impairment of iv GTT was also probably due to the decreased ability of endogenous insulin to suppress gluconeogenesis. The mean $K_G$ value was significantly lower in the elderly (Table 29), while the mean peak insulin level, although lower, was not significantly so (Table 30).

The logarithm values of $K_G$ were significantly correlated with 120' blood glucose values during oral GTT in the combined group of the obese, elderly and control subjects ($p < 0.001$; Fig. 32). This suggests that iv GTT would be just as good (or as bad) as the oral GTT in detecting impairment in glucose tolerance.

C. Insulin Sensitivity:
1. Blood glucose and NEFA levels:

While interpretation of the iv GTT might be ambiguous, the iv GTT seems
Figure 22: Correlation between $K_u$ value (mL/min.) during iv GTT and 120° value of blood glucose concentration during oral GTT, in the obese, geriatric and control subjects.

(●) obese patients. (○) overt diabetic obese patient.
(▲) geriatric patients. (▲) overt diabetic geriatric patient.
(■) normal control subjects.
$K_g$ during iv GTT (%/ml)

120° blood glucose value during oral GTT (m mol/l).
Table 30

The mean peak insulin concentrations during oral GTT and iv GTT (± SEM), in control, obese and geriatric subjects. Number of observations in parenthesis.

<table>
<thead>
<tr>
<th></th>
<th>Oral GTT</th>
<th>iv GTT</th>
<th>Ratio of oral:iv</th>
</tr>
</thead>
<tbody>
<tr>
<td>I Control (9)</td>
<td>72.0 ± 7.26</td>
<td>54.0 ± 13.60</td>
<td>1.33</td>
</tr>
<tr>
<td></td>
<td>III</td>
<td>ns</td>
<td></td>
</tr>
<tr>
<td>II III</td>
<td>160.6 ± 24.98</td>
<td>138.4 ± 11.17</td>
<td>1.16</td>
</tr>
<tr>
<td>II Obese patients (5)</td>
<td>III</td>
<td>108.6 ± 28.11</td>
<td>1.15</td>
</tr>
<tr>
<td></td>
<td>III</td>
<td>48.0 ± 5.34</td>
<td>41.6 ± 5.19</td>
</tr>
</tbody>
</table>

*p <0.05; ** p <0.01; *** p <0.001; ns = not significant
quite clearly to measure peripheral tissue responsiveness. It is very unlikely that liver gluconeogenesis was not suppressed (even in the obese and the elderly) by the relatively high concentration of exogenous insulin which was given. The circulating levels 10 minutes after injection of insulin was found to lie in the range of 150 units/ml to 400 units/ml, i.e. about 5 to 10 times higher than peak levels of endogenous insulin measured during iv GTT. Both the obese and the elderly showed significantly decreased mean $K_g$ values (Table 29), indicating that peripheral tissue response to insulin (as judged by glucose uptake) is reduced in these obese and elderly people.

In the elderly, it has been argued that this impaired peripheral tissue sensitivity extends also to suppression of hepatic glucose output (see Chapter II B. Oral GTT). There seems no good reason why these arguments should not also apply, though perhaps to a lesser degree, to the interpretation of the oral GTT of the obese.

Both in the study in obesity and old age, the evidence showed that this decrease in insulin sensitivity in relation to carbohydrate is more pronounced than in relation to fat metabolism. This is shown by the absence of any significant difference in the NEFA curves during oral GTT (Figs. 18C and Fig. 27C) or $K_f$ values during iv GTT (Table 29), suggesting that the lipolytic action is not yet affected by obesity or old age.

This is perhaps not surprising since insulin concentrations which maximally stimulate glucose uptake by insulin sensitive tissues are considerably higher than concentration required to inhibit lipolysis.
2. Correlation of glucose tolerance ($K_G$) with insulin sensitivity ($K_G + 1$)

This work demonstrated highly significant correlations between $K_G$ and $K_G + 1$ values ($p < 0.001$, Table 27, Fig. 33). It is interesting that this significant correlation was present in even the obese group alone ($p = 0.01$) or the geriatric group alone ($p = 0.05$), and given a larger number of control subjects, they would certainly have shown the same correlation. Another interesting fact is that in each individual group, the shape of the regression line was almost identical, except in the geriatric group which was slightly lower (Table 27). Perhaps this is a sign of some degree of cell failure.

3. Hypersensitivity to insulin in 'normal' subjects:

Some apparently normal subjects showed very high values for $K_G + 1$ and therefore, also for $K_G$. It has been suggested in Part III, Chapter IV, that these subjects may be in an early phase of 'active' obesity. A longitudinal study of such people may or may not reveal that this speculation is true.

This speculation is based on the similar pattern of changes in $K_G$ and $K_G + 1$ found in experimental animals. These animals were fed on diets marginally deficient in protein (Heard and Turner, 1967; Heard and Stewart, 1971). In all cases, hypersensitivity to insulin was the earliest phase and led on to impaired glucose tolerance and diminished insulin sensitivity.

It would remain also to attempt to distinguish genetic from dietary influences in the development of obesity.
Figure 32. Regression line between the values of $K_G$ and $K_{G+1}$ in the combined group of obese (O), geriatric (A) and normal control subjects (○).
The phrases 'active' and 'passive' in regard to obesity, may have been independently used by other authors in a different context; e.g., Craddock (1973) used these terms for the ability or inability of obese subjects to gain more weight. While this work uses these phrases in relation specifically to insulin sensitivity (in respect to carbohydrate metabolism). (See Part III, Chapter V).

As it was shown (Part III, Chapter III), that treatment of obesity is very difficult and unreliable, a longitudinal study of insulin sensitivity might detect subjects in the 'active' pre-obese phase or those who are prone to obesity.

Prevention of obesity rather than treatment is likely to offer greater success.

4. What determines insulin sensitivity?

Two main groups of factors must have been likely to be important. They are: a. anti-insulin hormones, insulin antagonists, etc. (see Part II, Chapter I), and b. cellular factors including availability of receptor sites. Early enthusiasm for the concept that insulin sensitivity and receptor availability would always correlate exactly, has been rather dampened (Cuatrecasas, 1974; Kern, 1975) and more work on this aspect is still needed.
CHAPTER V

DIAGNOSTIC SIGNIFICANCE OF THE TESTS

Obviously a combination of tests would be ideal in determining an impairment in glucose tolerance. For practical purposes, however, using only one particular test, and even in extreme cases, only looking at fasting blood glucose values, would probably be sufficient; although, a few borderline cases may escape from detection.

Arbitrary elimination of subjects who had fasting blood glucose concentrations higher than 6.11 mmol/l (thus all having normal fasting blood glucose), 120' value for blood glucose during oral GTT revealed that some of the obese (> 6.11 mmol/l) and some of the geriatric subjects (> 7.77 mmol/l) were 'diabetic' (Fig. 52). Furthermore, although it was shown earlier that the logarithmic values for KG during IV GTT were significantly correlated with 120' values of blood glucose during oral GTT, there were some subjects who would be normal by one test but 'diabetic' by the other. If one's aim is to get early detection of a disease, or an impairment, then a combination of tests is very necessary (Fig. 52).

IV GTT is best carried out immediately after IV GTT, because it could serve as a measure of peripheral tissue responsiveness to insulin, since the effect of liver gluconeogenesis has been eliminated.
A. Surgical Patients:

A nitrogen balance study showed a negative balance amounting to 50 g protein loss per day for a period of 5 to 6 days after the operation. This period of negative nitrogen balance coincided with elevated fasting levels of plasma glucagon, NEFA, branched-chain amino acids, urinary free cortisol, urinary 17-OH-corticosteroids and with a decrease of total amino acids. Fasting levels of plasma insulin and plasma cortisol were only significantly elevated on day 1 post-operatively.

A two hour infusion of glucose (0.35 g kg\(^{-1}\) h\(^{-1}\)) on day 1, resulted in hyperglycaemia and hyperinsulinaemia, suggesting a 'temporary' insulin resistance. Glucose also suppressed glucagon secretion to the same extent on day 1, and on 'recovery'. It also decreased plasma NEFA, total amino acids and plasma cortisol in both infusions. But, the fall in plasma cortisol was probably due to the effect of resting rather than the actual effect of glucose.

Several questions remained unanswered:

1. Insulin resistance seems to protect the subjects from the less desirable features of elevated insulin levels. Then perhaps amino acid administration rather than glucose would be more beneficial, since it improves the nitrogen balance without having to increase plasma insulin levels and permits mobilization of fat (Blackburn, et al. 1973). More work, however, is still needed to establish the best post-operative regime for patients undergoing surgery.
It is known that protein synthesis is decreased following surgery (O'Keefe, et al., 1974; Crone, et al. 1976). Whether insulin resistance is also responsible in causing the decrease of protein synthesis should also be investigated.

B. Obese Subjects:

This work demonstrates that obese subjects showed impaired response to oral, and iv GTT. The impairment was associated with hyperinsulinaemia. The results showed that $K_G$ or $K_G + 1$ values were not statistically correlated with fasting or peak insulin levels during iv GTT. However, higher values for $K_G$ or $K_G + 1$ were usually associated with lower values of fasting or peak insulin. There was a significant correlation between $K_G$ and $K_G + 1$ values in combined groups of patients and control subjects.

The logarithm values for fasting insulin were correlated with % ideal body weight ($p < 0.001$). $K_G$ or $K_G + 1$ were not statistically correlated with % ideal body weight however, lower values for $K_G$ or $K_G + 1$ were usually associated with higher % ideal body weight.

Unlike that of carbohydrate metabolism, this present work was unable to show any significant impairment of insulin sensitivity in regard to fat metabolism (judged by the difference in NEFA curves during oral GTT; $K_p$ during iv GTT).

Oral GTT, iv GTT and iv GTT did not give any prediction of the possible success or failure of any dietary treatment of an obese patient.
This work speculates that there are two types of obesity (based on insulin sensitivity): a. 'active' obesity, judged by the relatively low % ideal body weight (<160%) low values for \( K_G \), \( K_G + I \) and low fasting insulin; b. 'passive' obesity judged by high % ideal body weight, low values for \( K_G \), \( K_G + I \) and high fasting insulin; and c. apparently normal subjects who had very high values of \( K_G \) and \( K_G + I \) are probably in an early stage of 'active' obesity (see Chapter IV, C).

There are a few aspects of this study which need further investigation:

I. More 'normal' subjects with high \( K_G \) and \( K_G + I \) values to be investigated. Longitudinal study of such people may or may not reveal that the above speculation is true.

II. More obese patients are needed, so that they can be classified by the combination of age and % ideal body weight. This is hoped to throw some light on the development of obesity.

C. Elderly Subjects:

This work demonstrates the familiar impairments in oral GTT and iv GTT in the elderly. Although the impairment of glucose tolerance was associated with hypoinsulinemia and decreased peripheral tissues insulin sensitivity, the decreased ability of endogenous insulin to switch off liver gluconeogenesis seemed to be the major cause of hyperglycaemia. After intravenous injection of l-alanine, the elderly showed increased levels of blood glucose which were not suppressed by their endogenous insulin secretion.
As in the study on obesity, this work confirms earlier findings in animal experiments (Turner, 1966; Heard and Turner, 1967; Heard and Henry, 1969a), about the significance of insulin sensitivity ($K_G + \|$) in determining glucose tolerance rather than the actual levels of circulating plasma insulin. This was shown by the significant correlation between the $K_G$ and $K_G + \|$ values in combined groups of elderly patients and control subjects, and also in the combined group of obese, elderly and normal control subjects.

Also, as in the obese, this work was unable to show any significant impairment of insulin sensitivity in regard to fat metabolism (NEFA curves during oral GTT; $K_p$ values during iv GTT).

Few aspects in the study in the elderly need further investigation:

I. As old age is not merely the passing of years, but a generalized picture of many malfunctions added together, the question now arises, whether the ageing phenomenon should be prevented. And if it should, in what way?

II. As skinfold measurements are unreliable (see Chapter II, C) and % Ideal body weight is unable to be measured, what is a good, simple criterion in judging the nutritional status of the very old?

III. A possible role of the liver in producing hyperglycaemia needs further investigation. By including a tracer dose of labelled glucose in the ordinary glucose load, and measuring the plasma glucose concentrations and the specific activity of labelled glucose at various times during the test, one would be able to get more information about the impaired suppressibility of liver gluconeogenesis, in the elderly (perhaps also in the obese).
**REFERENCES**

Abel, J.J. (1926)

Crystalline Insulin


Control of hepatic mitochondrial CO₂ fixation by glucagon, epinephrine and cortisol
J. Biol. Chem., 244, 6444 - 6450

Adibi, S.A. (1968)

Influence of dietary deprivation on plasma concentration of free amino acids of man.
J. Appl. Physiol., 25, 52-56

Agate, J. (1963)

The practice of geriatrics, pp 112
William Heinnemann Medical Books Ltd., London


Intravenous glucose tolerance, insulin, and free fatty acid levels in burned patients.
Lancet, 2, 1113 - 1116

Andres, R. (1973)

Aging and carbohydrate metabolism in: Nutrition and Old Age, pp. 24 - 29

In: Symposia of the Swedish Nutritional Foundation, Vol. 10.
Ed. Gartson, L.A.
Almqvist and Wiksell, Stockholm, Sweden.

Andres, R., Pozetsky, T., Swendloff, R.S. and Tobin, J.D. (1970)

Effect of ageing on carbohydrate metabolism in: Early Diabetes, pp. 349
Eds. Camerini-Davalos, R.A. and Cole, H.S.
Areataeus (AD 30 - AD 90)

A translation of his works by
Adams, F. (1856)
Areataeus, the Cappadocian, pp. 339
Sydenham Society, London.

Armitage, P. (1971)
Statistical method of medical research, pp. 117
Blackwell Scientific Publication, Oxford and Edinburgh

Avicenna (930 - 1033)

Quoted by Beet, C.H. (1960), in:
Epoch in the history of diabetes. In: Diabetes, pp. 1
Ed. Williams, R.M.
Harper and Brothers, New York.

The effect of insulin on the metabolism of adipose tissue in
Handbook of Physiology, Section 7, Vol. 1, pp. 545
Ed. Greep, R.O. and Astwood, E.B.,
American Physiological Society, Washington, D.C.

Baig, H.A. and Edoozien, J.C. (1965)
Carbohydrate metabolism in kwashiorkor.
Lancet, 2, pp. 662 - 663

Bagdade, J.D., Bierman, E.L. and Porte, D.J. (1967)
The significance of Basal Insulin Levels in the Evaluation of
the Insulin Response to Glucose in Diabetic and Non-Diabetic
Subjects.
J. Clin. Invest., 46, pp. 1549 - 1557

Operation of the 'Glucose-fatty acid cycle' during experimental
elevations of plasma free fatty acid levels in man.

Banting, F.G. and Best, C.H. (1922)
Internal secretion of pancreas.
Bean, A.G., Billing, B. and Sherlock, S. (1951)
The effect of adrenaline and nonadrenaline on hepatic blood
flow and splanchnic carbohydrate metabolism in man.
J. Physiol., 115, 430 - 441

Beck, P., Koumans, J.H.T., Winterling, C.A., Stein, M.F.
Daughaday, W.H. and Kipnis, D.M. (1964)
Studies of insulin and growth hormone secretion in human
obesity.

Aging and endocrine responses to environmental factors:
with particular reference to mammals
In:
Hormones and the Environment, pp. 303
Eds. Benson, G.K. and Phillips, J.G.,
Cambridge University Press.

Berlyne, G.M. (1958)
The cardiorespiratory syndrome of extreme obesity.
Lancet, 2, pp. 939 - 940

Best, C.J., Jephcott, C.M. and Scott, C.A. (1932)
Insulin in tissues other than pancreas.
Am. J. Physiol., 100, pp. 285 - 294

Peripheral Intravenous feeding with isotonic amino acid solution.
Am. J. Surgery, 125, pp. 447 - 454

Bloom, S.R. (1973)
Glucagon, a stress hormone.

Bowles, M.D. (1964)
Intravenous glucose tolerance in kwashiorkor and marasmus

Bowen, H.F. and Moorhouse, J.A. (1973)
Onset diabetes.
J. Clin. Invest., 52, pp. 3033 - 3045
Brondt, R.L. (1960)
Decreased carbohydrate tolerance in elderly patients.
Geriatrics, 15, pp. 315 - 325

Bray, G.A. (1972)
Lipogenesis in human adipose tissue: some effects of nibbling and gorging.

Brunner, J.C. (1683)
Experimenta nova circa pancreas.

Endocrine changes.

Diabetes survey in Bedford, 1962, pp. 4
Section of Epidemiology, Royal Society of Medicine, London.

Starvation in man.

Insulin and muscle protein loss.
Handbook of Physiology.
Section 7, Vol. I, pp. 563
Eds. Greep, R.O. and Astwood, E.B.
American Physiological Society, Washington, D.C.

Cahill, G.F., Herrera, M.G., Morgan, A.P., Soeldner, J.S.,
Hormone-fuel interrelationship during fasting.

Epoch in the history of diabetes.
In: Diabetes, pp. 1
Ed. Williams, R.H.
Harper and Brothers, New York.
Antagonism between glucose and epinephrine regarding secretion. A dose-response study in man.

Ostadard, J.A. (1908)
Avicenna and Arabian medicine.

Excessive serum insulin response to oral glucose in obesity and mild diabetes.
Diabetes, 19, pp. 458 - 464

Chlouverakis, C., Jarrett, R.J. and Keen, H. (1967)
Glucose tolerance, age and circulating insulin.
Lancet, 1, pp. 806 - 809

Obesity and insulin resistance in obese hyperglycaemic mouse (obob).
Metabolism, 18, pp. 998 - 1005

Isolation of proinsulin connecting fragment (C-peptide) from bovine and human pancreas.

Cockford, P.M., Harbeck, R.J. and Williams, R.H. (1966).
Influence of age on intravenous glucose tolerance and serum immuno-reactive insulin.
Lancet, 1, pp. 456 - 461

Conard, V. (1955)
Cliniques.

ACTH levels in plasma in preoperative and surgically stressed patients.
J. Clin. Invest., 41, pp. 1699 - 1705

Obesity and its management.
2nd ed.


Protein turnover in patients before and after elective orthopaedic operations.
Brit. J. Surgery, in press.


Membrane receptors.


The contribution of different organs and tissues of the rat to assimilation of glucose.
Diabetologia, 5, pp. 384 - 391.


Physical injury and its effects on protein metabolism in:
Mammalian Protein Metabolism Vol. II, pp. 373
Eds. Munro, H.N. and Allison, J.B.


Metabolism during post-injury period.


Human Nutrition and Dietetics.
6th Ed., pp. 288


Insulin hypersensitivity and physiological insulin antagonist.
Department of Health & Social Security (1976)

Prevention and Health: Everybody's business, pp. 11
Her Majesty's Stationary Office, London.

Doe H. B. (1966)

Protein Calorie Deficiency and Stress pp. 29
PhD. Thesis, University of London.


Enstneck, J. W. and Williams, R. H. (1972)

Hormonal and non-hormonal factors modifying man's response to insulin in:
Handbook of Physiology, Section 7, Vol. I., pp. 665
Eds. Greep, R. O. and Astwood, E. B.,
American Physiological Society, Washington, D. C.

Exton, J. H. (1972)

Gluconeogenesis
Metabolism, 21, pp. 945 - 990

Felig, P. (1973)

The glucose-alanine cycle
Metabolism, 22, pp. 180 - 207


Role of substrate in the regulation of hepatic gluconeogenesis.
Adv. Enzyme Regul., 7, pp. 41 - 46


Amino acid metabolism during prolonged starvation.


Amino acid metabolism in exercising man.
J. Clin. Invest., 50, pp. 2703 - 2714
The role of plasma free fatty acids in development of fatty liver.
J. Clin. Invest. 40, pp. 2171 - 2179

Hepatic phosphorylase deficiency. Its differentiation from other hepatic gluconeoses.
Arch. Dis. Child., 49, pp. 186 - 191

Few, J.D. and Cashmore, G.C. (1975)
The determination of plasma cortisol concentration by competitive protein binding.

Foa, F.P. (1972)
The secretion of glucagon in:
Handbook of Physiology, Section 7, Vol. 1, PP. 261
Eds. Greep, R.O. and Astwood, E.B.
American Physiological Society, Washington, D.C.

Franckson, M. Jr., Malaisse, W., Amouil, Y., Basde, E., Ooms, H.A.,
Glucose kinetics in human obesity
Diabeterologia, 9, pp 94 - 103

The physiology of obesity; clinical implications in:
Energy balance and obesity in man.
Ed. Garow, J.S.
North Holland Publishing Co., Amsterdam.

Morphine anaesthesia blocks cortisol and growth hormone response
to surgical stress in humans.

Kwsdikor and medttion in human
Arch. Wsokem Wok, 14, 195 - 196.
Gelguy Scientific Tables (1970)
Ed. Diem, K. and Lammer, C.,
7th Ed., pp. 711
Gelguy, Basle, Switzerland.

Gopalan, C. (1968)
Kwashiorkor and marasmus: evolution and distinguishing features in
Calorie Deficiencies and Protein Deficiencies, pp. 49 - 58

A critical appraisal of methods of estimating urinary 17-oxosteroids
and 17-oxogenic sterols.
Lancet, 1, pp. 124 - 127

Growth Hormone secretion in response to stress in man
Nature, 210, pp. 540 - 541

Effect of nibbling versus gorging on glucose tolerance.
Lancet, 2, pp. 165 - 167

Hadden, D.R. (1967)
Glucose, free fatty acid and insulin interrelations in kwashiorkor
and marasmus.
Lancet, 2, pp. 850 - 856

Immuno-assay of insulin with insulin antibody precipitate.
Biochem. J., 88, pp. 137 - 144

Heard, C.R.C. (1966)
Effect of severe protein-calorie deficiency on the endocrine control
of carbohydrate metabolism.
Diabetes, 15, pp. 78 - 79

Glucose tolerance and insulin sensitivity
Clin. Sci., 37, pp 37 - 44
Heard, C.R.C. and Henry, P.A.J. (1968)
Insulinogenic response to intravenous glucose in dogs fed diets of different protein value.
J. Endocr., 45, pp. 375 - 385

Heard, C.R.C., Plott, B.S., Stewart, R.J.C. (1958)
The effects on pigs of a low protein diet with and without additional carbohydrate.

Heard, C.R.C. and Stewart, R.J.C. (1971)
Protein calorie deficiency and disorders of the endocrine glands.
Hormones, 2, pp. 40 - 64

Glucose tolerance and related factors in dogs fed on diets of suboptimal protein value.
Diabetes, 16, pp. 96 - 107

Insulin and glucose to reduce catabolic response to injury in burned patients.
Lancet, 1, 767 - 770

Chemistry of insulin in:
Handbook of Physiology, Section 7, Vol I, pp. 111
Eds. Greep, R.O. and Astwood E.B.,
American Physiological Society, Washington, D.C.

Liver glycogen in man. Effect of different diets and muscular exercise in:
Muscle metabolism during exercise, pp. 143,
Eds. Pernow, B. and Saltin, B.,

Ikkos, D. & Luft, R. (1957)
On the intravenous glucose tolerance test.
Acta Endocr., 25, pp. 312 - 334
Comparison of glucose determination obtained from whole
blood and plasma
Clin. Biochem., 4, pp. 297 - 301

Persistent impairment of insulin secretion and glucose
tolerance after malnutrition

Effect of hormones on adipose tissue lipogenesis
Third International Meeting of Endocrinologists
Eds. Vogue, J. and Denton, R.M.
Excerpta Medica Foundation, Amsterdam

The role of the liver in the disposal of orally administered
14C-glucose in the normal rat
Diabetologia, 4, pp. 308 - 313

The assessment of the nutritional status of the community
pp. 1-106
World Health Organization, Geneva

Johnston, T.B. and Whillis, J. (1954)
(Editors)
Gray's Anatomy
21st ed., pp. 1060

Joslin, E.P. (1921)
The prevention of diabetes
J. Am. Med. Assoc., 76, pp. 79 - 84

Keen, H. (1975)
The incomplete story of obesity and diabetes in
Recent Advances in Obesity Research, I, pp. 116
Ed. Howard, A.

Hypoglycaemia in infantile malnutrition
Acta Paed. Scand. Suppl. 172, pp. 119


Hypoglycaemia and the regulation of fasting glucose metabolism
in malnutrition, in:
Endocrine aspects of Malnutrition, pp. 313
Ed. Gardner, L.I. and Amacher, P.
The Kroc Foundation, Santa Ynez, California.

Kipnis, D.M. (1965)

Growth hormone and insulin antagonism, in:
On the nature and treatment of Diabetes, pp. 258
Eds. Leibel, B.S. and Wrenshall, G.A.
Excerpta Medica F.

Kipnis, D.M. (1966)

Insulin Antagonism and Diabetes, Int.
Diabetes, pp. 433
Eds. Osman, J. and Milner, R.D.G.
Excerpta Medica Foundation, Amsterdam


The amino acid composition of actin, myosin, tropomyosin
and the meromyosins
Arch. Biochem. Biophys., 50, pp. 148 - 159


Lactate turnover and gluconeogenesis in normal and
obese humans. Effects of starvation
Diabetes, 19, pp. 53 - 63


Misinterpretation of 'K' values
Brit. Diab. Assoc., Med. Sec., Spring Meeting

Langerhans, P. (1869)

Beiträge zur mikroskopischen Anatomie der Bauchspeicheldrüse. (Thesis)
Medizinischen Facultät der Friedrich-Wilhelm-Universität
Buchdruckerei von Gustav Lange, Berlin.
Pancreatic alpha-cell function in trauma.
JAMA, 227, pp. 757 - 761

Evidence for the release of individual amino acids from resting forearm.
Nature, 208, pp. 588 - 589

Carbohydrate metabolism in man; effect of elective operations and major injury.
J. Appl. Physiol., 31, pp. 110 - 116

Macdonald, I. (1967)
Physiological role of dietary carbohydrates, in:
World Review of Nutrition and Dietetics, Vol. 8, pp. 143
Ed. Bourne, G.H.,

Madison, L.L. (1969)
Role of insulin in hepatic handling of glucose.

Sites of hormonal regulation of protein metabolism.
Mammalian Prot. Met. 4, pp. 229 - 297

Marks, H.H. (1960)
Influence of obesity on morbidity and mortality.

Maya, I. (1957)
Some advances in the study of the physiological basis of obesity.
Metabolism, 6, pp. 435 - 446

The composition of foods.

McLeod, J.J.R. (1922)
The source of insulin. A study of effect produced on blood sugar by extracts of the pancreas and principal islets of fishes.
J. Metab. Res. 2., pp 149 - 172

Comparative glycemic responses to alanine in normal and small-for-gestational-age infants.
J. Pediat., 85, pp. 276 - 278

Montagu, A. (1966)

Obesity and the evolution of man.
JAMA, 193, pp. 149 - 151

Moorhouse, J.A. (1964)

Pyruvate-tolerance tests in healthy and diabetic subjects.
Lancet, 1, 689 - 693

Munro, H.N. (1964)

General aspects of regulation of protein metabolism by diet and hormone, in:
Mammalian Protein Metabolism, Vol. I, pp. 381
Ed. Munro, H.N. and Allison, J.B.

Munro, H.N. (1969)

Evolution of Protein Metabolism in Mammals, In:
Mammalian Protein Metabolism, Vol. III, pp. 133
Ed. Munro, H.N.

Munro, H.N. (1970)

A General Survey of Mechanisms regulating protein metabolism in mammals, In:
Mammalian Protein Metabolism, Vol. III, pp. 3
Ed. Munro, H.N.

Munro, H.N. (1976)

Eukaryote protein synthesis and its control, In
Protein Metabolism and Nutrition, pp. 1
Ed. Cole, D.J.A., Booman, K.N., Buttery, P.J.,
Lewis, D., Neale, R.J. and Swan, H.
Butterworths, London, Boston, Sidney, Wellington, Dubbo and Toronto
Ageing and variation

'Catabolic' loss of body nitrogen in response to surgery.
Lancet, 2, pp. 1035 - 1038

Olesen, K.H. (1965)
Body composition in normal adult, In
Human body composition, pp. 177
Ed. Brazek, J.

Omenn, G.S. (1970)
Ectopic polypeptide hormone production by tumour

Liver and kidney metabolism during prolonged starvation
J. Clin. Invest., 48, pp. 574 - 583

Oyer, P.E., Cho, S., Peterson, J.D. and Steiner, D.F. (1971)
Studies of human proinsulin isolation and amino acid sequence of the human pancreatic C-peptide.
J. Biol. Chem., 246, pp. 1375 - 1386

Disturbances of carbohydrate metabolism in infantile marasmus

Hepatic fructose-1, 6-diphosphatase deficiency: a cause of lactic acidosis in infancy.
J. Clin. Invest., 51, pp. 2115 - 2123

Energy utilization in overfed, thin young men

The effect of overfeeding on two fat young women
Brit. J. Nutr., 17, pp. 373 - 377

Paulin, J.E. and Sauls, H.C. (1922)

A study of glucose tolerance test in the obese
Southern Med. J., 15, pp. 249 - 252


Plasma insulin responses to glucose and tolbutamide of normal weight and obese diabetics and non-diabetic subjects.
Diabetes, 15, pp. 867 - 874

Platt, B.S. (1958)

Malnutrition and the pathogenesis of disease.

Porte, D. (1975)

Pathophysiology of insulin secretion in man.
Acta. Endocr. (Kbh) Suppl., 199, p. 70


Human insulin secretion: An integrated approach


Amino acid balance across tissues of the forearm in post-absorptive man. Effect of insulin at two dose levels.
J. Clin. Invest., 48, pp. 2273 - 2282


Some endocrine and metabolic aspects of obesity.


The glucose-fatty acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus.
Lancet, 1, pp. 785 - 789


Steady state of plasma insulin response to continuous glucose infusion in normal and diabetic subjects.
Diabetes, 18, pp. 273 - 279
Reilly, P.E.B. (1975)
Determination of "Cl-labelled plasma L(+)alanine specific activity.
Ann. Biochem., 65, pp. 298 - 304

Reiser, P. (1967)
Insulin, in:
Membranes and Metabolism, pp. 43
Williams and Wilkins, Baltimore

Roe, J.H. and Rice, E.W. (1948)
A photometric method for determination of free pentoses in animal tissues
J. Biol. Chem., 173, pp. 507 - 512

Rallly, (1921)
Zum Stoffwechsel bei der Fettzug.

Rossell, S. (1966)
Release of free fatty acids from subcutaneous adipose tissue in dogs following sympathetic nerve stimulation
Acta physiol. Scand., 67, pp. 343 - 351

Effect of abdominal operation on glucose tolerance and serum levels of insulin, growth hormone and hydrocortisone
Lancet, 2, pp. 563 - 566

Rubenstein, A.M. and Steiner, D.F. (1971)
Proinsulin

Hyperglycagrowth in surgical patients
Brit. Med. J., 2, pp. 10 - 12

The disulphide bonds of insulin.
Biochem. J., 60, pp. 541 - 556
Samols, E. and Marks, V. (1965)
Interpretation of the intravenous glucose test
Lancet, 1, pp. 462 - 463

Samols, E., Tyler, J., and Marks, V. (1972)
Glucagon-insulin interrelationships, glucagon: molecular physiology, clinical and therapeutic implications, pp. 151
Ed. by P. J. Letebrere, R. H. Unger.

Sanger, F. (1949)
Fractionation of oxidized insulin.
Biochem. J., 44, pp. 126 - 128

Schanheyder, F., Hellskaow, N. S. C., and Olesen, K. (1954)
Isotopic studies on the mechanism of negative nitrogen balance produced by immobilization

Sender, P. M., James, W. P. T., Garlick, P. J., Heard, C. R. C., and Waterlow, J. C. (1975)
The effect of dietary energy and protein restriction on tyrosine and leucine metabolism in obesity, in:
Recent Advances in Obesity Research: 1, pp. 83
Ed. Howard, A.
Newman Publishing Ltd., London

Insulin secreting bronchial carcinoid tumour with widespread metastases.

Glucagon and glucose regulation in normal, obese and diabetic subjects

Age differences in the intravenous glucose tolerance tests and the response to insulin
J. Clin. Invest. 36, pp. 504 - 513
Aspects of carbohydrate metabolism in kwashiorkor with
special reference to spontaneous hypoglycaemia
Brit. Med. J., 1, pp. 32 - 34

Smith, N. and Levine, R. (1964)
Obesity and diabetes

Society of Actuaries (1939)
Build and blood pressure study,
Vol. 1, pp. 14
Chicago

Automatic recording apparatus for use in the chromatography
of amino acids
Ann. Chem., 30, pp. 1190 - 1205

Steiner, D.F., Kemmler, W., Clark, J.L. Oyer, P.E. and Rubenstein, A.H. (1972)
The biosynthesis of insulin, In:
Handbook of Physiology, Section 7, Vol. 1, pp. 175
Ed. Greep, R.O. and Astwood, E.B.,
American Physiological Society, Washington, D.C.

Stem, S.J. and Hirsch, J. (19/2)
Obesity and pancreatic function, In:
Handbook of Physiology, Section 7, Vol. 1, pp. 641
Ed. Greep, R.O. and Astwood, E.B.,
American Physiological Society, Washington, D.C.

Stewart, R.J.C. and Heard, C.R.C. (1959)
Pancreatic islet cells and blood regulation in pigs
maintained on low protein diets

Reduced glucose tolerance in elderly human subjects
Diabetes, 14, pp. 579 - 583
Interrelationships between protein calorie deficiency, glucose tolerance age and reproductive performance in dogs and rats. pp. 154  
Ph.D. Thesis, University of London

Unger, R.H. (1972)  
Insulin/glucagon ratio  
Is. J. Med. ScI., 8, pp. 252 - 257

Van Mering, J. and Minkowski, O. (1890)  
Diabetes mellitus nach Pankreasektirpation.  
Arch. Exper. Pathol. Pharmakol., 26, pp. 371 - 387

Wehlberg, F. and Thomasson, B. (1968)  
Glucose tolerance in ischemic cardiovascular diseases. In: Carbohydrate Metabolism and Its Disorders, Vol. 2, pp. 185  
Academic Press, London and New York

Adrenal medullary secretion in hemorrhagic shock  
Am. J. Physiol., 197, pp. 773 - 780

Protein malnutrition in children: advances in knowledge in the last ten years.  

Webster, S.G.P. and Leeming, J.T. (1973)  
Assessment of small bowel function in the elderly using a modified xylose tolerance test  
Gut, 16, pp. 109 - 113

Blood glucose, lactate and pyruvate in kwashiorkor  

Wiklund, L. and Jarlskildt, L. (1975)  
Effects of abdominal surgery under general anaesthesia and of postoperative analgesic therapy on splanchnic exchange of some blood borne energy metabolites  
Acta. anaesth. Scand., 19, Suppl. 58, pp. 41 - 58
W.H.O. (1965)

Diabetes mellitus, pp. 12
Technical Report Series, No. 310,
W.H.O., Geneva

Williams, C.D. (1933)

A nutritional disease of children associated with maize diet.
Arch. Dis. Childn., 8, pp. 423 - 433

Willis, T. (1682)

Pharmacetica rationalissimae, sive diatriba de medicamentorum
operationibus in humana corpori, pp. 64
In:
Med. Doct. Opera Omnia,
Apost. Hier. Wetstenium, Amstelaedami


Hyperglucagonaemia after burns
Lancet, 1, pp. 73 - 75


The glycemic response to alanine: Index of glucagon secretion in man


Evaluation of $\beta$-cell function by infusion of alanine in normal,
diabetic and obese subjects

Wootton, I.D.P. (1964)

Micro-analysis in medical chemistry,
4th Ed., pp. 140

Working Party appointed by the College of General Practitioners (1963)

Glucose tolerance and glycosuria in the general population

Yates, F.E. and Urquhart, J. (1962)

Control of plasma concentrations of andrenocortical hormones
Physiol. Rev., 42, pp. 359 - 443


Total human body protein synthesis in relation to protein requirements
at various ages
Nature, 233, pp. 192 - 193
MORPHOLOGIC AND HORMONAL CHANGES AFTER SURGERY: HYPERINSULINISM AND GRAMICIDIN GLUCOSE INFUSION.

W.E. SMERNOFF, I.C., M. NEAL, J. T. W. JAMES, J. T. P. E., AND K. B. BLOOM.

London School of Hygiene and Tropical Medicine and Royal Post-Graduate Medical School, London.

Eleven patients were studied, 5 with chest and 6 with abdominal surgery. Measurements of N balances showed the equivalent of about 50 g protein loss per day for 5-10 days post-operative. This period was followed by elevated levels of fasting plasma glucose, NEFA, branched-chain amino acids, urinary free cortisol, urinary 17-OH-corticosteroids and with a decrease of total plasma amino acids. Fasting blood glucose, plasma insulin and plasma cortisol were elevated only on day 1 after operation.

A 2-hour glucose infusion (0.5 g glucose/kg/hr) was carried out on day 1 after operation and on "recovery" (day 9-21). Mean blood glucose levels during infusion were not significantly different on the 2 occasions, but there was a trend to a higher 2-hour level on day 1 (220 mg/100ml on day 1 and 186 mg/100ml on "recovery"). Both curves were significantly higher than in normal subjects in whom blood glucose values reached a plateau at 110 mg/100 ml.

Infusion of glucose caused a fall in plasma glucagon, NEFA and amino acids concentrations. The rise in plasma insulin relative to glucose level was much greater on day 1 than on "recovery" when the response, though approaching normal was still elevated. (See Fig.)

This work confirms that hyperglycaemia follows surgical operation (1) and demonstrates that this is suppressible with glucose. Although low plasma insulin-glucose values have been reported in severe burns and during operation (1, 2), after operation the insulin response is markedly exaggerated, suggesting insulin resistance.

REFERENCES:
Glucose tolerance, plasma insulin levels and insulin sensitivity in geriatric patients.

By C. R. C. Heard, L. B. Sowiodhoto and Sylvia M. Francis,
Clinical Nutrition and Metabolism Unit, Department of Human Nutrition, London School of Hygiene and Tropical Medicine, London WC1E 6HT, and A. N. Exton-Smith, Department of Geriatrics, University College Hospital, London

Venous blood glucose values, 120 min after an oral load of 50 g glucose (G100) are used to diagnose diabetes (WHO, 1965). Values <6.71 mmol/l are classified as normal and >7.81 mmol/l as diabetic. However, G100 increases steadily with age and this raises problems in the elderly both of clinical significance and of physiological interpretation.

This communication reports the results of an investigation of twenty-four geriatric patients (mean age 79 years) in whom both availability of insulin and insulin sensitivity were assessed.

Each patient received two tests on successive days: (1) oral glucose tolerance test (GTT) (50 g glucose) lasting 150 min, (2) intravenous (i.v.) GTT (o.33 g glucose/kg) lasting 60 min followed immediately by i.v. glucose + insulin (o.33 g glucose and o.133 units insulin/kg) with blood sampling for a further 60 min (Heard & Henry, 1969). Half the patients had the oral test on the first day, half had the i.v. test. Patients were fasted from midnight. Blood was sampled and glucose and insulin injected via an indwelling butterfly needle in the arm. Glucose (glucose oxidase method) and insulin (Radiochemical Centre method) were estimated in plasma.

Glucose disappearance rates (k, % per min) in the i.v. tests were calculated to give kG for glucose alone and kG+I for glucose + insulin. Normal values are about 8 and 3% per min respectively (Franckson, Malaise, Arnould, Rasio, Raffe, Conrad & Bentien, 1964).

Although only one patient was overtly diabetic (fasting glucose >10 mmol/l), sixteen of the twenty-four had G100 values >7.77 mmol/l. Of these, fourteen also had severely impaired i.v. glucose tolerance (kG <1% per min). Only two other patients had kG <1% per min. Clear signs of glucose malabsorption occurred in three patients, who therefore showed very low plasma insulin levels during the oral GTT compared with values during the i.v. GTT. Another five patients without malabsorption also showed low plasma insulin levels during the oral GTT suggesting impairment of insulinogenic gut factors. Although plasma insulin levels during both tests were lower than those reported for young normal subjects, insulin sensitivity (kG+I) was also low in all the patients (mean 14% per min). The shape of the oral GTT curves suggested that failure to suppress hepatic glucose release was a feature of this insulin insensitivity.

The extent to which these changes are typical of old age per se and whether deterioration in nutritional status contributes to the effects remains to be established.

REFERENCES


WHO (1965), Diabetes 18, 627.